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Abstract 
Emerging evidence implicates the regulation of higher-order chromatin structure in brain 
development, maturation, and function. Human mutations in two important regulators of 
chromatin structure, ATRX and CTCF, cause microcephaly and intellectual disability and 
have been identified in several cancers, suggesting an important role for these proteins in 
the developing brain and to suppress tumourigenesis. This thesis demonstrates that 
chromatin structure is critical to the differentiation and survival of neural progenitor cells, 
and explores the mechanisms of ATRX and CTCF function in brain development. The 
first chapter identifies that Atrx deficiency induces replicative DNA damage at telomeres 
and pericentromeric heterochromatin, and the mutant mice display signs of premature 
aging, providing novel evidence that genetic damage restricted to the central nervous 
system can result in systemic defects that resemble aging. The second chapter 
demonstrates that the genome organizer CTCF is required for neural progenitor survival 
and to maintain the correct balance between proliferative and differentiative divisions in 
the mouse neocortex. The third chapter investigates the mechanism underlying p53- and 
PUMA-dependent apoptosis in Ctcf-null neural progenitor cells, focusing on a role for 
the protein in preventing replicative stress-induced apoptosis. Together, the findings 
presented here indicate that chromatin architectural proteins, such as ATRX and CTCF, 
are required for genomic stability to promote neural progenitor cell survival and support 
correct brain development. 
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Chapter 1 
1 General Introduction 
Our knowledge of the genome has expanded considerably in the past decades, with the 
decreasing costs of high-throughput sequencing technologies and the completion of the 
human genome project. We now know that DNA sequence does not simply dictate 
function, but rather that protein factors and chemical modifications “above” the genome 
can dramatically alter the organization of DNA within the nucleus and constitute a major 
mechanism underlying transcriptional regulation, DNA replication, and DNA repair 
dynamics.  
Sequencing of the human genome has also greatly expanded our understanding of human 
disease etiology, and new technologies continue to drive progress in the field. Recent 
advances in exome sequencing, i.e. sequencing of codon sequences that constitute 1% of 
the genome, has demonstrated that neuropsychiatric diseases, such as those on the autism 
spectrum, are primarily caused by mutations in synaptic proteins and epigenetic factors 
(De Rubeis et al., 2014; Pinto et al., 2014). This highlights the importance of chromatin 
regulation in brain development and function. Moreover, microcephaly and intellectual 
disability (ID) are caused by disruptions in the DNA damage response and cell cycle 
regulatory pathways, which coalesce at the level of chromatin regulation. However, the 
dynamic interplay between DNA damage signaling and chromatin structure, and how 
they are integrated into cell cycle regulation is not well understood, especially in the 
context of brain development. 
The work herein describes a role for two important regulators of chromatin structure, 
ATRX and CTCF, in genomic stability to promote neuroprogenitor cell survival and 
correct brain development, and explores the functional means by which these essential 
proteins exert their actions. 
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1.1 ATRX is essential for brain development and the suppression of 
tumourigenesis 
1.1.1 The ATRX Gene and Protein 
The alpha thalassemia mental retardation, X-linked (ATRX) protein was first cloned over 
twenty years ago and described as a putative helicase protein due to sequence homology 
with the Rad54 helicase (Stayton et al., 1994). ATRX is comprised of 36 exons and spans 
approximately 300 kilobases (kb) of DNA sequence located on the long arm of the 
human X chromosome (Xq21.1) (Picketts et al., 1996; Villard et al., 1997). The gene is 
conserved between mouse and human (85% homologous), and homologs of the protein 
have been identified in Drosophila melanogaster (dATRX; 66% homologous), and 
Caenorhabditis elegans (xnp-1; 52% homologous) (Lee et al., 2007; Picketts et al., 1996; 
Villard et al., 1999). In vivo expression patterns demonstrated that ATRX is a ubiquitous 
nuclear protein that may play an important role in neuronal differentiation since protein 
levels were highest in fetal brain (Gecz et al., 1994). ATRX is a member of the SNF2 
subgroup of the SWI/SNF protein superfamily that can incorporate themselves into multi-
subunit complexes and utilize the energy of ATP to remodel chromatin (Picketts et al., 
1996). SWI/SNF members are involved in transcriptional regulation, DNA repair, and 
mitotic recombination (Carlson and Laurent, 1994; Eisen et al., 1995; Picketts et al., 
1996). 
ATRX contains two highly conserved domains: a globular ATRX-DNMT3-DNMT3L 
(ADD) domain in the amino (N)-terminus, and a carboxy (C)-terminal helicase domain 
(Aapola et al., 2000; Argentaro et al., 2007; Picketts et al., 1998; Xie et al., 1999) (Figure 
1-1a). The ADD domain is cysteine-rich and contains two types of zinc finger motifs: a 
plant homeodomain (PHD) finger flanked by a GATA-1-like C2C2 motif (Gibbons et al., 
1997). The de novo DNA methyltransferases (DNMT) DNMT3A, DNMT3B, and 
DNMT3L are the only other proteins that contain this type of domain (Xie et al., 1999). 
ADD can bind both DNA and RNA, and has an affinity for H3K9me3-containing 
nucleosomes in the absence of H3K4 methylation (Argentaro et al., 2007; Dhayalan et 
al., 2011; Eustermann et al., 2011; Iwase et al., 2011; Mitson et al., 2011; Sarma et al., 
2014) (Figure 1-1b). Furthermore, the ADD domain is one of the only known readers of 
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the H3K9me3-S10ph combinatorial modification (Eustermann et al., 2011; Kunowska et 
al., 2015; Noh et al., 2014). H3K9me3-S10ph has been shown to modulate binding of 
polycomb proteins during differentiation (Sabbattini et al., 2014), and H3S10ph is 
induced under periods of high neuronal activity at the promoter of immediate early genes 
(Crosio et al., 2003). The ATRX helicase domain exhibits ATPase chromatin remodeling 
activity that can be stimulated by nucleosomes or DNA (Tang et al., 2004; Xue et al., 
2003).  
Characterization of the full-length ATRX gene revealed that it gives rise to at least three 
alternative transcripts (Berube et al., 2000; Garrick et al., 2004; Picketts et al., 1996). 
Two of the transcripts depend on alternative splicing of exon 6, which lies upstream of 
the ADD domain, and generate transcripts of approximately 10.5 kb that give rise to 
proteins of 265 and 280 kDa, respectively (Picketts et al., 1996; Villard et al., 1997). The 
third isoform of ATRX results from a failure to remove intron 11, generating a premature 
stop codon and C-terminal truncated protein (ATRXt) of approximately 180 kDa (Berube 
et al., 2000; Garrick et al., 2004). The functional significance of different ATRX isoforms 
is not understood, however ATRXt likely does not perform identical activities as full-
length ATRX since it lacks the ATPase domain. 
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Figure 1-1 The ATRX protein and function 
(A) Structure of the ATRX protein. Conserved domains and relevant protein interaction 
sites are indicated. (B) Model of ATRX recruitment to heterochromatin. The ADD 
domain of ATRX recognizes the combinatorial signature of H3K4me0 (white circle)-
H3K9me3 (navy circle), the LxVxL motif within the linker domain interacts with HP1 
(Lechner et al., 2005), and DAXX interacts with the ATPase domain of ATRX. ATRX-
DAXX deposits H3.3 in heterochromatin (Drane et al., 2010; Goldberg et al., 2010; 
Lewis et al., 2010; Pathak et al., 2014), while restricting incorporation of macro H2A 
(Ratnakumar et al., 2012).  
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1.1.2 ATRX is a heterochromatin-associated protein 
ATRX is an exclusively nuclear protein that associates with the nuclear matrix during 
interphase (Berube et al., 2000). At the onset of mitosis ATRX is phosphorylated and 
released from the nuclear matrix (Berube et al., 2000). Throughout the cell cycle ATRX 
localizes to pericentromeric heterochromatin (PCH) and interacts directly with 
heterochromatin protein 1 α (HP1α) (Berube et al., 2000; Lechner et al., 2005; McDowell 
et al., 1999). Depletion of ATRX has minimal effect on HP1 localization (Huh et al., 
2012; Ritchie et al., 2008; Wong et al., 2010), while loss of HP1 results in abnormal 
targeting of ATRX to heterochromatin (Kourmouli et al., 2005), suggesting that HP1 is 
involved in recruitment or stabilization of ATRX. Mutation to the LxVxL HP1 
interaction motif (Figure 1-1a) reduced ATRX localization at heterochromatin to a lesser 
extent than mutations in the ADD domain (Eustermann et al., 2011), pointing to a 
stabilization role for HP1 in ATRX localization rather than recruitment per se. 
ATRX can also interact with the methyl CpG binding protein 2 (MeCP2) through its C-
terminal helicase domain, and together the proteins co-localize at DAPI-bright 
heterochromatin bundles in the nucleus (Kernohan et al., 2010; Nan et al., 2007). 
MeCP2-deficient neurons display abnormal targeting of ATRX to heterochromatin 
(Baker et al., 2013; Nan et al., 2007). C-terminal fragments of ATRX require MeCP2 for 
heterochromatic localization while N-terminal fragments of the protein localize to DAPI-
bright heterochromatin in a MeCP2-independent manner (Nan et al., 2007), indicating 
that the N-terminus contains elements required for ATRX targeting. Further support for 
this stems from the fact that the short isoform of ATRX (ATRXt) is capable of localizing 
to PCH despite lacking the C-terminal MeCP2-interaction domain (Garrick et al., 2004). 
Indeed, the N-terminal ADD domain of ATRX can recognize the H3K4me0-H3K9me3 
repressive histone signature that is often enriched at heterochromatin (Dhayalan et al., 
2011; Eustermann et al., 2011; Iwase et al., 2011; Mitson et al., 2011) (Figure 1-1b). 
ATRX depletion does not alter cellular H3K9me3 distribution (Ritchie et al., 2008), 
however more precise techniques like chromatin immunoprecipitation followed by high 
throughput sequencing (ChIP-sequencing) will be required to determine if ATRX is 
required for establishment or maintenance of this type of chromatin modification. ATRX 
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also localizes to the heterochromatic inactive X chromosome and can interact with the 
repressive histone variant macroH2A following the onset of X chromosome inactivation 
(Baumann and De La Fuente, 2009; Ratnakumar et al., 2012; Sarma et al., 2014).  
ChIP-sequencing has demonstrated that ATRX binds intergenic regions and within gene 
bodies, in addition to highly repetitive DNA sequences such as telomeres, rDNA, and 
PCH (Law et al., 2010). Repetitive elements are susceptible to the formation of complex 
secondary structures such as hairpins/cruciforms, Z-DNA, triplexes, and tetraplexes, 
especially when the DNA is unwound during transcription or replication (Zhao et al., 
2010). Telomeric DNA is particularly prone to the formation of G-quadruplex (G4) DNA 
structures, since the sequences of telomeres are GC-rich (Biffi et al., 2013; Lipps and 
Rhodes, 2009). In fact, ATRX is enriched at predicted G4-DNA-forming sequences and 
recombinant ATRX can interact with G4-DNA oligonucleotides in vitro (Law et al., 
2010). 
Taken together, these data indicate that ATRX targeting to heterochromatin is likely 
mediated through direct interaction and recognition of modifications on the histone H3 
tail by the ADD domain, and that stabilization of ATRX at heterochromatin requires 
protein-protein interaction with MeCP2 and HP1. ATRX may also be capable of 
recognizing complex secondary G4-DNA structures in vivo, resulting in ATRX 
recruitment to specific sites enriched in G4-DNA, such as telomeres. However, the 
precise biochemical interaction between G4-DNA structures and ATRX is not well 
understood and deems clarification. Furthermore, the relationship between ATRX and 
macroH2A in the context of heterochromatin requires further characterization, as it may 
also play an important role in ATRX targeting. 
 
1.1.3 ATRX forms a chromatin-remodeling complex with DAXX  
An unbiased proteomic analysis to isolate ATRX interacting partners identified the death-
associated protein 6 (DAXX) (Xue et al., 2003). The majority of ATRX molecules are in 
complex with DAXX (Xue et al., 2003), indicating that DAXX likely participates in 
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ATRX cellular functions. DAXX interacts with the linker region of ATRX located 
between the ADD and ATPase domains (Figure 1-1a,b) (Tang et al., 2004). Together, 
ATRX/DAXX exhibits ATP-dependent chromatin remodeling activities such as 
disruption of DNA-histone interactions and translocation of histones on DNA, but does 
not display helicase activity (Tang et al., 2004; Xue et al., 2003). However, DAXX is not 
required for the chromatin remodeling ability of the complex (Tang et al., 2004), which is 
consistent with the fact that ATRX, and not DAXX, contains an ATPase domain (Figure 
1-1a). At imprinting control regions (ICRs), ATRX mediates nucleosome remodeling to 
facilitate recruitment of the chromatin architecture protein CCCTC-binding factor 
(CTCF), likely through its ATPase domain (Kernohan et al., 2014). The relationship 
between ATRX and CTCF will be touched upon in section 1.3.3 and 5.9.   
All activities that involve the DNA template, such as transcription, replication, and repair, 
must be accomplished in the context of chromatin and require extensive remodeling of 
the nucleosome. Together, ATRX and DAXX are responsible for replication-independent 
deposition of the histone H3 variant H3.3 at telomeres, PCH, and rDNA (Drane et al., 
2010; Goldberg et al., 2010; Lewis et al., 2010). DAXX acts as a chaperone through 
direct interaction with H3.3, and deposition requires the chromatin remodeling activities 
of ATRX (Drane et al., 2010; Lewis et al., 2010). The significance of ATRX/DAXX-
dependent H3.3 deposition at repetitive elements is not well understood. H3.3 is typically 
enriched at transcriptionally active sites, which is believed to be a consequence of the 
inherent instability of nucleosomes containing H4-H3.3 dimers (Jin and Felsenfeld, 
2007). ATRX loss results in a failure to incorporate H3.3 and induces a DNA damage 
response at telomeres and PCH, suggesting that H3.3 incorporation is required to 
maintain stability of these elements (Goldberg et al., 2010; Huh et al., 2012; Watson et 
al., 2013; Wong et al., 2010). However, this idea is difficult to reconcile with the inherent 
instability of H3.3-containing nucleosome, which is consistent with the finding that 
ATRX facilitates RNA polymerase elongation through intragenic deposition of H3.3 in a 
small subset of genes that contain predicted G4-DNA structures (Levy et al., 2014). 
Transcription of repetitive elements is important for maintenance of heterochromatin 
(Buhler et al., 2007; Schoeftner and Blasco, 2009). Despite a failure to incorporate H3.3 
at telomeres and PCH in ATRX- or DAXX-depleted cells, there have been conflicting 
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reports of transcriptional dysregulation of pericentromeric and telomeric (TERRA) 
transcripts (Drane et al., 2010; Goldberg et al., 2010; Levy et al., 2014). A recent study 
demonstrated G2/M-specific upregulation of TERRA in HeLa cells depleted for ATRX 
(Flynn et al., 2015), providing an explanation for the discrepancies in earlier findings of 
TERRA regulation. Together these data suggest a potential role for ATRX in resolution 
of G4-DNA to facilitate transcriptional elongation and replication of heterochromatin 
(Figure 1-1b), however future efforts will be necessary to dissect the functional 
significance of ATRX/DAXX-dependent H3.3 incorporation at repetitive elements and 
other locations. 
ATRX and DAXX localize to promyelocytic leukaemia nuclear bodies (PML-NBs), 
which are subnuclear structures implicated in transcriptional activation, DNA replication, 
apoptosis, and viral infection (Bernardi and Pandolfi, 2007; Ishov et al., 1999; Ishov et 
al., 2004). PML-NBs can be found in most cell lines and tissue types; in a normal 
mammalian cell there are approximately 5-30 PML-NBs (Melnick and Licht, 1999). Over 
100 proteins have been associated with PML-NBs, many of which show dynamic 
localization (Weidtkamp-Peters et al., 2008). In contrast to heterochromatic localization, 
ATRX localization at PML-NBs is DAXX-dependent (Ishov et al., 2004). It is 
hypothesized that PML-NBs serve as platforms for heterochromatin remodeling post 
replication in G2 phase of the cell cycle, which is supported by the dynamic 
colocalization of ATRX/DAXX/H3.3, heterochromatin, and PML-NBs during this time 
(Chang et al., 2013; Ishov et al., 2004). Furthermore, PML-NBs have been suggested to 
be sites of H3.3 storage within the nucleus and function as a gathering point for proteins 
involved in replication-independent H3.3 assembly (Corpet et al., 2014). In fact, PML 
depletion results in dissociation of PML-NBs and decreased ATRX/H3.3 at telomeres, 
suggesting that the subnuclear structures are important for maintaining H3.3 at telomeres 
(Chang et al., 2013).  
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1.1.4 ATRX regulates DNA replication and cell division 
Subnuclear distribution of ATRX is cell cycle-dependent. As mentioned previously, 
ATRX is phosphorylated at the onset of mitosis resulting in its dissociation from the 
nuclear matrix (Berube et al., 2000). ATRX is enriched at DAPI-bright heterochromatin 
throughout all stages of the cell cycle (McDowell et al., 1999; Nan et al., 2007). ATRX 
localization at telomeres of embryonic stem (ES) cells occurs primarily during mid-to-
late S phase, which may indicate a specific requirement for ATRX in facilitating 
replication or remodeling of telomeric heterochromatin (Wong et al., 2010). This is 
consistent with its localization pattern in replicating myoblasts: pulse-labeling cells with 
the thymidine analog bromodeoxyuridine (BrdU) demonstrated colocalization of ATRX 
with large BrdU foci characteristic of late-replicating heterochromatin (Huh et al., 2012). 
Replication of heterochromatin and S phase progression are tightly interrelated (Quivy et 
al., 2008), which may explain the increased DNA damage response observed in late-
replicating chromatin and S phase lengthening of Atrx-null cells (Clynes et al., 2014; Huh 
et al., 2012; Watson et al., 2013). The mechanism of ATRX function in replication is not 
well characterized. A prevalent hypothesis is that ATRX resolves G4-DNA to allow 
progression of the replication fork through regions prone to forming the complex 
secondary structures, such as telomeres (Clynes et al., 2013; Gibbons and Higgs, 2010), 
which is supported by the finding that Atrx-null cells are sensitive to chemically induced 
G4 stabilization (Watson et al., 2013). However, there is also evidence to suggest a more 
direct function for ATRX in replication, as Atrx-null cells show reduced origin firing and 
ATRX interacts with components of the MRE11-RAD50-NBS1 (MRN) complex that 
facilitates replication fork restart (Clynes et al., 2014; Leung et al., 2013). The MRN-
ATRX interaction may occur in the context of telomeric chromatin, as the ataxia 
telangiectasia-mutated (ATM) kinase, MRN, and homologous recombination (HR) 
machinery are all recruited to newly replicated telomeres for reformation of the protective 
t-loop structure (Verdun et al., 2005; Verdun and Karlseder, 2006).  
Enrichment of ATRX at pericentromeric heterochromatin (PCH) and highly condensed 
mitotic chromosomes suggests a function for the protein during cell division (Berube et 
al., 2000; McDowell et al., 1999). Indeed, studies have demonstrated a requirement for 
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ATRX in both meiosis and mitosis (Baumann et al., 2010; De La Fuente et al., 2004; 
Ritchie et al., 2008; Ritchie et al., 2014). In human HeLa cells and mouse 
neuroprogenitors, ATRX loss causes chromosome congression defects and a prolonged 
prometaphase-to-metaphase transition that ultimately results in increased mitotic defects 
such as anaphase bridging and micronuclei formation (Ritchie et al., 2008; Ritchie et al., 
2014). In mouse oocytes, ATRX depletion disrupts alignment of chromosomes at the 
metaphase II spindle and causes defective chromosome cohesion, similarly resulting in 
micronuclei formation and centromere instability (Baumann et al., 2010; De La Fuente et 
al., 2004).  
Replicative stress, or DNA damage that occurs during replication, can be carried over 
into mitosis if the damage is not severe enough to induce checkpoint activation and cell 
cycle arrest (Wilhelm et al., 2014). Ultimately, this can result in abnormal cell division, 
as under-replicated regions of chromosomes remain physically joined and eventually 
break or shatter to cause micronuclei or chromothripsis, respectively (Crasta et al., 2012). 
Therefore, it is possible that the mitotic/meiotic defects associated with ATRX loss could 
be a consequence of increased stress during replication. However, replicative stress and 
increased DNA damage can also result from abnormal cell division (Ganem and Pellman, 
2012). It remains unclear whether ATRX deficiency causes replicative stress that 
precedes mitotic/meiotic dysfunction or vice versa. Nevertheless, there is ample evidence 
to conclude that ATRX is required throughout the cell cycle for both replication and cell 
division.  
 
1.1.5 Inherited hypomorphic ATRX mutations cause syndromic and 
non-syndromic intellectual disability 
The ATRX gene was originally identified through genetic linkage studies indicating that 
numerous mutations within the coding region of ATRX cause a rare mental retardation 
syndrome (ATR-X; OMIM#301040) characterized by a wide array of developmental 
abnormalities, alpha-thalassemia, and severe cognitive deficits (Gibbons, 1995). ATRX 
mutations have also been identified in patients with Chudley-Lowry (OMIM#303600), 
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Juberg-Marsidi, Carpenter-Waziri, and other less well-characterized X-linked intellectual 
disability (ID; OMIM#309580) (Abidi et al., 1999; Lossi et al., 1999; Villard et al., 1999; 
Villard et al., 1996). Interestingly, ATR-X syndrome is the first identified human disease 
caused by mutations in a chromatin remodeling factor, establishing the functional 
significance of epigenetic regulation in human disease pathogenesis (Gibbons et al., 
1997). 
Patients with ATRX mutations show profound intellectual disability (95% of patients), 
microcephaly (76%), seizures (35%), characteristic facial features (94%), skeletal 
abnormalities (90%), HbH inclusions (87%), and genital abnormalities (80%) (Gibbons 
and Higgs, 2000). Magnetic resonance imaging of ATR-X patients identified 
abnormalities in grey and white matter of the brain, implicating ATRX in the production 
of neuronal/glial cells and myelination, respectively (Wada et al., 2013). Modeling of 
patient mutations demonstrated that missense mutations often had little effect on protein 
levels, however point mutations affecting the zinc-coordinating cysteines, surface 
residues, and the structural core of the ADD domain resulted in a 50-90% reduction in 
ATRX levels, likely due to protein destabilization (Argentaro et al., 2007; McDowell et 
al., 1999).  
Our understanding of ATR-X pathogenesis has been aided through genotype-phenotype 
correlations. Over 95% of identified ATRX mutations lie within the conserved ADD and 
ATPase domains of ATRX, indicating that these domains are essential for correct 
function (Gibbons, 2006). The lack of identified mutations outside of these domains 
suggests that mutations elsewhere are non-viable or that regions outside of the ADD and 
ATPase domains are dispensable for ATRX function. Patient mutations in the ATPase 
domain of ATRX result in abnormal targeting to PML-NBs, implicating the subnuclear 
structures in disease pathogenesis (Berube et al., 2008). Additionally, patient mutations 
within the ADD domain result in abnormal targeting to heterochromatin (Eustermann et 
al., 2011; Iwase et al., 2011; Mitson et al., 2011). Together these data emphasize the 
importance of ATRX targeting to PML-NBs and heterochromatin, and indicate that 
defects in these pathways can contribute to ATR-X pathogenesis. Truncating mutations in 
the C-terminus consistently result in patients with severe urogenital abnormalities, 
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suggesting that this region may play a key role in urogenital development (Gibbons and 
Higgs, 2000). While genotype-phenotype correlations have been informative, there exists 
phenotypic variability even in patients with the same mutation: 15 unrelated individuals 
with the same mutations showed variable levels of HbH inclusions (Gibbons et al., 1997). 
Variability in the degree α-thalassemia presentation in ATR-X patients has been 
correlated with the length of the ψζ variable nucleotide tandem repeat (VNTR) adjacent 
to the α-globin gene cluster that is predicted to form G4-DNA structures and is enriched 
for ATRX binding in normal individuals (Law et al., 2010). This finding implies that 
ATRX is likely targeted to this VNTR sequence due to its propensity to form non-β G4-
DNA structures, and that it is required to prevent repression of nearby pathologically 
relevant genes. This function of ATRX may also have consequences for DNA replication 
and repair, as a failure to resolve G4-DNA could cause replication fork stalling and 
collapse into DNA double-strand breaks (DSBs) (Lipps and Rhodes, 2009). Indeed, 
ATR-X patient lymphocytes exhibited phosphorylation of the histone H2A variant H2AX 
(γH2AXS139) and of p53 (pp53S15), suggestive of an increased DNA damage response 
(Huh et al., 2012). 
The study of X-linked intellectual disability syndromes resulting from ATRX mutations 
has been pivotal in furthering our knowledge of ATRX function. These human disorders 
clearly demonstrate a requirement for ATRX in development of the brain, urogenital and 
skeletal systems, and provide evidence that ATRX is necessary for transcriptional 
regulation of the α-globin gene cluster. 
 
1.1.6 ATRX is required for mouse brain development 
The overt neurological dysfunction associated with human ATRX mutations implies a 
requirement for ATRX in brain development, maturation, and/or function. Mouse models 
have been useful in studying the effects of genetically altering ATRX levels globally and 
specifically in the brain.  
Overexpression of ATRX causes neurodevelopmental and craniofacial defects, 
suggesting that ATRX is required in correct stoichiometric amounts for normal 
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development (Berube et al., 2002). Forebrain-specific deletion of the full-length Atrx 
isoform causes increased p53-dependent apoptosis of neuroprogenitor cells (NPCs), 
resulting in decreased neonatal cortical size and hippocampal dysgenesis (Berube et al., 
2005; Seah et al., 2008). ATRX is required to specify the correct number of GABAergic 
interneurons and hippocampal dentate granule precursors, and this function contributes to 
the abnormal cortical and hippocampal development of forebrain-specific mutants (Seah 
et al., 2008). Generation of p53/ATRX double mutant mice effectively rescued apoptosis, 
however failed to completely restore neonatal forebrain size, indicating that ATRX 
functions outside of promoting cellular survival to regulate brain size (Seah et al., 2008). 
Indeed, Atrx-null NPCs exhibit premature differentiation into neurons, resulting in early 
depletion of the progenitor pool and a failure to sustain birth of late-born neurons (Ritchie 
et al., 2014).  
AtrxΔE2 mice were generated to mimic an ATR-X patient mutation and study the 
consequence of Atrx exon 2 deletion in brain development and function (Nogami et al., 
2011). AtrxΔE2 mice were smaller than controls, displayed normal spatial learning and 
memory by the Morris water maze test, and did not display any overt differences in brain 
morphology (Nogami et al., 2011). However, the AtrxΔE2 mice exhibited impaired 
contextual fear memory and long-term potentiation (LTP), which was attributed to 
aberrant activation of the LTP effectors calcium/calmodulin-dependent protein kinase II 
(CaMKII) and the glutamate receptor 1 (GluR1) in the hippocampus and medial 
prefrontal cortex, and associated with abnormal dendritic spines (Nogami et al., 2011; 
Shioda et al., 2011).  
Collectively, animal models of ATRX dysfunction have illustrated a requirement for the 
protein in both brain development and maturation and provide some insight into the 
mechanisms underlying developmental abnormalities, such as intellectual disability and 
microcephaly, associated with ATRX mutations.  
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1.1.7 Somatic ATRX loss-of-function mutations drive cancer 
progression 
The first clue that ATRX may be required to prevent malignancy came from the 
identification that alpha-thalassemia myelodysplasia syndrome, somatic (ATMDS; 
OMIM#300448), a rare pre-leukemic condition, is caused by acquired somatic ATRX 
mutations (Gibbons et al., 2003).  
Somatic ATRX loss-of-function mutations have been identified in numerous tumour types 
by exome sequencing, such as neuroblastoma, glioma, pancreatic neuroendocrine 
tumours (PanNETs), and paediatric osteosarcoma (Chen et al., 2014; Jiao et al., 2012; 
Jiao et al., 2011; Kannan et al., 2012; Liu et al., 2012; Molenaar et al., 2012; 
Schwartzentruber et al., 2012). The ATRX mutational landscape includes point mutations 
scattered throughout the coding sequence, as well as large deletions of the N terminus. 
Mutations in DAXX, a protein partner of ATRX, were also reported in the tumour 
subtypes but never overlapped ATRX mutations, implying that they function in the same 
pathway. ATRX/DAXX mutations commonly occurred in conjunction with mutations in 
the tumour suppressors p53 or IDH1 (Liu et al., 2012; Schwartzentruber et al., 2012). 
These findings invoke a model whereby epigenetic factors like ATRX may act as 
“backseat drivers” in a tissue-specific manner to suppress oncogenic pathways upstream 
of master regulators common to a broad range to tumours, like p53 (Elsasser et al., 2011). 
An inverse relationship between ATRX and macroH2A levels is associated with 
melanoma progression, and ATRX can interact with macroH2A to negatively regulate its 
deposition (Kapoor et al., 2010; Qadeer et al., 2014; Ratnakumar et al., 2012). Further 
analysis of the full spectrum of ATRX mutations in cancer and the different tumour 
subtypes that are defined based on ATRX/DAXX perturbations will help to uncover the 
mechanism underlying tumourigenesis stemming from mutations in these epigenetic 
factors.  
In addition to mutations in ATRX/DAXX, sequencing of paediatric glioma tumour samples 
identified K27M missense mutations in the gene encoding histone H3.3 (H3F3A) 
(Khuong-Quang et al., 2012; Schwartzentruber et al., 2012; Wu et al., 2012). This 
provides direct evidence that in addition to the proteins involved in the histone deposition 
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pathway, alterations in the histone proteins themselves can promote cancer. Analysis of 
the H3.3K27M mutant demonstrated alterations in genome-wide H3K27me3 levels 
through inhibition of the Polycomb repressive complex 2 (PRC2) enzymatic component 
EZH2 (Bender et al., 2013; Chan et al., 2013; Lewis et al., 2013). These findings are 
particularly intriguing given that ATRX is responsible for H3.3 deposition at specific 
genomic positions, and that ATRX interacts with EZH2 (Cardoso et al., 1998; Drane et 
al., 2010; Goldberg et al., 2010; Lewis et al., 2010; Sarma et al., 2014). Furthermore, the 
K27M mutation synergizes with p53 loss in neural progenitor cells resulting in neoplastic 
transformation (Funato et al., 2014). Together, the data suggests that the ATRX-DAXX-
H3.3 pathway may genetically interact with the PRC2-H3K27me3 pathway in cancer 
progression. 
A common theme in tumour samples with mutations in ATRX/DAXX is the appearance of 
the alternative lengthening of telomeres (ALT) phenotype (Bower et al., 2012; Heaphy et 
al., 2011a; Lovejoy et al., 2012; Schwartzentruber et al., 2012). Tumourigenesis, or 
uncontrolled cell growth, is limited by replicative senescence that occurs as a 
consequence of telomere shortening every S phase (Hastie et al., 1990). Most tumour 
cells overcome this hurdle by hijacking telomerase to maintain telomere length and 
suppress senescence (Counter et al., 1994). Interestingly, telomerase reverse transcriptase 
(TERT) promoter mutations that result in increased telomerase expression are mutually 
exclusive with ATRX mutations in glioma, suggesting that the growth advantage afforded 
by TERT mutation would be equivalent to that of ATRX mutation (Killela et al., 2013). 
Approximately 5% of human cancers will instead utilize the ALT pathway to lengthen 
their telomeres via homologous recombination (Cesare and Reddel, 2010). ALT is 
prevalent in specific cancer types that can arise from mutations in ATRX, such as 
osteosarcoma and glioma (Heaphy et al., 2011b), however the mechanism by which 
ATRX mutations result in the ALT phenotype and drive cancer progression is largely 
unknown. Although ATRX loss has been correlated with telomere dysfunction (Flynn et 
al., 2015; Goldberg et al., 2010; Huh et al., 2012; Watson et al., 2013; Wong et al., 2010), 
its loss is not sufficient to drive ALT (Clynes et al., 2014; Flynn et al., 2015; Lovejoy et 
al., 2012), suggesting that additional genetic or epigenetic changes are necessary to 
establish the phenotype. ATRX may function rather to poise telomeres for ALT, as its 
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loss results in persistent association of replication protein A (RPA) with telomeric 
ssDNA, a key intermediate of homologous recombination (HR), as well as increased 
TERRA levels at telomeres (Flynn et al., 2015). 
Interestingly, ALT is associated with the appearance of large PML-NBs (referred to as 
ALT-associated PML-NBs, or APBs) that contain telomeric DNA, the DNA repair MRN 
complex, replication factor A (RPA), and telomeric-repeat binding proteins TRF1 and 
TRF2 (Luciani et al., 2006; Wu et al., 2003; Wu et al., 2000; Yeager et al., 1999). The 
appearance of APBs is a robust marker for tumours that utilize ALT, and APBs rapidly 
assemble upon ALT induction (Costa et al., 2006; Henson et al., 2005; Perrem et al., 
2001), suggesting that APBs may be involved in the mechanism underlying ALT. This is 
intriguing since ATRX/DAXX/H3.3 are PML-associated factors and mutations in this 
pathway drive cancers with a high frequency of ALT. It is possible that defects in the 
ATRX/DAXX pathway results in a loss of heterochromatic features at telomeres, such as 
H3.3 enrichment, leading to increased homologous recombination rates that are 
associated with ALT activity, but it remains unclear as to how PML-NBs fit into this 
picture exactly.  
 
1.2 CTCF is a multifunctional and essential protein 
1.2.1 The CTCF gene and protein 
CCCTC-binding factor (CTCF) is a conserved zinc finger (ZF) DNA binding protein that 
can interact with highly divergent genomic targets through the combinatorial use of its 
eleven ZFs (Burcin et al., 1997; Filippova et al., 1996) (Figure 1-1a). The ZF domain of 
CTCF is 100% identical between human, mouse, and chicken, and the full-length protein 
shows 93% conservation across species (Filippova et al., 1996). CTCF is conserved in 
most bilaterial phyla but is absent in yeast, Caenorhabditis elegans and plants (Heger et 
al., 2012). The promoter of CTCF contains a binding site for the transcription factor ying-
yang 1 (YY1), and elements that are conserved in cell cycle-regulated genes (Klenova et 
al., 1998). In fact, CTCF mRNA levels oscillate during the cell cycle, peaking in S/G2 
phase, and decreasing in terminally differentiated cells (Delgado et al., 1999; Klenova et 
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al., 1998). Exons 2 to 8 contain the ZF domains, with several individual fingers being 
split between intron-exon boundaries (Ohlsson et al., 2001). The stop codon resides in 
exon 10, followed by a long 3’UTR that likely regulates CTCF translation (Klenova et 
al., 1997). The first 10 ZFs are typical units of 30 residues containing a pair of cysteines 
invariantly separated by 12 amino acids from the pair of histidines that inserts into the 
major groove of DNA (el-Baradi and Pieler, 1991; Klug and Schwabe, 1995). The 
eleventh C-terminal ZF is structurally similar to the friend of GATA (FOG) proteins that 
can interact with GATA-containing proteins (Fox et al., 1999).  
CTCF is a nuclear protein that is generally restricted from heterochromatin, and can 
interact with the nuclear matrix (Dunn et al., 2003). Unlike many other DNA-binding 
proteins, CTCF remains associated with chromatin during mitosis through its C-terminal 
domain (Burke et al., 2005), yet this appears to be locus-specific since CTCF binding is 
no longer detected at the MYC insulator element during this time (Komura et al., 2007). 
The molecular mass of CTCF is 82 kDa, however due to amino acid sequences in the N- 
and C-terminus, CTCF migrates aberrantly in SDS-PAGE gels at around 130 kDa, and 
truncation of the C-terminus results in a 70 kDa isoform (Klenova et al., 1997; 
Lobanenkov et al., 1990).  
CTCF was initially characterized as a transcription factor capable of activating or 
repressing gene expression in heterologous reporter assays (Baniahmad et al., 1990; 
Lobanenkov et al., 1990), and was later found to exhibit insulator activity (Bell et al., 
1999). Insulator proteins are capable of buffering position effect variegation caused by 
heterochromatin spreading (barrier activity) and/or the communication between cis 
regulatory elements, such as enhancers and promoters (enhancer blocker function) (Bell 
et al., 2001). Recently, however, the broad properties of CTCF and its ability to mediate 
long-range chromatin interactions have led to its description as an architectural rather 
than insulator protein per se (Ong and Corces, 2014).  
 
 
18 
 
 
Figure 1-2 The CTCF protein, binding partners, and model of function in genome 
organization 
(A) Structure of the CTCF protein. Nucleic acid-binding domains highlighted in orange 
and protein partners highlighted in purple text. Known sites of post-translational 
modification (SUMOylation and CKII-dependent phosphorylation) are indicated in 
green. Intellectual disability (ID)/autism patient mutations are indicated in pink (Gregor 
et al., 2013; Iossifov et al., 2014). (B) CTCF binding sites at TAD borders are potentially 
involved in organizing the domains (left), while binding sites within TAD interiors often 
colocalize with cohesin (orange ring) and facilitate gene expression by mediating 
interactions between distal enhancers (E) and promoters (P). Over 90% of chromatin 
loops are anchored by CTCF motifs in convergent orientation (Rao et al., 2014). 
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1.2.2 Regulation of CTCF functions 
The ZFs of CTCF are capable to binding to both DNA and protein; for example, ZFs 5-7 
mediate CTCF binding to the amyloid precursor protein (APP) promoter and the ZF 
domain also mediates CTCF interaction with the chromodomain helicase DNA binding 
protein 8 (CHD8) (Ishihara et al., 2006; Quitschke et al., 2000) (Figure 1-2a). Mapping of 
CTCF binding sites in numerous cell lines and tissues have provided functional insights: 
CTCF is enriched at ~55,000-65,000 sites in mammalian genomes with a genomic 
distribution of ~50% intergenic, ~35% intragenic, and ~15% at promoters (Chen et al., 
2012; Chen et al., 2008; Kim et al., 2007b). Of CTCF binding sites, ~5,000 are highly 
conserved between mammalian species and tissues and correspond to high affinity sites 
(Schmidt et al., 2012), while 30-60% of sites are cell-type specific and tend to exhibit low 
occupancy of CTCF (Barski et al., 2007; Chen et al., 2008; Essien et al., 2009; Kim et al., 
2007b). Paradoxically, CTCF is enriched at enhancer elements, which in stark contrast to 
its originally identified role as an enhancer-blocker, indicating that CTCF sites likely play 
different functional roles in a context-dependent manner and some sites may be involved 
in establishing cell type-specific transcriptional programs (DeMare et al., 2013; Song et 
al., 2011). Interestingly, CTCF binding sites are carried in transposable elements and 
evidence points to the expansion of repetitive elements as a driver of new CTCF binding 
events in diverse mammalian lineages (Bourque et al., 2008; Schmidt et al., 2012). 
CTCF binding sites contain a 12- to 20-bp consensus motif (Bell and Felsenfeld, 2000; 
Kim et al., 2007b), however the basis of CTCF recruitment to genomic sites is not well 
understood. The CTCF consensus motif is not present in all binding sites and not all such 
motifs bind CTCF (Kim et al., 2007b), suggesting that CTCF recruitment is more 
complicated. DNA methylation plays a widespread role in modulating CTCF binding: 
41% of cell type-specific CTCF binding events are linked to differential methylation 
concentrated at base pairs (bp) 1 and 11 of the consensus motif (Mukhopadhyay et al., 
2004; Wang et al., 2012). CTCF can also directly affect DNA methylation through 
interaction and activation of poly(ADP-ribose) polymerase 1 (PARP1), which inhibits 
DNA (cytosine-5)-methyltransferase 1 (DNMT1) through poly(ADP-ribosyl)ation 
(Guastafierro et al., 2008; Zampieri et al., 2012). Despite this, the presence of cell-type 
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specific CTCF binding sites that are not differentially methylated suggests additional 
mechanisms that affect CTCF occupancy. CTCF is typically located in nucleosome-
depleted linker regions surrounded by well-positioned nucleosomes, suggesting that 
nucleosome phasing is an essential upstream factor that regulates CTCF enrichment 
(Cuddapah et al., 2009; Fu et al., 2008). This idea is supported by evidence that CTCF 
recruitment or maintenance at the H19-Igf2 and Gtl2-Dlk1 ICRs requires local 
nucleosome remodeling by ATRX (Kernohan et al., 2014). Furthermore, the interaction 
of CTCF and CHD8 suggests that CHD8 may facilitate local chromatin remodeling to 
mediate CTCF binding, however this idea has not been tested experimentally (Ishihara et 
al., 2006). While DNA methylation and nucleosome phasing are important regulators of 
CTCF binding, it is likely that additional contributing mechanisms have not yet been 
identified. 
The addition of covalent post-translational modifications has been linked to differential 
binding and functions of CTCF. For instance, CTCF itself can be poly(ADP-ribosyl)ated, 
which has been linked to its insulator (Yu et al., 2004) and barrier functions (Witcher and 
Emerson, 2009), as well as subnuclear localization (Guastafierro et al., 2013; Ong et al., 
2013; Torrano et al., 2006). Four serines in the C-terminus of CTCF are phosphorylated 
by casein kinase II (CKII; Figure 1-2a), potentiating its growth suppressive functions 
(Klenova et al., 2001). Interestingly, mutation at this same motif present in the p53 
tumour suppressor protein abrogates its growth inhibition function, and selective 
phosphorylation of the motif is regulated in response to genotoxic stress by the CKII-
FACT (facilitates chromatin transcription) complex (Keller et al., 2001; Milne et al., 
1992). The PC2 small ubiquitin-like modifier (SUMO) ligase can SUMOylate residues in 
the N-terminus of CTCF, contributing to its repression of MYC transcription without 
affecting its ability to bind DNA (MacPherson et al., 2009) (Figure 1-2a). Together, 
analysis of CTCF post-translational modifications demonstrates the complexity of CTCF 
regulation. 
Interactions between CTCF and other proteins may also represent an additional 
mechanism by which the protein achieves functional diversity (Zlatanova and Caiafa, 
2009). CTCF interacts with the large subunit of RNA polymerase II (RNAPII) through its 
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C terminal domain (Figure 1-2a) and intragenic peaks of RNAPII overlap sites of CTCF 
enrichment (Chernukhin et al., 2007; Wada et al., 2009).  Functionally, this may be a 
consequence of a role for CTCF in promoting polymerase pausing, rather than 
recruitment per se, since on a global scale CTCF binding has been implicated in 
generating a “poised” promoter state (promoter-proximal pausing) and in the pre-mRNA 
processing decisions associated with alternative splicing (Paredes et al., 2013; Shukla et 
al., 2011). In addition to RNAPII, CTCF can interact with numerous protein partners 
such as zinc finger protein 143 (ZNF143), the Kaiso transcription factor, nucleophosmin, 
lamin A/C, ying yang 1 (YY1), and CHD8 to name a few (Zlatanova and Caiafa, 2009) 
(Figure 1-2a). Further complicating this issue is the recent finding that the C-terminus of 
CTCF can interact with RNA, which is important for its role in transcriptional regulation 
of p53, X chromosome inactivation, and in stabilizing protein-protein interactions (Kung 
et al., 2015; Saldana-Meyer et al., 2014; Sun et al., 2013; Yao et al., 2010) (Figure 1-2a). 
RNA-immunoprecipitation followed by high throughput sequencing (RIP-sequencing) 
identified that CTCF can interact with ~15,000 different RNA species (Kung et al., 2015; 
Saldana-Meyer et al., 2014), indicating that the interaction likely represents a more 
widespread mechanism of CTCF function.  
While the aforementioned partners can influence CTCF activities at specific loci, a 
pervasive relationship has been established with the cohesin complex (Parelho et al., 
2008; Rubio et al., 2008; Wendt et al., 2008). The cohesin complex is composed of four 
subunits: the structural maintenance of chromosomes 1 (SMC1) and SMC3, radiation 
mutant 21 (Rad21), and stromal antigen 1 or 2 (SA1 or SA2), and was initially 
characterized as being required for sister chromatid cohesion during mitosis (Barbero, 
2011; Michaelis et al., 1997; Moser and Swedlow, 2011; Uhlmann and Nasmyth, 1998). 
The high degree of overlap between cohesin and CTCF binding sites genome-wide 
suggests a functional relationship: depending on the cell type, ~50-80% of CTCF binding 
sites are co-occupied by cohesin, and there is a mutualistic relationship between their 
binding (Parelho et al., 2008; Rubio et al., 2008; Wendt et al., 2008). By-and-large CTCF 
is required for cohesin recruitment, while cohesin appears to be required to stabilize most 
CTCF-mediated chromosomal contacts and to be essential for CTCF function at most 
genomic sites (Hou et al., 2010; Nativio et al., 2009). Physical interaction of the proteins 
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occurs between the SA1/2 subunit of cohesin and the C terminus of CTCF (Xiao et al., 
2011) (Figure 1-2a). Despite this close relationship, evidence suggests that the 
CTCF/cohesin interaction is independent from cohesin’s role in mediating sister 
chromatid cohesion, as CTCF-depleted cells do not exhibit cohesion defects (Parelho et 
al., 2008).  
 
1.2.3 CTCF regulates higher-order chromatin organization  
CTCF can mediate long-range intra- and inter-chromosomal interactions in mammalian 
cells (Kurukuti et al., 2006; Ling et al., 2006; Splinter et al., 2006) (Figure 1-2b). This 
function of CTCF is best characterized at the imprinted H19-Igf2 locus where allele-
specific binding of CTCF at the maternal H19 ICR results in expression of H19 and 
paternal expression of Igf2 through physical interactions with the differentially 
methylated regions upstream of the Igf2 promoter (Kurukuti et al., 2006; Murrell et al., 
2004). CTCF is also required for interchromosomal interaction between the H19-Igf2 and 
Wsb1/Nf1 imprinted clusters (Ling et al., 2006), which is thought to help establish co-
regulation of an imprinted gene network (Andrade et al., 2010; Kernohan and Berube, 
2010; Varrault et al., 2006).  
The discovery that CTCF interacts with the cohesin ring complex led to a model wherein 
long-range interactions mediated by CTCF are clamped together and stabilized by 
cohesin (Haering et al., 2008; Ohlsson et al., 2010b) (Figure 1-2b). This matches with the 
finding that CTCF binding to the DNA duplex asymmetrically bends the DNA but is 
unable to form a loop alone (Liu and Heermann, 2015). Indeed, cohesin is required for 
higher-order chromosome conformation at H19-Igf2 (Nativio et al., 2009) and many 
other sites co-occupied with CTCF (Merkenschlager and Odom, 2013). Despite this, it 
remains unclear whether CTCF and cohesin work independently or in concert to define 
loop interactions; in general, cohesin depletion affects larger loops (100-200 kb 
interaction range), while CTCF depletion affects shorter loops (<100 kb) (Zuin et al., 
2014). Moreover, CTCF depletion resulted in a gain of chromatin interactions (Zuin et 
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al., 2014), further complicating our understanding of the mechanisms underlying genome 
organization. 
Hi-C maps of global chromatin interactions have identified that the genome is partitioned 
into large (~1 Mb) domains referred to as topologically associating domains (TADs) that 
are defined based on a higher interaction frequency within domains that between domains 
(Dixon et al., 2012; Lieberman-Aiden et al., 2009). Intriguingly, domain boundaries are 
enriched for housekeeping genes, short interspersed elements (SINEs), and CTCF 
binding sites in convergent orientation, implicating these features in the establishment of 
TADs (Dixon et al., 2012; Rao et al., 2014) (Figure 1-2b). CTCF depletion does not 
dramatically alter global domain organization, suggesting that it is likely not the sole 
determinant of TAD formation (Zuin et al., 2014). However, deletion of specific CTCF 
binding sites on the X chromosome or within the HoxA cluster results in structural TAD 
reorganization, indicating that at least in some contexts CTCF is required to delimit TAD 
boundaries (Nora et al., 2012). The influence of CTCF on other features regulated by 
TAD organization, such as replication timing (Pope et al., 2014), has yet to be 
characterized. 
Chromatin interaction analysis by paired-end sequencing (ChIA-PET) analysis of CTCF-
mediated chromatin interactions in ES cells identified ~1,800 interactions involving 
~3,300 CTCF binding sites (~5-10% of total CTCF binding sites). In contrast to its 
characterized role as an insulator protein, the majority of CTCF/cohesin sites facilitate 
enhancer-promoter interactions (Handoko et al., 2011; Sanyal et al., 2012). The finding 
that only a small proportion of CTCF sites are involved in higher-order interactions 
suggests additional DNA-dependent functions for CTCF. Furthermore, the average cell 
contains ~200,000 CTCF molecules but only ~30,000-60,000 CTCF binding sites, 
perhaps indicating DNA-independent functions for the protein as well (Heath, 2007).  
Together, global analysis of chromatin interactions in the context of CTCF binding 
suggests that enhancer blocking or barrier insulation activities of CTCF may only occur 
in a context-dependent manner as a consequence its primary role in mediating long-range 
interactions (Handoko et al., 2011; Phillips-Cremins et al., 2013; Sanyal et al., 2012) 
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(Figure 1-2b). Analysis of CTCF function in TAD architecture is still in its infancy, but 
emerging technologies to study large-scale chromatin interactions such as Hi-C and 
ChIA-PET will indisputably uncover the functional significance of higher-order genome 
organization. 
1.2.4 Evidence of CTCF function during replication   
In addition to its well-characterized functions in transcriptional regulation, transcription-
independent roles for CTCF have also been described in the literature.  For instance, 
CTCF regulates stability of numerous regions implicated in trinucleotide repeat 
expansion disorders such as spinocerebellar ataxia type 7 (SCA7) and myotonic 
dystrophy type I (DM1) (Filippova et al., 2001; Libby et al., 2008; Sopher et al., 2011). 
At the DM1 locus, CTCF binding upstream of the repeat is required to slow DNA 
polymerase before replication of the repetitive tract, and mutations in the CTCF binding 
site results in repeat expansion likely due to strand slippage (Cleary et al., 2010). 
Intriguingly, DM1 is asymmetrically replicated (Rajcan-Separovic 1998) and CTCF 
regulates asymmetric replication of the H19/Igf2 imprinted domain (Bergstrom et al., 
2007). Therefore, the effect of CTCF on replication may be limited to certain loci, as 
direct roles for the protein have only been described at asymmetrically replicated regions.  
CTCF has also been implicated in replication origin firing, as overexpression of the 
oncogenic replication licensing factor Cdc6 causes CTCF dissociation from the 
promoters of the tumour-suppressor genes CDH1 and INK4/ARF, resulting in reduced 
expression and activation of adjacent replication origins (Sideridou et al., 2011). It was 
suggested that because replication origins are defined by structural chromatin context 
rather than DNA sequence (Antequera, 2004; Cvetic and Walter, 2005), CTCF might 
facilitate higher-order organization of replication origins.  
The CTCF partner cohesin is implicated in organizing replication factories and 
controlling S phase progression, however CTCF depletion had little effect on cell cycle 
dynamics or the overall size of replicon units identified by the DNA halo assay (Guillou 
et al., 2010). A more global role for CTCF in DNA replication and/or organizing 
replication factories has not yet been thoroughly investigated, but is of interest given the 
importance of CTCF in replication timing, progression, and origin firing at individual 
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loci. Furthermore, the finding that TADs regulate replication timing suggests that CTCF 
may participate in this process if indeed CTCF is involved in orchestrating TAD 
organization (Dixon et al., 2012; Pope et al., 2014) (Figure 1-3). 
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Figure 1-3 The relationship between chromosome territory organization in the 
nucleus, topologically associating domains (TADs), and replication timing 
(Left) Chromosome territory organization within the nucleus represented by four 
chromosomes of different colours for simplicity. (Right) The replication domain model 
described in (Pope et al., 2014): TADs within the nuclear interior (green) actively fire 
origins and replication proceeds passively into TADs at the nuclear exterior (red). CTCF 
(yellow) binding at TAD borders is shown. 
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1.2.5 In vivo functions of CTCF 
Most of our knowledge of CTCF activities has been derived from in vitro studies using 
immortalized cell lines (Ohlsson et al., 2010a), yet CTCF function has rarely been 
approached in an organismal context. Using transgenic RNA interference (RNAi), 
Fedoriw and colleagues demonstrated that both zygotic and maternal stores of CTCF are 
essential for preimplantation development (Fedoriw et al., 2004; Wan et al., 2008). These 
studies also indicated a requirement for CTCF in cellular survival since CTCF depletion 
caused meiotic and mitotic defects that culminated in apoptosis (Wan et al., 2008). 
Generation of a Ctcf-null allele (Ctcf-/-) confirmed the essential nature of CTCF in early 
development, as homozygous mutants are lethal prior to E3.5 (Heath et al., 2008). 
Heterozygotes (Ctcf+/-) are viable, fertile, and do not exhibit any overt phenotypes, 
however the decreased ratio of wild type to heterozygote mice suggests that 
heterozygosity of Ctcf does compromise survival to some extent (Heath et al., 2008). 
Tissue-specific deletion of CTCF has yielded more insight into its function in 
development and has pointed to an essential role for the protein in cell survival and cell 
cycle progression. For instance, Ctcf deletion in the developing limb bud resulted in 
upregulation of the pro-apoptotic p53 upregulated modulator of apoptosis (PUMA), 
massive apoptosis, and a complete loss of forelimb structure (Soshnikova et al., 2010), 
while deletion of Ctcf in post-mitotic neurons did not cause apoptosis (Hirayama et al., 
2012). Deletion of Ctcf in T cells resulted in a decreased number of cells, suggestive of 
increased cell death, and caused a cell cycle block due to transcriptional upregulation of 
p21 and p27 (Heath et al., 2008).  
A requirement for CTCF in neuron-specific gene expression programs has recently been 
demonstrated (Chang et al., 2010; Hirayama et al., 2012). Brain derived neurotrophic 
factor (BDNF) is a critical mediator of neurogenesis, synaptic plasticity, and neuronal 
survival (Greenberg et al., 2009). Methylation-sensitive binding of CTCF to the Bdnf 
gene is required for its activity-dependent transcriptional activation (Chang et al., 2010). 
Additionally, CTCF is an important transcriptional regulator of the protocadherin cluster 
of genes (Hirayama et al., 2012). Protocadherins are largely expressed in the nervous 
system and encode cell adhesion molecules located at the pre- and post-synaptic 
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membrane. Cells express variable sets of protocadherin proteins, and each set may serve 
as a molecular barcode for neuron identity (Frank and Kemler, 2002). Therefore, at least 
in neurons, CTCF is required for the establishment of transcriptional programs that help 
to shape individual cell-specific identity (Dekker, 2012).   
 
1.2.6 CTCF mutations linked to cancer and neuropsychiatric disease 
Few human CTCF mutations have been reported, which likely reflects the essential 
nature of the protein (Fedoriw et al., 2004; Heath et al., 2008; Moore et al., 2012; Wan et 
al., 2008; Watson et al., 2014). Chromosomal deletion at 16q22.1, however, is well 
documented in several human cancers and is one of the most common genetic events in 
breast cancer (Filippova et al., 1998; Rakha et al., 2006). CTCF maps to 16q22.1 and has 
been demonstrated to function as a haploinsufficient tumour suppressor in mice, as Ctcf+/- 
mice are susceptible to spontaneous and chemical/radiation-induced tumours of 
epithelial, mesenchymal, and hematopoietic origin (Kemp et al., 2014). Furthermore, 
analysis of ~5,000 tumours across 21 cancer types revealed that CTCF was one of the 
most frequently mutated genes (Lawrence et al., 2014). A high proportion (21%) of 
CTCF mutations identified in human cancers were missense mutations in the ZF domain 
predicted to alter DNA sequence recognition, implicating this domain in the suppression 
of tumourigenesis (Kemp et al., 2014). Together, these data implicate a broad role for 
CTCF in tumour suppression, yet the mechanism of CTCF function in cancer prevention 
is not fully understood. Hemizygous loss of Ctcf destabilized DNA methylation in mouse 
tumours, however it remains unclear as to whether this is a direct or secondary cause of 
CTCF loss (Kemp et al., 2014).  
Recently, de novo mutations in CTCF were identified in patients with intellectual 
disability (ID), microcephaly, and autistic features (Gregor et al., 2013; Iossifov et al., 
2014) (Figure 1-2a) and single nucleotide polymorphisms at the CTCF locus have been 
associated with schizophrenia (Juraeva et al., 2014). This adds to the growing list of 
epigenetic regulators implicated in neuropsychiatric disease and suggests that CTCF 
function is particularly important in the developing brain, as evidence suggests that 
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autism and schizophrenia are developmental in origin (Cook and Scherer, 2008; 
Guilmatre et al., 2009; Millan, 2013; Mitchell, 2011; Pinto et al., 2014; Sebat et al., 
2009). Since there have been very few patients identified with CTCF mutations it is 
difficult to generate conclusions based on genotype-phenotype correlations. However, 
one patient has a missense mutation (R567W) located in the eleventh ZF that does not 
affect mRNA or protein levels, implicating abnormal targeting of CTCF in the 
pathogenesis of ID (Gregor et al., 2013). Identification of the full spectrum of CTCF 
mutations in the human population will undoubtedly expand our understanding of CTCF 
function and the pathogenesis of ID.  
   
1.3 The regulation of higher-order chromatin structure 
1.3.1 Higher-order chromatin architecture 
Nuclear architecture is a key regulator of transcription, replication, and repair (Misteli, 
2007). The term nuclear architecture refers to higher-order chromatin structure, nuclear 
compartments, and non-random spatial genome organization (Bickmore and van 
Steensel, 2013). Nuclear compartmentalization has been shown to be critical in the 
regulation of DNA metabolism: for instance, artificial tethering of genes to the nuclear 
periphery results in transcriptional silencing (Finlan et al., 2008; Reddy et al., 2008), and 
nuclear positioning has been linked to replication timing (Gilbert, 2001; Pope et al., 
2014). 
The fundamental unit of chromatin is the nucleosome, which is comprised of ~147 base 
pairs of DNA wrapped around a (H3-H4)2-(H2A-H2B)2 histone octamer. The 
nucleosome is organized into a fiber, which is further condensed to generate 
chromosomes. Within the nucleus chromosomes occupy distinct territories, and 
chromatin folds in cis to mediate interactions between regulatory elements as well as 
bring genomic regions from long distances or different chromosomes into close spatial 
proximity for co-regulation (Cremer and Cremer, 2001). Large-scale genome 
organization was later confirmed by 3C-based experiments, demonstrating that different 
chromosomes display different propensity to form inter-chromosomal interactions: 
30 
 
chromosomes of similar size and density have a higher likelihood of interaction 
(Lieberman-Aiden et al., 2009; Zhang et al., 2012). Nuclear compartments differ with 
regards to chromatin and genic features: DNAse I hypersensitive, active, and gene-rich 
loci cluster together and are separate from gene-poor, transcriptionally silent chromatin 
(Lieberman-Aiden et al., 2009; Zhang et al., 2012). The compartments primarily appear 
to relate to gene expression and as such are cell-type specific.  
Chromosome compartments are further organized into domains of 100 kb-1 Mb that are 
topologically separated from one another (TADs) and flanked by insulators (Dixon et al., 
2012; Rao et al., 2014; Sexton et al., 2012). As opposed to chromosome territories, which 
are related to gene expression, TADs are largely conserved across cell types (Dixon et al., 
2012; Nora et al., 2012). Deletion of a TAD boundary region in the X chromosome 
inactivation center resulted in partial fusion of the flanking TADs, suggesting that TAD 
boundaries are genetically defined (Nora et al., 2012). This, in conjunction with the 
finding that TAD boundaries are enriched for particular genomic features i.e. CTCF 
binding sites (Dixon et al., 2012), begs the question of whether specific elements are 
involved in the formation of TADs (Figure 1-3). 
Global comparisons between genome topological organization and replication timing 
programs support a model that TADs (i.e. regions of the genome that interact with 
themselves more often than they interact with neighbouring regions) regulate replication 
timing (Dixon et al., 2012; Pope et al., 2014) (Figure 1-3). Since CTCF has been 
implicated in the establishment of TADs, it may play an important role in regulating the 
replication timing program (Dixon et al., 2012). Depletion of Ctcf by RNAi resulted in 
subtle relaxation of TAD organization and increased inter-TAD interactions (Zuin et al., 
2014), however the consequences of these changes on global replication timing are 
unknown and the effects of complete CTCF loss rather than depletion have not been 
assessed. CTCF is necessary for asynchronous replication of the H19-Igf2 imprinted 
domain, demonstrating that it is important for replication timing in some capacity 
(Bergstrom et al., 2007).  
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The significance of higher-order chromatin organization and TAD formation is not well 
understood, however the finding that compartments are correlated with transcription and 
that domains are units of DNA replication suggests functional importance (Markaki et al., 
2010; Pope et al., 2014). 
 
1.3.2 Interplay between CTCF, cohesin and ATRX 
The first indication of a relationship between ATRX and cohesin was the finding that 
ATRX depletion in HeLa cells causes chromosome cohesion defects (Ritchie et al., 
2008). An interaction between ATRX and the SMC1 and SMC3 subunits of cohesin can 
be detected by co-immunoprecipitation in neonatal mouse brain extracts (Kernohan et al., 
2010), and recruitment of CTCF and cohesin to imprinting control regions is dependent 
on nucleosome-remodeling activities of ATRX (Kernohan et al., 2010; Kernohan et al., 
2014). Preliminary analysis of ATRX-dependent CTCF recruitment indicates that ATRX 
is required for enrichment at a number of sites in the postnatal mouse brain (Levy et al., 
unpublished data), raising the intriguing possibility that ATRX may help recruit CTCF to 
specific sites through nucleosome remodeling and/or interaction with the cohesin 
complex.  
 
1.4 Genome stability in the context of brain development 
1.4.1 The response to DNA damage 
The genome is constantly bombarded with sources of stress, both exogenous and 
endogenous, that can result in the accumulation of genetic lesions (Ciccia and Elledge, 
2010). It is estimated that tens of thousands of damaging events occur daily in each cell 
(De Bont and van Larebeke, 2004). Chemotherapeutic agents, ultra-violet (UV) radiation 
from the sun, and other frequencies of radiation such as x- and gamma (γ)-rays, are all 
examples of exogenous sources of DNA damage, while damage can also result from 
endogenous sources such as replication errors and oxidative stress caused by metabolic 
by-products (Mirkin and Mirkin, 2007; Ward, 1988). The type of damage lesion can vary 
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widely from single- to double-strand breaks, interstrand cross-links, and base 
modifications i.e. alkylation, depurination, oxidation. The strategy for repair depends on 
the type and location of the lesion as well as cell cycle stage. The cell has evolved a 
complex DNA damage response (DDR) that is responsible not only for detection and 
repair of damage, but also to coordinate repair with other cellular processes such as 
chromatin remodeling, transcription, cell-cycle progression, and apoptosis (Jackson and 
Bartek, 2009). Following detection of DNA damage, genome surveillance pathways 
become activated to block progression through the cell cycle in order to repair damaged 
DNA prior to cell division and ensure that daughter cells do not inherit the damage. 
The most common type of lesion is likely single-strand breaks (SSBs), which can occur 
during base excision repair (BER) or from abortive topoisomerase I (TOP1) reactions 
(Caldecott, 2008). TOP1 generates a nick, also known as a cleavage complex 
intermediate, to relax DNA during transcription and replication (Wang, 2002). These 
intermediates are usually transient and rapidly resealed by TOP1, however collision with 
DNA/RNA polymerases can convert them into TOP1-linked SSBs (Pommier et al., 
2003). Repair of single-strand breaks requires the generation of a 3’ hydroxyl and 5’ 
phosphate compatible for ligation by a DNA ligase, such as DNA ligase 1 (LIG1). Base 
modifications, such as oxidation or alkylation, are another common source of DNA 
damage. Organs with high metabolic demand, such as the brain, are particularly 
vulnerable to oxidative base modifications caused by reactive oxygen species (ROS), 
such as 8-oxo-dG (Iyama and Wilson, 2013). Oxidative lesions are repaired by the base 
excision repair (BER) pathway, in which DNA glycosylases cleave the N-glycosidic 
bond of modified bases (Lindahl, 1974) and processing occurs through the action of 
APE1, DNA polymerase β, and XRCC1 (Hegde et al., 2008; Mitra et al., 2001). 
Structural distortions of the DNA, such as “bulky” pyrimidine dimers and DNA adducts 
are repaired by nucleotide excision repair (NER). NER can be broadly characterized into 
global-genome NER, which scans the genome for helix-distorting lesions, and 
transcription-coupled NER, which is activated in response to damage on the transcribed 
stand of active genes (de Laat et al., 1999). Both BER and NER utilize the same general 
program: detection, excision, gap-filling synthesis, and ligation (Kamileri et al., 2012a).  
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DNA damage associated with replication, commonly referred to as replication stress, 
requires signaling of the ATM and Rad3 related (ATR) kinase, which responds to 
replication protein A (RPA)-coated ssDNA found at stalled or collapsed replication forks 
(Cimprich and Cortez, 2008) (Figure 1-4). Interstrand cross-link repair and mismatch 
repair also function to overcome errors that can occur during DNA replication (Deans 
and West, 2011; Jiricny, 2006). Replication-associated damage and other sources of 
endogenous damage will be further discussed in Section 1.4.3. 
The most deleterious form of DNA damage is a double-strand break (DSB) since they 
can result in the loss of a substantial amount of genetic information and/or cause large 
chromosomal rearrangements that can lead to cell death or tumourigenesis. DSBs can 
arise endogenously as a result of abortive topoisomerase II activity, replication fork 
collapse, and even neuronal activity (Gomez-Herreros et al., 2013; Nitiss, 2009; Saleh-
Gohari et al., 2005; Suberbielle et al., 2013), as well as exogenous sources such as 
ionizing radiation and chemotherapy agents (Jekimovs et al., 2014; Ward, 1988). DSBs 
are detected by the MRN complex, which promotes recruitment of repair factors and 
activation of cell cycle checkpoints through activation of the ATM kinase (Stracker and 
Petrini, 2011) (Figure 1-4). The strategy of repair is dependent on cell cycle stage: while 
the majority of DSBs are repaired through non-homologous end joining (NHEJ), the 
extra copy of genetic information that exists in S/G2-phase cells allows for homology-
directed repair (also referred to as homologous recombination; HR) (Lombard et al., 
2005). In NHEJ, DSB ends are recognized by Ku70/Ku80 heterodimers that recruit and 
activate the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs), which 
facilitates recruitment of end processing proteins that prepare the DNA ends for ligation 
by DNA ligase IV (Waters et al., 2014). Deletions can be introduced during the end 
processing stage of NHEJ, making this type of repair strategy error-prone. HR, however, 
is virtually error-free since it utilizes the homologous sister chromatid as a template for 
repair. HR repair is initiated through dsDNA end resection to generate 3’ ssDNA end on 
which the RAD51 recombinase is loaded, resulting in invasion of a homologous DNA 
duplex that primes DNA synthesis and DNA polymerase-mediated copying of the intact 
DNA molecule (Li and Heyer, 2008). Many other molecules also play key roles in HR 
repair, such as breast cancer 1, early onset (BRCA1) and BRCA2, Rad54, and XRCC2 
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(Chen et al., 1999; Liu et al., 1998). Furthermore, the cohesin complex is important for 
activation of DNA damage-induced intra-S phase and G2/M checkpoints downstream of 
DSB signaling (Kim et al., 2002; Luo et al., 2008; Qiu et al., 2015; Watrin and Peters, 
2009; Yazdi et al., 2002), and replication-associated cohesion generated by cohesin is 
required for post-replicative HR repair (Sjogren and Nasmyth, 2001). This role of cohesin 
has not been investigated with respect to its interaction with CTCF or ATRX.  
The DNA damage repair and response cascade is an energy-consuming process that can 
in itself perturb cellular homeostasis if over activated. It is estimated that 104 ATP 
molecules are required to repair one DSB (Hoeijmakers, 2009), and PARP1 activation 
during the DDR can lead to nicotinamide adenine dinucleotide (NAD+) depletion, 
disrupting NAD-dependent enzymes like sirtuins and/or promote cell death through the 
release of apoptosis-inducing factor (AIF) (Alano et al., 2010). Timely and accurate 
repair of DNA damage is therefore essential for cellular survival and homeostasis. 
Cell cycle arrest and apoptotic pathways are largely intertwined, and the p53 protein is an 
upstream master regulator of both facets of tumour suppression (Lane, 1992) (Figure 1-
4). DNA damage, oncogene activation, hypoxia, and oxidative stress are cellular stressors 
that induce activation of p53, a transcription factor that binds to target gene promoters in 
a sequence-specific manner (Kern et al., 1991). The cellular outcome of the p53 pathway 
is contingent on the target activated: p21 is a major mediator of p53-dependent cell cycle 
arrest (Vogelstein et al., 2000), while Puma is responsible for apoptotic activation 
downstream of p53 (Jeffers et al., 2003; Villunger et al., 2003) (Figure 1-4). p21 induces 
cell cycle arrest by inhibiting cyclin D/cyclin-dependent kinase (Cdk) 4, 6 and cyclin 
E/Cdk2 complexes, resulting in retinoblastoma (Rb) hyperphosphorylation and arrest at 
the G1/S phase transition (Stewart and Pietenpol, 2001). G2 phase arrest can also be 
mediated by p21-dependent inactivation of cyclin B1 and Cdc2 (Flatt et al., 2000; 
Innocente et al., 1999). PUMA promotes cell death through BAX activation, resulting in 
apoptosis-inducing factor and cytochrome c release from the mitochondria and activation 
of the caspase cascade (Sionov and Haupt, 1999). 
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Figure 1-4 Cellular response to telomere uncapping, DNA double-strand breaks 
(DSBs), and replication stress 
In the CNS, telomere uncapping results in ATR-to-ATM signaling, checkpoint activation 
and cell cycle arrest or apoptotic induction (Lee et al., 2014). DSBs cause MRN 
activation, resulting in ATM-dependent signaling (pATMS1981) to induce cell cycle 
arrest via Chk2 (pChk2T68) activation or p53-dependent apoptosis (pp53S18). 
Replicative stress typically causes an accumulation of RPA (pRPAS33), which activates 
ATR-dependent checkpoint activation via Chk1 (pChk1S317/345) or apoptotic induction 
via p53 (pp53S18). Genotoxic stress-induced apoptosis in neuroprogenitor cells is 
primarily mediated by p53-dependent transcriptional induction of Puma (Jeffers et al., 
2003). Incorporation and phosphorylation of H2AX (S139; γH2AX) is a common event 
in response to many types of damage and is mediated by ATM and ATR kinases.   
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1.4.2 DNA damage response and repair in the context of chromatin 
Since virtually all DNA damage occurs in the context of chromatin, interplay between 
higher-order chromatin structure and the DDR is crucial for timely detection and repair of 
damage. Historically, chromatin has been viewed as a barrier that has to be alleviated 
during repair and then restored afterwards (Smerdon, 1991). However, chromatin 
components have also been shown to promote DNA damage repair and signaling, 
resulting in the proposition of a “prime-repair-restore” model that suggests a more active 
role for chromatin in the DDR (Soria et al., 2012). 
Several types of chromatin remodeling are important for DNA repair such as chaperone-
mediated incorporation of histone variants, histone post-translational modifications, and 
ATP-dependent chromatin remodeling. There is also crosstalk between these 
mechanisms, as ATP-dependent chromatin remodeling is necessary for nucleosome 
eviction to allow for histone chaperone-mediated deposition of variants, underscoring the 
complexity of chromatin contributions to the DDR. Histone variants and modifications 
can function to organize and/or stabilize DNA repair machinery, and chromatin can also 
help to restrain transcription and signaling at the site of damage. Furthermore, higher-
order 3D chromatin architecture likely plays an important role in facilitating repair, at the 
very least HR repair, although this has not yet been intensely studied. 
The most well-characterized histone variant and modification in the context of the DDR 
is phosphorylation of histone H2A variant H2AX at serine 139 (γH2AX) by the PI-3 
kinases ATM, ATR, or DNA-PK (Kinner et al., 2008). The FACT (facilitates chromatin 
during transcription) complex is responsible for deposition of H2AX (Heo et al., 2008). 
Immediately following induction of a DSB, γH2AX can be detected at the site of damage, 
which eventually spans at least a megabase of chromatin surrounding the break 
(Nakamura et al., 2010; Rogakou et al., 1998) (Figure 1-4). Spreading of γH2AX is a 
discontinuous process influenced by both transcription (Iacovoni et al., 2010) and cohesin 
binding (Caron et al., 2012). The DNA repair process manifests cytologically as DNA 
repair foci that are formed by the recruitment and accumulation of DNA repair factors at 
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sites of DNA damage. γH2AX is a major constituent of DNA repair foci, and serves as a 
beacon for the assembly of repair factors and to coordinate the DDR with other cellular 
functions such as cell cycle arrest (Polo and Jackson, 2011). H2AZ and macroH2A are 
other H2A variants with documented roles in the DDR. Replacement of H2AX with 
H2AZ is dynamically regulated at damage sites, stimulating DSB end resection and 
promoting an open chromatin conformation to help recruit repair machinery to sites of 
DSB (Kalocsay et al., 2009; Xu et al., 2012). MacroH2A accumulates at DNA damage 
sites in a PARP-dependent manner and is required for HR repair (Khurana et al., 2014). 
Histone H3 variant H3.3 has been shown to mediate replication fork restart and 
transcriptional recovery after UV-induced DNA damage in a HIRA-dependent manner 
(Adam et al., 2013; Frey et al., 2014), however the requirement for H3.3 incorporation at 
other damage lesions has not been addressed and may require distinct pathways for 
deposition. For instance, in distinct cellular contexts different pathways of histone 
deposition may be required, and it has been shown that DAXX mediates H3.3 deposition 
at some neuronal activity-dependent genes (Michod et al., 2012). Collectively, these data 
underscore the importance of chromatin dynamics in the DDR and reveal that our 
understanding of the contributions of histone variants to DNA damage repair and 
signaling is only beginning to emerge.  
As mentioned in Section 1.3.1, a key feature of the nucleus is its non-random 
organization of chromosomes into distinct subdomains (Bickmore and van Steensel, 
2013; Cremer and Cremer, 2001; Misteli, 2007). It has been well established that there 
are dedicated centers in the nucleus for transcription and replication, termed “factories”, 
begging the question of whether “repair factories” exist. Low-dose irradiation in yeast 
leads to ~2-4 DNA repair foci, however higher doses induce larger instead of more foci, 
suggesting that newly formed lesions are recruited to pre-existing sites for repair (Lisby 
et al., 2003a; Lisby et al., 2003b; Lisby and Rothstein, 2004). This may be different in 
mammalian cells, where DSBs appear immobile in the nucleus (Soutoglou et al., 2007), 
and despite some evidence of repair center formation (Aten et al., 2004) their existence 
has been debated extensively (Dion and Gasser, 2013). While the relevance of higher-
order chromatin structure has been thoroughly studied in the context of transcriptional 
regulation, we know very little of how 3D chromatin architecture influences replication 
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and repair. Recent evidence indicates that topologically associating domains (TADs) 
function as stable units of replication timing (Pope et al., 2014) (Figure 1-3). It is 
unknown whether DNA damage induces TAD reorganization, yet evidence that 
demonstrates relocation of damaged heterochromatin suggests changes to 3D structure in 
some capacity. Relocation of heterochromatic breaks to outside of heterochromatin 
domains by HR factors has been observed in Drosophila and is believed to prevent 
recombination between repetitive sequences that are often found in heterochromatin 
(Chiolo et al., 2011). This relocation of DSBs to the periphery of chromocentres is 
reminiscent of the location of major satellites replication (Guenatri et al., 2004; Quivy et 
al., 2004), raising the idea that a common mechanism may underlie the two processes, 
especially since similar proteins are implicated. DSBs in heterochromatin are 
characterized by slower repair kinetics than those in euchromatic regions (Goodarzi et al., 
2008). Moreover, ES cells with reduced levels of the linker histone H1 display an 
enhanced cellular response to DSBs, which has been ascribed to the less compacted 
chromatin in the absence of H1 since histone deacetylase (HDAC) inhibitor trichostatin A 
(TSA)-induced global chromatin decompaction has a similar effect on repair efficiency 
(Murga et al., 2007). Collectively these results demonstrate that chromatin structure 
influences the repair process and that chromatin organizing proteins may help fine-tune 
the cellular response to DNA damage. Furthermore, the notion of cohesin mediating the 
spatial proximity of sister chromatids during HR implies that reorganization of higher-
order chromatin structure is necessary. Studying how nuclear positioning is determined 
and how it may influence repair and replication will be essential to fully understand 
tumourigenesis and human pathology. 
 
1.4.3 Endogenous sources of DNA damage 
As mentioned in section 1.4.1, DNA lesions can arise spontaneously as a result of 
reactive oxygen species, abortive topoisomerase I/II reactions, or replication errors. 
Spontaneous replication-associated DNA damage is particularly relevant to this thesis 
and will therefore be the focus of this section.  
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Replication of genetic information is a fundamental biological process, and accurate 
replication is essential to maintain genome stability and suppress cancer (Allen et al., 
2011). Apart from exogenous sources of damage, DNA can be damaged by replication 
errors that often occur at genomic regions prone to slowed replication forks, such as 
chromosomal fragile sites, telomeres, unusual secondary structures, DNA-RNA hybrids 
and repetitive sequences (Aguilera and Gomez-Gonzalez, 2008; Durkin and Glover, 
2007; Mirkin and Mirkin, 2007; Sfeir et al., 2009; Szilard et al., 2010; Tuduri et al., 
2009). There are a number of conserved tumour-suppressive mechanisms in place to 
ensure correct replication and repair of replicative errors that cause cell cycle arrest, 
death, or senescence. Cells are also quite vulnerable to DNA damage during replication 
since virtually all DNA damage blocks the replication fork, causing replication stress. 
Damage can therefore be a cause or consequence of replicative stress. 
Although replication stress has been widely recognized as a significant hurdle to 
overcome in order to maintain cellular homeostasis, there is yet to be a single unifying 
description of the phenomenon. This is likely because replicative stress can arise from a 
variety of sources, and ultimately cellular indicators of replicative stress are shared with 
other DNA damage response/repair pathways. Typically, the persistence of ssDNA bound 
by RPA generates a signal to activate ATR and other replication-stress-response proteins, 
resulting in intra-S or G2/M phase arrest to allow the cell to repair damaged DNA before 
entering mitosis (Abraham, 2001; Branzei and Foiani, 2007; MacDougall et al., 2007; 
Marechal and Zou, 2013; Nam and Cortez, 2011; Zou and Elledge, 2003) (Figure 1-4). 
ATR-dependent phosphorylation and activation of RPA (pRPAS33) and checkpoint 
kinase 1 (pChk1S345) and detection of ssDNA are the best-known indicators of 
replicative stress (Zeman and Cimprich, 2014) (Figure 1-4). However, replicative stress 
may occur but is not severe enough to induce ATR activation and phosphorylation of its 
downstream targets (Koundrioukoff et al., 2013). To date, the best detection method for 
replicative stress is the DNA fiber assay, which allows direct measurements of DNA 
synthesis through the use of thymidine analogs (Bianco et al., 2012).  
 
40 
 
1.4.4 DNA damage response in the developing central nervous 
system 
Genesis of the central nervous system requires enormous expansion of neuroprogenitor 
cells (NPCs) that give rise to a diverse array of cell types. Brain development and 
maturation requires the generation of correct cell numbers and their integration into a 
complex network of neurons that are metabolically and functionally supported by 
astrocytes and oligodendrocytes. Before the onset of neurogenesis, NPCs (also referred to 
as neuroepithelial cells at this time) undergo rapid symmetric divisions to expand the 
progenitor pool (Figure 1-5a). At ~E11 in the neocortex, some NPCs begin to divide 
asymmetrically to generate one progenitor cell and one post-mitotic neuron (Figure 1-5a). 
Newborn neurons then migrate from the proliferative zone to their final destination where 
they further differentiate and become integrated into functional networks (Greig et al., 
2013). 
A functioning DNA damage response (DDR) and repair system are extremely important 
in these early developmental stages since unrepaired lesions can greatly influence the 
formation of a functional nervous system (McKinnon, 2013). Overall, the nervous system 
has a low threshold for DNA damage, which makes sense since integrating dysfunctional 
cells into the neuronal network may be more detrimental than eliminating them (Lee and 
McKinnon, 2007), and the nervous system already utilizes apoptosis to eliminate over-
produced cells during normal brain development (Nijhawan et al., 2000; Yoshida et al., 
1998). Indeed, enhanced sensitivity to DNA damage following TopBP1 deletion was 
observed in early-born compared to later-born cortical progenitors, and irradiation of 
mouse brain leads to elevated levels of apoptosis in the neocortex at E11.5 compared to 
E14.5 (Lee et al., 2012a). These data indicate a propensity for NPCs to undergo apoptosis 
in response to DNA damage rather than risk expanding progenitors with abnormal DNA. 
The requirements for genome maintenance change substantially during the transition 
from neurogenesis to nervous system maturation. During neurogenesis, a primary source 
of damage results from replication errors due to the high proliferative index of progenitor 
cells (McKinnon, 2009). Differentiated neural cells are incredibly long-lived and must 
withstand the genetic damage throughout the entire life of an organism. Byproducts of 
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metabolism, such as ROS, are the primary source of damage in post-mitotic neurons due 
to the high energy demand of the mature brain (Harris et al., 2012). Despite these 
differences, there remains a constant requirement for the maintenance of genomic 
stability in the CNS.    
DNA integrity is maintained during development by coordinated signaling pathways that 
pause cell proliferation to repair damage or, alternatively, activate apoptotic pathways to 
eliminate damaged cells and avoid acquisition of mutations. Damage signaling requires 
the ATM and ATR kinases, which have largely distinct roles in maintaining genome 
stability in the nervous system since they respond to different types of DNA damage 
(Herzog et al., 1998; Lee et al., 2012b) (Figure 1-4). The nervous system contains the full 
repertoire of DNA repair and signaling pathways that were outlined in Section 1.4.1.  
The requirement of genome surveillance for proper brain development is clearly 
illustrated by mouse models of DDR-deficiency (Frappart and McKinnon, 2008). Mice 
lacking the essential HR factor XRCC2 (X-ray repair complementing defective repair in 
Chinese hamster cells 2) exhibit extensive apoptosis in the brain by E10.5, correlating 
with the period of neural progenitor proliferation, while mice deficient in the necessary 
NHEJ factor DNA ligase IV (LIG4) display apoptosis at E12.5 in differentiating NPCs 
(Orii et al., 2006). These findings indicate that the developing brain is vulnerable to 
endogenous DSBs and strengthen the idea that HR is the preferred method of DSB repair 
in proliferating cells, while post-mitotic cells default to utilizing NHEJ. However, a new 
finding that RNA can be used as a template for homology-directed repair demands 
reconsideration of this narrow view (Keskin et al., 2014), since it implies HR capabilities 
in all stages of the cell cycle. Nevertheless, the benchmark study by Orii et al. 
demonstrates that the types of DNA damage encountered in post-mitotic neurons are 
different than those observed in cycling neuroprogenitors and that distinct repair 
pathways are utilized (Orii et al., 2006). NPCs have a high proliferative index and thus 
encounter replication-associated damage, however post-replicative mature neurons 
encounter a high degree of metabolic damage, such as oxidative stress. DNA lesions in 
differentiated cells typically do not activate apoptosis, but can interfere with transcription 
if unrepaired and located in the vicinity of coding sequence (McKinnon, 2013). Along 
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these same lines, persistent DNA damage in mature neurons can cause redistribution of 
the histone deacetylase SIRT1 on chromatin, causing dysregulation of aging-associated 
genes (Oberdoerffer et al., 2008). 
Differential susceptibility of progenitors to DNA damage may be linked to cell cycle 
dynamics, as cell cycle regulation of NPCs is a key aspect of cortical development and 
involves dynamic changes in G1 and S phase duration (Arai et al., 2011; Dehay and 
Kennedy, 2007; Gotz and Huttner, 2005) (Figure 1-5b). A key difference between 
proliferating and neurogenic progenitors is the length of S phase; a three-fold longer S 
phase is associated with expanding neural progenitors compared to committed neural 
cells, which are characterized by a prolonged G1 phase (Arai et al., 2011) (Figure 1-5b). 
This is likely due to the increased need for genome surveillance in non-committed 
progenitors to prevent transmission of genetic errors. Chromatin state is also an important 
determinant of neurogenic potential (Kishi et al., 2012), in addition to its defined roles in 
DNA damage response and repair (Soria et al., 2012), however our understanding of the 
relationship between chromatin structure, cell cycle regulation, and the DDR in the 
context of brain development is limited. 
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Figure 1-5 Timeline of corticogenesis and cell cycle dynamics in proliferative versus 
neurogenic cortical progenitors 
(A) Neuroepithelial (NE) cells divide symmetrically to produce two NE cells and expand 
the progenitor pool before the onset of neurogenesis. In the neurogenic stage, NE cells 
acquire characteristics of radial glia (RG) and are termed apical progenitors (AP). APs 
and outer radial glia (oRG) progenitors divide asymmetrically to self-renew and generate 
a cell of neurogenic fate such as a postmitotic projection neuron or basal progenitor (BP). 
The earliest born neurons form the preplate, which eventually splits to form the subplate 
(SP) and marginal zone (also termed cortical layer I). The cortical plate forms in between 
these two layers in an inside-out fashion, with later born neurons migrating past earlier 
born neurons using the basal process of AP or oRG. The generation of glial cells 
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(oligodendrocytes and astrocytes) begins in late gestation at approximately E18. This 
schematic was largely reproduced using information derived from (Grieg et al., 2013). 
(B) Different subtypes of postmitotic neurons are born in overlapping temporal waves. 
Subplate neurons (SPN) are born at approximately E11.5, followed by corticothalamic 
projection neurons (CThPN) that are born at approximately E12.5. At the same time, 
callosal projection neurons (CPN) are generated throughout E12.5-E16.5. Subcerebral 
projection neurons (SCPN) are born at E13.5, followed by the generation of layer IV 
granular neurons (GN) at E14.5. (C) Proliferative and neurogenic progenitors exhibit 
differential cell cycle parameters, namely proliferative NPCs are characterized by a 
lengthened S phase (8 h versus 2.4 h) and neurogenic NPCs are characterized by a 
lengthened G1 phase (17.1 h versus 12.7 h) (Arai et al., 2011). VZ: ventricular zone; 
SVZ: subventricular zone; CR: Cajal-Retizus. 
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1.4.5 Microcephaly is caused by defective cell cycle regulation, DNA 
damage response, and centrosome biology 
Microcephaly is defined as head circumference two- to three-standard deviations below 
the mean, is often equivalent to microencephaly (reduced brain size), and is frequently 
associated with intellectual disability, or impaired cognition or adaptive functioning 
(Dolk, 1991). Microcephaly is a clinically heterogeneous disease and can present in the 
absence (primary microcephaly) of syndromic features or as a characteristic of specific 
syndromes, like ATR-X syndrome (Gibbons, 2006). Microcephaly is caused by 
abnormalities in cellular production, and as such the study of developmental 
microcephalies have taught us an enormous amount about how the brain generates the 
correct number of neurons to support brain size (Gilmore and Walsh, 2013). By and 
large, microcephaly-associated gene products are components of the centrosome, regulate 
cell cycle dynamics, or are involved in the DNA damage response. How these particular 
types of proteins are linked to microcephaly is still unresolved. It is possible that 
defective cell cycle regulation can lead to cellular proliferation deficiencies and/or 
apoptotic induction, which have both been observed in mouse models of microcephaly. 
For instance, deletion of Cdk5rap2 causes excessive cell death (Lizarraga et al., 2010) 
and ASPM (abnormal spindle-like, microcephaly-associated) influences progenitor 
proliferation by controlling WNT signaling (Buchman et al., 2011). 
Remarkably, all genes associated with primary microcephaly encode proteins associated 
with the centrosome or centrosomal-related activities (Bond et al., 2002; Bond et al., 
2005; Guernsey et al., 2010; Jackson et al., 2002; Kalay et al., 2011; Kumar et al., 2009; 
Kumar et al., 2002; Nicholas et al., 2010; Yu et al., 2010b). Centrosomes are organelles 
with a critical role during mitosis where they associate with microtubules and are 
involved in formation of the mitotic spindle. How centrosomal defects cause 
microcephaly is not well understood. There is also crosstalk between centrosomal 
components, DNA damage signaling, and cell cycle regulation. For instance, the primary 
microcephaly gene product microcephalin (MCPH1) couples the centrosomal cycle with 
mitotic entry through phosphorylation of Cdc25/Chk1 (Gruber et al., 2011), and recruits 
the SWI/SNF complex to DNA damage sites facilitate local chromatin remodeling and 
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proper DDR signaling (Peng et al., 2009). This example highlights the dynamic interplay 
between the DNA damage response and cell cycle control, and underscores the 
importance of these processes in neurodevelopment since MCPH1 mutations in humans 
solely affect the brain. 
Microcephaly can also be caused by mutations in DNA repair pathway genes including 
NBS1, XLF, DNA ligase IV, and MCPH1 (Ben-Omran et al., 2005; Buck et al., 2006; 
Carney et al., 1998; O'Driscoll et al., 2001; O'Driscoll and Jeggo, 2008; Xu et al., 2004). 
A question in the field is why defects in the DNA damage response pathway particularly 
affect brain development. During neurogenesis, replicative stress is a primary source of 
endogenous damage due to the rapid proliferative index of NPCs (McKinnon, 2013). 
Since DNA damage can lead to altered cell cycle dynamics, defects in the cellular 
response to or repair of damage may perturb the precise balance between NPC 
proliferation, differentiation and cell death. Excessive cell death during brain 
development would result in decreased neuronal numbers, and is one of the potential 
mechanisms underlying the microcephaly phenotype. 
 
1.4.6 The DNA damage theory of aging 
It has been well established that DNA damage and mutations accumulate as we age (Vijg, 
2000). This fact has led to the DNA damage theory of aging, which postulates that the 
accumulation of genetic lesions is the major cause of the accelerated physiological 
decline associated with aging (Freitas and de Magalhaes, 2011; Gensler and Bernstein, 
1981; Kirkwood and Holliday, 1979; Szilard, 1959). Aging is a natural process that 
affects most biological functions and appears to be a consequence of the cumulative 
action of various stressors such as telomere attrition, oxidative damage, and the decline of 
DNA repair (Kirkwood, 2005; Vijg and Campisi, 2008). Understanding the biological 
mechanisms underlying aging is of utmost importance since age is the primary risk factor 
for most human diseases, including neurodegeneration and cancer. 
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Human progeroid syndromes exhibit clinical manifestations that resemble accelerated 
aging, and have been linked to defects in DNA repair or processing. Genetic 
manipulation of DNA repair or response factors in mice result in the appearance of aging-
like phenotypes, supporting the idea that DNA damage may be directly linked to aging. 
However, the best proof of principle would be to decrease physiological levels of DNA 
damage to lengthen lifespan in these models, which is difficult, if not impossible, to 
accomplish in vivo. The study of progeroid syndromes for the understanding of normal 
aging is controversial, since mouse models and even human progeria patients only exhibit 
a subset of the symptoms of normal aging and are therefore often referred to as 
“segmental progeria” (Miller, 2004). Nevertheless, progeroid and accelerated aging 
syndromes clearly demonstrate that disruption of DNA repair pathways can elicit aging 
phenotypes. 
Hormone signaling plays a key role in the regulation of aging: in particular, the 
somatotroph (insulin-like growth factor 1/growth hormone) axis is a critical regulator of 
metabolism and longevity (Russell and Kahn, 2007) (Figure 1-6). An intriguing aspect of 
these longevity pathways is that they function non-cell autonomously; mutations or 
abnormalities in one cell type can alter the entire organism. Specifically, neuronal cells 
play a special role in cell non-autonomous lifespan regulation by the IGF-1 pathway in C. 
elegans (Wolkow et al., 2000). Chronic activation of the stress response is associated 
with human aging, and causes transcriptional changes associated with dampening of the 
somatotroph axis (Bartke, 2005; Lombardi et al., 2005). This molecular signature is also 
observed in mouse models that exhibit accelerated aging (Niedernhofer et al., 2006; van 
der Pluijm et al., 2007).  Signaling between the hypothalamus, the pituitary gland, and the 
thyroid gland is essential for metabolic regulation (Figure 1-6). The hypothalamus senses 
low circulating levels of thyroid hormone and responds by releasing thyrotropin-releasing 
hormone (TRH). TRH stimulates the pituitary to produce thyroid-stimulating hormone 
(TSH), which in turn stimulates the thyroid to produce thyroid hormone (Dietrich et al., 
2012). Thyroid hormone (thyroxine/T4) levels are also critical for the regulation of IGF-1 
during prepubertal development (Xing et al., 2012) (Figure 1-6). Despite extensive 
evidence of a link between DNA damage and suppressed IGF-1 responses, there has not 
yet been satisfactory mechanistic explanation of the connection with aging.  
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Taken together, there is a strong relationship between DNA damage accumulation and 
the systemic defects associated with aging. Furthering our understanding of the complex 
interplay between DNA damage, metabolic signaling, and physiological decline will be 
necessary to solve the biological enigma of aging. 
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Figure 1-6 Insulin-like growth factor-1 (IGF-1) signaling controls organismal 
metabolism, growth and development, and longevity and can be controlled by 
thyroxine (T4) or growth hormone (GH) 
Thyrotropin-releasing hormone (TRH)-expressing cells in the hypothalamus release 
TRH, which acts on cells in the anterior pituitary (yellow) to produce and release thyroid 
stimulating hormone (TSH). TSH acts on the thyroid gland to produce thyroxine (T4), 
which is converted to the biologically active T3 form that acts on the liver to induce IGF-
1 production. This pathway is the major activator of IGF-1 signaling during prepubescent 
development (Xing et al., 2012). Alternatively, gonadotropin-releasing hormone (GnRH)-
expressing neurons in the hypothalamus act on cells in the anterior pituitary to produce 
and release growth hormone (GH), which is released into the blood stream and increases 
IGF-1 levels. 
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1.5 Thesis Overview 
The overarching goal of this thesis is to identify the molecular mechanism(s) underlying 
neurological disorders associated with defective chromatin structure.  
1.5.1 Rationale and Hypothesis 
Human mutations in ATRX and CTCF cause intellectual disability associated with 
microcephaly as well as various cancer subtypes, however we do not yet fully 
comprehend the role of ATRX or CTCF in brain development and suppression of 
tumourigenesis. Using mouse models deficient for Atrx and Ctcf in the embryonic brain, 
the work herein tests the hypothesis that chromatin regulation is critical for correct 
neurodevelopment by suppressing genomic instability and promoting NPC survival.  
1.5.2 Chapter Two: Atrx deficiency induces telomere dysfunction, 
endocrine defects and reduced lifespan 
This chapter describes work demonstrating that ATRX is required for NPC survival by 
suppressing DNA double-strand breaks at telomeric and pericentromeric heterochromatin 
during replication. Atrx-null NPCs are sensitive to telomestatin, a drug that selectively 
stabilizes G4-DNA structures, suggesting that ATRX may resolve G4-DNA to facilitate 
progression of the replicative machinery through repetitive sequences, i.e. telomeres, 
during late-S phase.  
1.5.3 Chapter Three: Dual effect of CTCF loss on neuroprogenitor 
differentiation and survival 
Chapter three provides evidence that CTCF is required for NPC survival, functioning to 
suppress p53/PUMA activation. Despite rescue of cell death in the embryonic brain, 
Ctcf/Puma-deficient mice display microcephaly, indicating that PUMA-dependent 
apoptosis does not completely explain the reduced brain size of Ctcf-deficient mice. 
Instead, Ctcf-deficient NPCs exhibit precocious differentiation, causing a depletion of the 
cortical progenitor pool. Together, these data indicate that CTCF functions to promote a 
balance between NPC proliferation/differentiation and to suppress p53/PUMA-mediated 
cell death for correct neurodevelopment.  
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1.5.4 Chapter Four: CTCF is required to prevent replicative stress 
and p53/PUMA-dependent apoptosis 
Chapter four explores the mechanism underlying NPC death in the Ctcf-deficient brain 
and demonstrates CTCF loss results in endogenous DNA breaks that correlate with active 
proliferation and Ctcf-null NPCs exhibit characteristics of replicative stress. Moreover, 
Ctcf-null NPCs are sensitive to exogenous replicative stress, indicating that CTCF may 
function to prevent or repair replication-associated damage. Together, the findings 
described in the final chapter of this thesis identify a novel role for CTCF in preventing 
replicative stress and uncovers the mechanisms involved. 
Overall, this thesis highlights the importance of two chromatin regulators in brain 
development and demonstrates that correct chromatin structure is critical to the 
differentiation and survival of neuroprogenitor cells. Dysfunctional chromatin induced by 
loss of ATRX or CTCF renders NPCs especially vulnerable to replication-associated 
damage and p53-dependent apoptosis. Not only do my findings provide some insight into 
mechanisms underlying defective brain development stemming from ATRX or CTCF 
mutation, it also has broad implications for the pathogenesis of complex neuropsychiatric 
diseases such as autism and schizophrenia. 
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Chapter 2 
2 Atrx deficiency induces telomere dysfunction, endocrine 
defects, and reduced lifespan 
Prior to the research presented in this chapter, we identified that ATRX is required for 
survival of neuroprogenitor cells, and that loss of ATRX results in p53-dependent 
apoptosis (Berube et al., 2005; Seah et al., 2008). In this chapter, I sought to investigate 
the molecular mechanism underlying p53-dependent apoptosis resulting from Atrx-
deficiency. 
This chapter was previously published as (Watson et al., 2013). Permissions for 
reproduction are found in Appendix A. 
2.1 Introduction 
Faithful replication of DNA maintains genomic stability, limits the accumulation of 
cancer-promoting mutations, and can extend life span. Replication stress can occur 
spontaneously from stalling of the replication machinery as it encounters obstacles on the 
DNA template, such as DNA lesions, intricate secondary structures, or DNA-bound 
proteins (Branzei and Foiani, 2010). Impaired progression of the replication machinery 
can also occur when cells are exposed to exogenous damage or drugs that limit the 
nucleotide pool, or that cause interstrand crosslinking. The stabilization of paused 
replication forks to allow restart involves activation of checkpoint signaling to provide 
the cell extra time to respond (Allen et al., 2011). Failure to stabilize stalled forks causes 
fork collapse, a process involving dissociation of the polymerases, exposure of extended 
single-stranded DNA (ssDNA) regions, improper processing, and DNA breakage. Stalled 
replication can have serious consequences, such as genomic instability, chromosomal 
rearrangements from illegitimate recombination events, and reduced cell viability 
(Branzei and Foiani, 2010). Constitutive heterochromatin, telomeric DNA, and other 
DNA structures can pose particular challenges to the replication machinery. To overcome 
such hindrances, specialized factors are required to resolve difficult DNA structures or to 
promote access of restart pathway proteins to stalled forks (Buonomo, 2010). 
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ATRX is a Rad54-like ATP-driven DNA translocase belonging to the Swi/Snf family of 
chromatin remodelers (Xue et al., 2003). The biological impact of ATRX mutations in 
humans appears to vary according to the extent and timing of disruption. In humans, 
ATRX somatic frameshift and nonsense mutations that completely abolish protein 
function have been identified in pancreatic neuroendocrine tumours (PanNETs) (Heaphy 
et al., 2011a; Jiao et al., 2011; Yachida et al., 2012), pediatric and adult glioblastoma, and 
other cancers of the CNS (Cheung et al., 2012; Jiao et al., 2012; Kannan et al., 2012; 
Molenaar et al., 2012; Schwartzentruber et al., 2012), underscoring the anti-tumourigenic 
roles of ATRX. Tumours with ATRX mutations often harbor long telomeres, which are 
characteristic of the telomere maintenance mechanism known as alternative lengthening 
of telomeres (ALT) (Heaphy et al., 2011a; Jiao et al., 2011; Kannan et al., 2012; Lovejoy 
et al., 2012; Nguyen et al., 2013). Conversely, hypomorphic inherited mutations of the 
ATRX gene cause a rare developmental disorder, ATR-X syndrome (OMIM 301040), 
with diagnostic features of severe cognitive deficits, microcephaly, seizures, short stature, 
developmental delay, and α-thalassemia, without increased neoplasia incidence (Gibbons 
and Higgs, 2000; Gibbons et al., 1995a; Gibbons et al., 1995b). Thus, inactivating 
mutations of the ATRX gene during development are likely embryonic lethal, while 
diminished ATRX activity leads to severe developmental and cognitive abnormalities. 
ATRX somatic inactivating mutations that arise later and consequently bypass embryonic 
development appear to drive cancer progression, particularly in the CNS. 
The cellular functions of ATRX are not completely clear; however, several lines of 
evidence point to a role in the maintenance of genomic integrity. Decreasing levels of 
ATRX by RNA interference induces spindle defects, as well as chromosomal alignment 
and segregation problems during mitosis and meiosis, and complete loss of ATRX in 
neuroprogenitor cells (NPCs) can also induce mitotic abnormalities (Baumann et al., 
2010; De La Fuente et al., 2004; Ritchie et al., 2008; Seah et al., 2008). Furthermore, 
ATRX-depleted mouse embryonic stem cells have unstable telomeres (Wong et al., 
2010). The ATRX protein can bind to specific genomic sites, including imprinting 
control regions and the Rhox5 promoter (Bagheri-Fam et al., 2011; Kernohan et al., 
2010), but is also highly enriched at repetitive regions, including ribosomal DNA repeats, 
pericentromeric heterochromatin, and telomeric chromatin, where it was proposed to 
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cooperate with DAXX to incorporate the histone variant H3.3 into chromatin (Baumann 
et al., 2008; Berube et al., 2000; Eustermann et al., 2011; Lewis et al., 2010; McDowell et 
al., 1999; Wong et al., 2010). 
In the present report, we demonstrate that ATRX deletion in NPCs causes excessive 
replication–related DNA damage, which is exacerbated by loss of p53, replication stress–
inducing drugs, and telomestatin (TMS), a G-quadruplex (G4) ligand. Unexpectedly, 
mutant mice lacking ATRX in the forebrain and pituitary had low circulating IGF-1, 
thyroxine (T4), and glucose levels and displayed degenerative phenotypes previously 
described in mouse models of progeria. Collectively, our data reveal that ATRX protects 
cells from replicative stress–induced DNA damage and telomeric fusions and that loss of 
ATRX in the embryonic CNS and anterior pituitary elicits systemic endocrine and 
metabolic abnormalities. 
2.2 Materials and Methods 
2.2.1 Mouse husbandry, genotyping, and tissue preparation 
Mice were exposed to 12-hour light/12-hour dark cycles and fed tap water and regular 
chow ad libitum. The AtrxloxP mice have been described previously (Berube et al., 2005; 
Garrick et al., 2006). AtrxloxP mice, when mated to mice expressing Cre recombinase 
under the control of the Foxg1 promoter (Foxg1KiCre/+) (Hebert and McConnell, 2000), 
produce male progeny (AtrxloxP/YFoxg1KiCre/+) with Atrx deficiency in the forebrain 
(AtrxFoxg1Cre). To account for heterozygosity of Foxg1 due to knock-in of the Cre 
recombinase gene, Cre+ males were used as controls. Trp53tm1Tyj/J mice were obtained 
from The Jackson Laboratory, and the mutant allele was introduced into the AtrxloxP and 
Foxg1KiCre/+ mice. Subsequent mating of this progeny yielded mice that are p53-null in all 
tissues and Atrx/p53 double-null in the forebrain. For timed matings, midday of discovery 
of the vaginal plug was considered to be E0.5. Yolk sac or tail DNA was used for 
genotyping. Atrx, Cre, and p53 genotyping was performed by PCR as previously 
described (Berube et al., 2005; Seah et al., 2008). 
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2.2.2 Immunofluorescence and antibodies 
Embryos were fixed overnight in 4% paraformaldehyde, washed 3 times in 1× PBS for 5 
minutes each, and dehydrated in 30% sucrose PBS. Postnatal mice were perfused with 
4% paraformaldehyde before PBS washes and dehydration. Brains were flash-frozen in 
liquid nitrogen using Cryomatrix (Thermo Scientific) cryoprotectant and sectioned as 
described previously (Berube et al., 2002). For immunofluorescence staining of 
cryosections, antigen retrieval was performed on slides by warming 10 mM sodium 
citrate pH 6 solution to approximately 95°C and microwaving slides in solution for 10 
minutes on low. After cooling, slides were washed and incubated with primary antibody 
overnight at 4°C. For detection of PCNA, primary antibody was incubated in 10 U/ml 
DNase I (Sigma-Aldrich) as previously described (Seah et al., 2008). Slides were washed 
in PBS and incubated with secondary antibody for 1 hour. Sections were counterstained 
with DAPI (Sigma-Aldrich) and mounted with Vectashield (Vector Laboratories) or 
SlowFade Gold (Invitrogen). For immunofluorescence staining of primary cortical 
culture, cells were incubated in blocking solution (PBS with 0.3% Triton-X and 5% 
normal goat serum) for 30 minutes and subsequently incubated with primary antibody 
overnight at 4°C. Cells were washed in PBS and incubated with secondary antibody for 1 
hour. Cells were counterstained with DAPI and mounted with Vectashield. 
The following primary antibodies were used: anti-ATRX, rabbit polyclonal (1:200; Santa 
Cruz Biotechnology Inc.); anti–cleaved caspase-3 (Asp175), rabbit monoclonal (1:400; 
Cell Signaling Technology); anti-γH2AX (Ser139), rabbit (1:100; Cell Signaling 
Technology); anti-γH2AX (Ser139), mouse monoclonal (1:400; Millipore); and anti-
PCNA, mouse monoclonal (1:100; Santa Cruz Biotechnology Inc.). The secondary 
antibodies used were goat anti-rabbit–Alexa Fluor 594 (1:800 dilution; Molecular Probes) 
and goat anti-mouse–Alexa Fluor 488 (1:800 dilution; Molecular Probes). 
2.2.3 Microscopy 
Experiments demonstrating colocalization of γH2AX and PCNA, γH2AX and major 
satellite repeats, and γH2AX and telomeres were captured using a laser scanning confocal 
microscope (FV1000, Olympus). z-Stacks were obtained at 0.25-µm z intervals generally 
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spanning 10–20 µm. Overlapping signal was scored as a colocalization event. For 
colocalization of γH2AX and PCNA, only cells in which PCNA staining was 
characteristic of late S phase were counted. Each cell (n = 300) was scored for the 
number of γH2AX foci that overlapped with PCNA foci divided by the total number of 
γH2AX foci per cell, to obtain a measure of the cellular levels of DNA damage (γH2AX) 
at late-replicating chromatin. All other images were captured using an inverted 
microscope (DMI 6000b, Leica). Digital microscopy images were captured with a digital 
camera (ORCA-ER, Hamamatsu). Openlab imaging software was used for manual and 
automated image capture, and processing was performed using Volocity software 
(PerkinElmer). For quantification of γH2AX foci per area, at least 6 serial cortical 
cryosections were assessed for γH2AX foci within the indicated regions. To obtain a 
relative measure of DNA damage, the ratio of γH2AX foci to area (mm2) was calculated. 
The same method was used to quantify the ratio of cleaved capsase-3+ and γH2AX+ cells, 
and for this experiment a Student’s t test was used to compare only the proportion of 
caspase-3+γH2AX+ cells between control and Atrx-null mice. 
2.2.4 Western blot analysis 
Nuclear protein was extracted from E13.5 telencephalon using a standard extraction kit 
(Thermo Scientific) and quantified using a Bradford assay. Protein (10 µg) was resolved 
on 6% SDS-PAGE and transferred onto nitrocellulose membranes (Bio-Rad). The 
membranes were probed with anti-ATM, rabbit monoclonal (1:500, Millipore); anti–
phospho-ATM (S1981), mouse monoclonal (1:250, Rockland); anti-ATR, goat 
polyclonal (1:250, Santa Cruz Biotechnology Inc.); anti–phospho-ATR (S428), rabbit 
polyclonal (1:250, Santa Cruz Biotechnology Inc.); and anti-INCENP, rabbit polyclonal 
(1:10,000, Sigma-Aldrich) antibodies, followed by the appropriate horseradish 
peroxidase–conjugated secondary antibodies (1:4,000, GE Healthcare). The membrane 
was incubated in ECL before exposure to X-ray film.  
2.2.5 Primary NPC cultures and manipulation 
Cortical progenitor cultures were prepared as described previously (Gloster et al., 1999; 
Slack et al., 1998) using cortices dissected from E13.5 embryos. Cells were seeded on 
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polyornithine-coated (Sigma-Aldrich) plastic plates or glass coverslips. Primary cortical 
cultures were treated with acute γ-irradiation (0, 1, 5, and 10 Gy) at 2 days after plating 
using a Cobalt-60 irradiator (Theratron 60, Atomic Energy of Canada Limited) located in 
the London Regional Cancer Center, London, Ontario, Canada. Cells were fixed in 4% 
paraformaldehyde for 10 minutes, washed in PBS, and stored in PBS at 4°C at 0, 3, and 6 
hours after treatment and processed for immunofluorescence. HU (Sigma-Aldrich), 
MMC (Sigma-Aldrich), γ-irradiation, and TMS (synthesized in the Biomedicinal 
Information Research Center, National Institute of Advanced Industrial Science and 
Technology, Tokyo, Japan) sensitivity assays in cultured NPCs were conducted 48 hours 
after plating cells. NPC cultures were treated with appropriate doses of HU, γ-irradiation, 
or TMS for the indicated length of time, and cell viability was measured using the trypan 
blue dye exclusion method. Cell counts were determined with a hemacytometer. 
2.2.6 FISH 
For DNA-FISH experiments, primary cortical cultures were permeabilized in CSK buffer 
with 0.5% Triton-X (Sigma-Aldrich) prior to fixation. For TelFISH, a fluorophore-
labeled DNA oligonucleotide probe, TAACCC7-Alexa 488-3′ (Integrated DNA 
Technologies), was dissolved at 1 pmol/µl in hybridization buffer. Hybridization was 
performed as previously described (Zhang et al., 2009). For major satellite FISH, 
immunofluorescence was performed first, followed by fixation with 4% 
paraformaldehyde for 10 minutes and subsequent hybridization with a major satellite 
repeat probe as previously described (Isaac et al., 2006). 
2.2.7 MEF cultures and manipulations 
E13.5 embryos were minced, digested in trypsin for 45 minutes at 37°C, and resuspended 
in DMEM (Sigma-Aldrich) containing 10% FBS, 50 U/ml penicillin, 50 µg/ml 
streptomycin, and 2 mM l-glutamine. Primary AtrxloxP/Y and wild-type MEFs were seeded 
at 1.5 × 106 cells per 6-well plate and transduced with adenovirus expressing Cre 
recombinase and a GFP reporter gene (Ad-CreGFP) or GFP only (Ad-GFP control) 
approximately 12 hours later. Three days after transduction, MEFs were counted and 
reseeded at 1.5 × 106 cells per 6-well plate (P5/P0). HU sensitivity in MEFs was 
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determined by transducing 1.5 × 106 cells with adenovirus, culturing for 72 hours, and 
treating cells with appropriate doses of HU for 24 hours, replacing medium, and 
measuring viability via trypan blue dye exclusion 2 days later. Sensitivity to γ-irradiation 
in MEFs was assessed by transducing 1.5 × 106 cells with adenovirus, waiting 72 hours, 
and treating cells with appropriate doses of γ-irradiation and measuring viability via 
trypan blue dye exclusion 48 hours later. 
2.2.8 qRT-PCR 
Total RNA was obtained from control and cKO liver with the RNeasy Mini Kit 
(QIAGEN) and reverse transcribed into cDNA as described previously (Kernohan et al., 
2010). Control reactions without reverse transcriptase were prepared in parallel. cDNA 
was amplified with gene-specific primers under the following conditions: 25–35 cycles of 
95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute. For qRT-PCR, cDNA 
was amplified with iQ SYBR Green Master Mix (Bio-Rad) by using the standard curve 
Ct method of quantification. Experiments were performed on a Chromo-4 thermocycler 
(MJ Research) and analyzed with Opticon Monitor 3 and GeneX (Bio-Rad) software. 
Gene expression analysis was repeated in triplicate for each sample. Conditions for 
amplification were as follows: 35 cycles of 95°C for 10 seconds, 55°C for 20 seconds, 
72°C for 30 seconds, and a final melting curve generated in increments of 0.5°C per plate 
read. Standard curves were generated for each primer pair with 3-fold serial dilutions of 
control cDNA. Primer efficiency was calculated as: E = (10[–1/slope] – 1) * 100%, 
where a desirable slope is –3.32 and r2 > 0.990. All data were corrected against Gapdh as 
an internal control. Error bars represent SEM. 
2.2.9 Alcian blue and alizarin red staining 
Skinned and eviscerated mouse carcasses at P17 were fixed overnight in 95% ethanol and 
transferred to acetone. Fixed skeletons were stained in alizarin red and alcian blue, as 
described previously (Wang et al., 2007). Images were captured using an Olympus SP-
57OUZ digital camera. Skeletal elements from at least 4 different littermate pairs were 
imaged using a Zeiss Stereo Zoom Microscope Stemi SV6, and measurements of 
individual bones were undertaken with a ruler accurate to 0.1 mm. 
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2.2.10 microCT 
Mice were euthanized on P17, skinned, eviscerated, and stored in formalin. Whole 
skeletons were scanned on a GE Locus Ultra scanner at 120 kV and 20 mA, with a 0.154-
mm3 voxel resolution with a total of 900 slices per scan. To assess bone density, hind 
limbs were scanned on a GE Locus scanner at 80 kV and 0.450 mA with a 0.020-mm3 
voxel resolution with 900 slices per scan. BMD, cortical thickness, and trabecular 
numbers were calculated using MicroView 3D visualization and analysis software 
(version 2.1.2, GE Healthcare Biosciences) (Ulici et al., 2008). BMD was determined 
from proximal tibias using the bone analysis module within MicroView by defining the 
region of interest (ROI) as the area between 0.3 mm and 0.6 mm proximal to the growth 
plate to include the trabecular spongiosa. The ROI was a cylinder fitting within the 
central region of the trabecular bone, excluding the cortical bone. Cortical bone–
mimicking epoxy (SB3, Gammex RMI) was used for calibration. Trabecular number was 
determined using the stereology function within MicroView, using the same ROI as used 
for BMD. Cortical thickness was determined at the tibial mid-diaphysis, defined as the 
distance halfway between the two ends of the tibia. Thickness of the bone was measured 
radially in each quadrant and averaged. 
2.2.11 Picosirius red staining of bone sections 
Fore- and hind limbs were dissected at P0, P7, P10, and/or P17 upon sacrifice and 
processed for histological analyses by 0.1% picrosirius red (Sigma-Aldrich, catalog 
P6744-16A) as described previously (Yan et al., 2012). Trabecular area (µm2) within an 
area of interest (AOI) was measured by observers blinded to the experimental protocol 
using Openlab 4.0.4 software (Improvision), with the AOI set from just below the 
hypertrophic chondrocytes to 200 µm below the growth plate in the trabecular bone area 
of the mineralized zone. The AOI measurements were adapted from (O'Connor et al., 
2009; Sawyer et al., 2003). Trabecular area was normalized to total AOI and expressed as 
a percentage. All images were taken with a Retiga EX camera (Leeds Precision 
Instruments Inc.) connected to a DMRA2 microscope (Leica). 
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2.2.12 Ex vivo tibia cultures 
Tibiae were isolated from P0 mutant and control mice using a Zeiss Stereo Zoom 
Microscope Stemi SV6 and dissection tools, as described previously (Agoston et al., 
2007). Isolated tibiae were plated in 12-well culture dishes and cultured with 1 ml per 
well of sterile organ culture α-MEM medium (Gibco, Life Technologies, catalog 
1257063) containing ascorbic acid (0.005%, Sigma-Aldrich, A4034), β-glycerophosphate 
(0.02%, Sigma-Aldrich, 819830), BSA (0.2%, Fisher Scientific, 9048486), 200 nM 
glutamine (0.25 ml, Gibco, Life Technologies, 25030081), and penicillin streptomycin 
(0.4 ml, Gibco, Life Technologies, 15140122) for 7 days at 37°C, 5% CO2. Organ culture 
medium was refreshed on days 2, 4, and 6. Tibia samples were fixed in 70% ethanol 
overnight at 4°C on day 7. Samples were processed, embedded in paraffin, and sectioned 
at the Molecular Pathology Core Facility, Robarts Research Institute, London, Ontario, 
Canada. Tibia lengths were measured on days 0 and 7 using the Zeiss Stereo Zoom 
Microscope Stemi SV6 with a ruler accurate to 0.1 mm. 
2.2.13 Measurements of IGF-1, GH, T4, and glucose 
Plasma and liver samples were collected from P17 mice. Blood was collected from the 
inferior vena cava. EDTA pH 7.0 was added to the blood sample and centrifuged at 
21,000 g for 10 minutes at 4°C. Plasma supernatant was collected and kept frozen at –
80°C. Liver samples were collected and homogenized by 2 freeze-thaw cycles. Liver 
homogenate supernatant was collected and assayed immediately. Plasma and liver IGF-1 
content were measured using a mouse IGF-1 ELISA kit (R&D Systems, catalog MG100). 
Plasma GH and T4 were assayed using Millipore (EZRMGH-45K) and Calbiotech 
(T4044T) ELISA kits, respectively, according to the manufacturers’ instructions. Blood 
glucose levels were measured immediately prior to sacrifice using the OneTouch 
FastTake Meter according to the manufacturer’s instructions. 
2.2.14 Cell cycle profiling 
Primary NPCs were cultured for two days and pulse-labeled with cell proliferation 
labeling reagent [10 mM bromodeoxyuridine (BrdU) and 1 mM fluorodeoxyuridine 
(FdU) in H2O] at 5 µl/ml media (GE Healthcare Life Sciences), fixed, and stained with 
94 
 
propidium iodide (PI). The proportion of cells in each phase of the cell cycle was 
determined by flow cytometry on a Beckman-Coulter Epics XL-MCL instrument, as 
described (Isaac et al., 2006). 
2.2.15 Statistics 
Statistical analysis was performed using GraphPad Prism software (4.02; GraphPad 
Software Inc.), and all results are expressed as the mean ± SEM unless indicated 
otherwise. Two independent data sets were compared with the Student’s t test (unpaired, 
2-tailed). Statistical analyses of Kaplan-Meier survival curves were performed using the 
log-rank test and the Gehan-Breslow-Wilcoxon test. P values of 0.05 or less were 
considered to indicate significance. 
2.2.16 Study approval 
All procedures involving animals were conducted in accordance with the regulations of 
the Animals for Research Act of the Province of Ontario and approved by the University 
of Western Ontario Animal Care and Use Committee. 
2.3 Results 
2.3.1 Endogenous DNA damage accumulates in the Atrx-null NPCs 
AtrxLoxP female mice (Berube et al., 2005) were mated to Foxg1Cre male mice (Hebert 
and McConnell, 2000) to generate male progeny lacking ATRX in the embryonic 
forebrain starting at E8.5 (referred to as cKO mice). Since ATRX depletion can induce 
telomeric instability in embryonic stem cells (Wong et al., 2010), we stained brain 
cryosections from E13.5 embryos with antibodies for the phosphorylated histone variant 
H2AX (γH2AX), a canonical marker for double-stranded breaks (DSBs) (Rogakou et al., 
1998). This analysis showed a high level of DNA damage throughout the cortex, 
hippocampal hem (future hippocampus), and basal ganglia in the cKO embryonic 
forebrain that was significantly increased compared with that in controls (Figure 2-1a). 
The level of DNA damage was appreciably lower in the neonatal brain; nevertheless, 
comparatively higher levels of γH2AX were observed in the neonatal hippocampus, a 
region that is still proliferative at this stage of development, as well as in the cortex of 
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mutants (Figure 2-1b). Thus, the pattern of DNA damage was generally confined to 
proliferative areas of the developing brain. To determine whether DNA damage incurred 
during the embryonic period persists in postmitotic cells, we examined γH2AX and 
ATRX staining patterns in P7 control and cKO forebrain cryosections. This analysis 
demonstrated that ATRX is indeed not expressed at the protein level and revealed that no 
damage was present or remained unrepaired in the absence of ATRX in the postnatal 
juvenile brain (Supplemental Figure 2-8a,b). Given the post-replicative state of the brain 
at this time, these data suggest that endogenous DNA damage due to loss of ATRX 
occurs primarily in proliferating cells in the embryonic and perinatal period. 
2.3.2 Accumulation of DNA damage in Atrx-null NPCs induces ATM 
activation and is exacerbated by p53 deletion 
Persistent DNA damage can result in the phosphorylation and upregulation of p53 by the 
ATR/Chk1 or ATM/Chk2 pathways, leading to cell cycle arrest or apoptosis (Roos and 
Kaina, 2006; Shiloh, 2001). We previously demonstrated that loss of ATRX results in a 
p53-dependent apoptotic response in cultured primary mouse NPCs and in vivo in the 
forebrain at E13.5 (Seah et al., 2008). To determine whether accumulated DNA damage 
could be the underlying cause of apoptosis, we performed double immunofluorescence of 
γH2AX and cleaved caspase-3, a marker of apoptotic cells. The majority of cells 
undergoing apoptosis (i.e., cleaved caspase-3+ cells) in the cKO telencephalon also 
stained positive for γH2AX, indicating that cell death is likely a downstream 
consequence of DNA damage (Figure 2-1c). To substantiate this conclusion and examine 
the role of p53, we generated ATRX/p53 compound mutant mice and assessed levels of 
DNA DSBs in the brain. γH2AX signal in cKO;p53–/– embryos was increased compared 
with that in cKO mice, suggesting that the accumulation of DNA damage in the ATRX-
deficient forebrain directly triggers a p53-dependent apoptotic response and that the 
absence of p53 prevents the removal of these cells by apoptosis (Figure 2-1a,b; right 
panels and graphs). We next explored the possible involvement of ATR and ATM 
signaling in the response to increased DNA damage. Western blot analysis of control and 
cKO E13.5 telencephalon protein extracts demonstrated similar activation of ATR in 
control and cKO samples. On the other hand, a clear increase in ATM activation was 
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observed in the cKO embryonic telencephalon (Figure 2-1d). Taken together, these 
findings show that loss of ATRX in the embryonic brain results in the accumulation of 
DNA damage, which triggers activation of ATM and p53, culminating in neuroprogenitor 
cell death. 
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Figure 2-1 Increased DNA damage leads to ATM activation and p53-dependent 
apoptosis in the Atrx-null embryonic brain 
(A) Immunostaining for γH2AX in E13.5 control (Ctrl), cKO, and cKO;p53–/– 
compound mutant cortical cryosections. Scale bar: 100 µm. DAPI staining of E13.5 
forebrain highlights in green the hippocampal hem (H), cortex (Ctx), and basal ganglia 
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(BG) regions where γH2AX foci per unit area were scored. Control, cKO, and cKO;p53-/-  
(n = 3); p53-/- (n = 2). (B) γH2AX staining in P0.5 control, cKO, and cKO;p53-/- cortical 
cryosections. Scale bar: 200 µm. DAPI staining of P0.5 forebrain highlights in green the 
hippocampus (H) and cortex (Ctx) regions where γH2AX foci per unit area were scored. 
Control and cKO (n = 3); cKO;p53-/- and p53-/- (n = 2). (C) Co-immunofluorescence 
detection of γH2AX (red) and activated caspase-3 (AC3; green) in E13.5 cortical 
cryosections. Scale bar: 30 µm. AC3+ cells were scored for the presence (AC3 + γH2AX) 
or absence (AC3 – γH2AX) of DNA damage (n = 3). (D) Western blot analysis of 
nuclear protein extracts obtained from E13.5 telencephalon (n = 3). While levels of ATR 
and phospho-ATR were not increased (left panels), phospho-ATM was noticeably 
increased in the cKO extracts compared with controls (indicated by an asterisk). Original 
magnification, ×100 (A and B); ×200 (C). *P < 0.05.  
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2.3.3 DNA damage response at telomeres and telomeric DNA end 
fusions 
To determine the specific genomic sites of DNA damage response incurred by loss of 
ATRX, we examined telomeres, since ATRX enrichment has been previously reported at 
these genomic regions. However, since it has been proposed that ATRX associates with 
telomeres only in pluripotent embryonic stem cells (Wong et al., 2010), we first assessed 
whether ATRX protein is present at telomeres in NPCs. ATRX immunofluorescence 
performed in conjunction with telomere FISH (Tel-FISH) in control NPCs demonstrated 
colocalization of ATRX and a subset of telomeres (Figure 2-2a). Next, we used Tel-FISH 
in combination with γH2AX immunostaining to determine whether the DNA repair 
machinery is activated at telomeric chromatin in cultured cKO NPCs. Confocal imaging 
showed that the number of telomere dysfunction–induced foci (TIFs) per nucleus was 
increased in the cKO compared with control NPCs (Figure 2-2b). In fact, 66.1% of all 
γH2AX foci were observed at telomeres in the cKO cells (Supplemental Figure 2-9b). 
ATRX protein also binds pericentromeric heterochromatin, and we repeated this 
experiment using major satellite-specific labeled DNA probes (MSat-FISH). Again, we 
found that γH2AX+/mSAT+ foci were more frequent in cKO NPCs and that a large 
proportion of DNA damage foci (69.51% ± 1.27%) corresponded to pericentromeric 
heterochromatin in cKO NPCs (Supplemental Figure 2-9a,b). These numbers reflect the 
acrocentric nature of mouse chromosomes, with some γH2AX foci overlapping with the 
p arm telomere and the adjacent pericentromeric region. Our results demonstrate that 
heterochromatic regions of the genome are prone to DNA damage in the absence of 
ATRX. To further explore the function of ATRX in genome stability, we examined 
metaphase spreads from control and cKO NPC cultures. ATRX immunostaining of 
control metaphase spreads revealed strong enrichment of the protein at pericentromeric 
heterochromatin and at some telomeres (Supplemental Figure 2-9c). Analysis of DAPI-
stained spreads revealed an increased frequency of chromosome fusions in cKO 
metaphase spreads compared with controls, as evidenced by overlapping chromosomes 
(Figure 2-2c). Centromere-to-centromere, centromere–to–q arm, and q arm–to–q arm 
fusions were observed. The number of chromosomes per metaphase spread was not 
affected in cKO NPCs (Supplemental Figure 2-9d). To further explore the nature of the 
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fusions, we performed TelFISH on control and cKO metaphase spreads and detected an 
increased incidence of telomeric DNA end fusions (Figure 2-2d). Other common defects 
included telomere deletions or duplications, as well as merged or bridged telomeres 
(Figure 2-2e). Overall, the frequency of all telomere defects was more than doubled in the 
cKO NPCs compared with controls, and defects involved the p and q arm telomeres at an 
equal frequency (Supplemental Figure 2-9e). 
2.3.4 ATRX is not required for the repair of DSBs 
Accumulation of DNA DSBs could occur if ATRX plays a direct role in DSB repair 
mechanisms. Two non–mutually exclusive pathways carry out repair of DNA DSBs: 
homologous recombination (HR) in proliferative cells; and non-homologous end joining 
(NHEJ) in postmitotic cells (Shrivastav et al., 2008). Since γH2AX foci were primarily 
concentrated in proliferative zones of the developing brain, we reasoned that ATRX may 
be specifically involved in the repair of DSBs via HR. To address this possibility, we 
cultured primary NPCs for 2 days in N2 neurobasal medium and exposed proliferative 
NPCs to γ-irradiation to induce DSBs and activate the HR pathway. The DNA damage 
response (i.e., γH2AX signal accumulation) was measured between 0 and 6 hours after 
irradiation, when damage induced by low doses of γ-irradiation should be actively 
resolved in control cells (Supplemental Figure 2-10). Both control and cKO NPC 
colonies showed a dose-dependent increase in γH2AX signal 3 hours after irradiation, 
which was subsequently resolved (i.e., decreased γH2AX staining) by 6 hours after 
treatment (Supplemental Figure 2-10). Therefore, we concluded that ATRX is not 
required for repair of exogenous irradiation–induced DSBs. 
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Figure 2-2 Increased DNA damage and telomere defects in cKO NPCs 
(A) Confocal immuno-FISH images of ATRX (red) and telomeres (Tel-FISH; green) in NPCs 
demonstrates colocalization of the ATRX protein with a subset of telomeres. Scale bar: 5 μm. (B) 
Confocal immuno-FISH images of γH2AX (red) and telomeres (Tel-FISH; green) shows 
increased incidence of TIF (γH2AX/Tel-FISH colocalization) in cKO compared with control 
NPCs (300 nuclei counted, n = 3 control/cKO littermate-matched pairs). Scale bar: 10 μm. (C) 
DAPI staining of control and cKO metaphase spreads shows representative chromosome fusion in 
cKO NPC metaphase (arrowhead). Frequency of fusions per metaphase was increased in cKO 
metaphases compared with control (control: 88 metaphases, cKO: 108 metaphases counted, n = 
3). (D) Tel-FISH (green) demonstrates increased telomeric fusions in cKO metaphase 
chromosomes compared with control (1,475 chromosomes counted; n = 3). (E) Telomere defects 
(deletion, merge, bridge, and duplication) were scored in control and cKO metaphase 
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Analysis of DAPI-stained spreads revealed an increased frequency 
of chromosome fusions in cKO metaphase spreads compared 
with controls, as evidenced by overlapping chromosomes (Fig-
ure 2C). Centromere-to-centromere, centromere–to–q arm, and 
q arm–to–q arm fusions were observed. The number of chro-
mosomes per metaphase spread was not affected in cKO NPCs 
(Supplemental Figure 2D). To further explore the nature of the 
fusions, we performed TelFISH on control and cKO metaphase 
spreads and detected an increased incidence f telomeric DNA 
end fusions (Figure 2D). Other common defects included telo-
mere deletions or duplications, as ell as merged or bridged telo-
meres (Figure 2E). Overall, the frequency of all telomere defects 
Figure 2
Increased DNA damage and telomere defects in cKO NPCs. (A) Confocal immuno-FISH images of ATRX (red) and telomeres (Tel-FISH; green) in 
NPCs demonstrates colocalization of the ATRX protein with a subset of telomeres. Scale bar: 5 μm. (B) Confocal immuno-FISH images of γH2AX 
(red) and telomeres (Tel-FISH; green) shows increased incidence of TIF (γH2AX/Tel-FISH colocalization) in cKO compared with control NPCs 
(300 nuclei counted, n = 3 control/cKO littermate-matched pairs). Scale bar: 10 μm. (C) DAPI staining of control and cKO metaphase spreads 
shows representative chromosome fusion in cKO NPC metaphase (arrowhead). Frequency of fusions p r metaphase was i creased in cKO 
metaphases compared with control (control: 88 metaphases, cKO: 108 metaphases counted, n = 3). (D) Tel-FISH (green) demonstrates increased 
telo eric fusions in cKO metaphase chromosomes compared with control (1,475 chromosomes counted; n = 3). (E) Telomere defects (deletion, 
merge, bridge, and duplication) were scored in control and cKO metaphase chromosomes. Representative images of defects appear to the right 
of quantification. In all cases, cKO chromosomes showed an increase in telomeric defects compared with control (1,475 chromosomes counted; 
n = 3). Original magnification, ×1,000 (A and B); ×630 (C–E). *P < 0.05.
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chromosomes. Representative images of defects appear to the right of quantification. In all cases, 
cKO chromosomes showed an increase in telomeric defects compared with control (1,475 
chromosomes counted; n = 3). Original magnification, x1,000 (A and B); x630 (C–E). *P < 0.05.  
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2.3.5 ATRX protects cells from replication stress 
Since ATRX does not appear to function in the repair of DSBs, we reasoned that it might 
help prevent DNA damage to preserve genomic integrity. Given that damage is restricted 
to proliferating regions of the cKO embryonic brain, we tested the possibility that cKO 
NPCs are particularly sensitive to DNA damage during S phase. We inactivated ATRX in 
AtrxloxP mouse embryonic fibroblasts (MEFs) with adenoviral delivery of Cre 
recombinase and treated them with hydroxyurea (HU), a drug that depletes 
deoxyribonucleotide pools, inhibits DNA synthesis, and causes replication fork stalling 
(Koc et al., 2004). MEFs were treated with increasing doses of HU for 24 hours, and cell 
viability was assessed 2 days later. MEFs lacking ATRX (Ad-CreGFP) were more 
sensitive to HU than untreated cells or cells treated with Ad-GFP. Ad-CreGFP treated 
MEFs were not more sensitive to γ-irradiation than Ad-GFP–transduced or untransduced 
cells (Figure 2-3a). We also treated control and cKO NPCs with HU and mitomycin C 
(MMC), a DNA crosslinker that also causes replication fork stalling. Both HU and MMC 
treatment caused decreased viability of cKO NPCs compared with control cells. As in 
MEFs, exposure to various doses of γ-irradiation did not alter cKO NPC viability 
compared with control NPCs, demonstrating a specific sensitivity to drugs that induce 
replication fork stalling (Figure 2-3b). 
Blocked replication forks could be a source of genomic instability in the cKO cells, since 
they can lead to collapse of the replisome and the formation of DSBs (Cahill et al., 2006). 
Replicating cortical NPCs lacking ATRX protein were assessed for DNA damage 
(γH2AX) at replication foci using an anti-PCNA antibody and imaged using confocal 
microscopy (Figure 2-3c). PCNA is a component of the replication machinery and 
exhibits a distinct staining pattern during S phase. In late S phase, the replication foci are 
observed in regions of the nucleus containing heterochromatin and as such colocalize 
with DAPI-bright heterochromatin bundles (Takanari et al., 1994). Atrx-null NPCs 
accumulated more DNA damage at these late replication foci compared with control 
cells, confirming an increase in DSBs during the replication process (Figure 2-3c). We 
also performed FACs analysis to determine whether S phase is extended in these cells. 
We detected a small but significant decrease in the G1 population and a modest increase 
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in S phase population in the cKO NPCs at 4 days in vitro. This suggests that difficulties 
in replicating heterochromatin result in a slight delay in S phase progression of cKO cells 
(Supplemental Figure 2-10b). We conclude from these findings that loss of ATRX results 
in an accumulation of endogenous replicative damage in cultured NPCs, specifically at 
late-replicating chromatin. 
2.3.6 G4-DNA stabilization exacerbates DNA damage and decreases 
viability of Atrx-null NPCs 
A potential function of ATRX is to stabilize stalled forks or facilitate the replication of 
complex secondary DNA structures, such as G4-DNA, which are found at telomeres, 
among other genomic sites (Wang and Patel, 1992). To test whether ATRX facilitates the 
replication of G4-DNA, we treated control and Atrx-null NPCs with TMS, a natural 
product isolated from Streptomyces anulatus that binds with high affinity to G4 structures 
(Shin-ya et al., 2001). Neuroprogenitors dissected from control and cKO embryonic 
forebrain were cultured and treated with 20 µM TMS for 24 hours. γH2AX staining was 
increased (Figure 2-3d), and cell viability was decreased (Figure 2-3e) in the TMS-
treated cKO NPCs compared with TMS-treated control cells. These findings suggest that 
ATRX deficiency in NPCs synergizes with G4-DNA stabilization to cause DNA damage 
and cell death. 
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Figure 2-3 ATRX-deficient cells are hypersensitive to replication stress-inducing 
agents and the G4-DNA ligand TMS 
(A) AtrxloxP/Y MEFs were untransduced or transduced with adenovirus expressing Cre 
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recombinase fused to GFP (Ad-CreGFP) or Ad-GFP and subsequently treated with HU 
for 24 hours or γ-irradiated at the indicated doses. Cell viability was measured at 24 hours 
after HU treatment (n = 4) and at 6 hours after irradiation (n = 3) via trypan blue dye 
exclusion. (B) Control and cKO NPCs were treated with HU or MMC for 24 hours or γ-
irradiated at the indicated doses. Cell viability was measured at 24 hours after HU and 
MMC treatment and at 6 hours after irradiation (n = 3). (C) Co-immunofluorescence 
detection of PCNA, a marker of replication foci, and γH2AX in control and cKO E13.5 
cortical cryosections. Results were quantified by measuring the ratio of γH2AX staining 
that localized to late-replicating PCNA foci to total γH2AX staining per cell, to account 
for overall lower levels of γH2AX signal in control cells (300 nuclei counted, n = 3). 
Scale bar: 12 µm. (D) Control and cKO NPCs were treated with 20 µm TMS for 2 hours, 
and γH2AX signal was imaged 6 hours after treatment. Scale bar: 70 µm. (E) Control and 
cKO NPCs were treated with TMS for 24 hours, and cell viability was measured 24 hours 
after treatment (n = 3). Original magnification, ×600 (C); ×100 (D). *P < 0.05.  
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2.3.7 Loss of ATRX shortens life span and induces progeroid-like 
phenotypes 
While a portion of mutant pups die in the neonatal period (Berube et al., 2005), many 
cKO male mice survived, but rarely longer than 30 days after birth (P30), with an average 
life span of 22.7 ± 1.7 days (Figure 2-4a). Moistening of food pellets to help with intake 
of solids did not improve life span, nor did the removal of siblings from the litter to 
reduce competition for breast milk (Figure 2-4a). Mutant mice at P20 had milk in the 
stomach, suggesting that starvation was not the cause of death or growth retardation. P17 
cKO mice had severely stunted growth compared with control littermates, as determined 
by measurements of body weight and length, as well as length of various skeletal 
elements (Figure 2-4b-e). Reduced body size was apparent at birth (Berube et al., 2005), 
but a more dramatic effect was seen from P5 onward. The tibia, femur, humerus, radius, 
ulna, and foot were significantly shorter in the cKO mice at P17 (Figure 2-4e). We 
confirmed specific deletion of ATRX in the forebrain of cKO mice at several postnatal 
time points, while ATRX remained expressed in other tissues, such as the liver, heart, 
thymus, spleen, testes, and skeletal growth plate of cKO mice (Supplemental Figure 2-
11a-d). 
Microcomputed tomography (microCT) analyses showed that cKO mutant mice 
displayed kyphosis, an abnormal curvature of the spinal column (Figure 2-5a), as well as 
decreased bone mineral density (BMD), lower trabecular number, and reduced bone 
cortical thickness (Figure 2-5a-d). Loss of trabecular bone was confirmed by picrosirius 
red staining of tibia, femur, and humerus of control and cKO mice at P17 (Figure 2-5e). 
To determine whether this effect stemmed from a developmental problem or was due to 
tissue degeneration, we also assessed trabecular bone at earlier ages. We found no 
difference in neonatal and P7 mice and detected an intermediate phenotype at P10, 
suggesting that bone development occurs initially normally, with evidence of 
deterioration from P10 onward (Supplemental Figure 2-11a). 
Extensive loss of subcutaneous fat (<25% of controls) was a constant characteristic of the 
mutant mice, while thickness of the dermis was not significantly affected (Figure 2-5f). 
Again, by measuring subcutaneous fat at various time points, we observed that this 
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phenotype was exacerbated at P20 compared with P10 (Supplemental Figure 2-12b,c). 
Mutant mice rarely opened their eyes, and analysis of the lens showed the formation of 
cataracts (Figure 2-5g). Accounting for decreased total body weight of the cKO mice, the 
spleen and liver were consistently smaller and the heart was significantly enlarged at P20 
(Figure 2-5h and Supplemental Figure 2-12d). These effects were also seen at P10 but 
were not as dramatic, as evidenced by a lack of significant difference between control 
and cKO organ size (Supplemental Figure 2-12d). The phenotypes described above 
strongly resemble those reported in several mutant mice displaying accelerated aging, but 
as the deterioration and death of the mice occurred rather quickly, it is difficult to 
completely distinguish between developmental and progeria-like phenotypes. 
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Figure 2-4 Reduced growth and life span in mice lacking ATRX in the forebrain 
(A) Kaplan-Meier survival curve of Cre+ control (n = 12) and cKO mice raised with 
(+sibs, n = 13) or without (–sibs, n = 11) siblings. Survival of cKO mice was significantly 
decreased compared with that of control mice (P = 0.0001). The survival of cKO mice 
was not significantly different whether they were raised with or without siblings (P = 
0.4974). (B) Representative pictures of P17 control and cKO littermates, illustrating size 
difference of the mice. (C) Body weight (g) and length (cm) measurements of control 
(Cre-, n = 25; Cre+, n = 8) and cKO (n = 24) mice. No significant difference was observed 
between Cre- and Cre+ control mice. (D) Skeletal elements of control and cKO mice were 
stained with alizarin red and alcian blue. (E) Length measurements of P17 control and 
cKO skeletal elements. (n = 5). *P < 0.05.  
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uncapping and initiation of the DNA damage response. This in 
turn may explain the increase in telomere fusions observed in Atrx-
null NPCs due to repeating break-fusion-br ak cycles. In contrast, 
heterochromatic regions flanking centromeres are AT rich, and 
a role for ATRX in facilitating replication of G4-DNA structures 
cannot explain the increased genetic damage at these sites. ATRX 
potentially plays a more general role in heterochromatin remodel-
ing/replication during late S phase or may be required to facilitate 
replication of other secondary structures. ATRX is associated with 
the DAXX histone chaperone and was proposed to participate 
in the incorporation of histone variant H3.3 at highly repetitive 
regions, including pericentric heterochromatin and telomeric chro-
matin (28, 49). There is evidence that promyelocytic nuclear bodies 
(PML-NBs) are involved in facilitating heterochromatin remodel-
ing/replication in late S/G2 phase (50). ATR-X syndrome patient 
mutations have been shown to alter ATRX targeting to PML-NBs, 
suggesting an important requirement for ATRX at these subnucle-
ar domains (51). ATRX and DAXX localize to PML-NBs during S 
phase and may be required for remodeling of heterochromat n dur-
ing replication, a process likely to involve nucleosome remodeling 
and histone variant deposition or ejection (52).
An important and unexpected finding from our studies is that 
specific loss of ATRX early during embryonic brain and pituitary 
development can influence postnatal health and life span. Sys-
temic loss or mutation of several factors required for telomeric 
stability, response to replication stress, or nucleotide excision 
repair (NER) cause phenotypes that resemble premature aging in 
mice (44, 53–60) and segmental progeria syndromes in humans, 
including XPF/ERCC1 in xeroderma pigmentosum, ERCC6/8 in 
Cockayne syndrome, and ATR in Seckel syndrome (61).
The link between excessive DNA damage and a suppressed IGF-1 
response, although reported in many progeria models, has not yet 
been satisfactorily explained. Here, we provide evidence that DNA 
damage in the embryonic pituitary leads to decreased expression 
of Tsh, with the predictable outcome of low thyroxine production 
by the thyroid. Recent reports have demonstrated that thyroid hor-
Figure 4
Reduced growth and life span in mice lacking ATRX in the forebrain. (A) Kaplan-Meier survival curve of Cre+ control (n = 12) and cKO mice 
raised with (+sibs, n = 13) or without (–sibs, n = 11) siblings. Survival of cKO mice was significantly decreased compared with that of control mice 
(P = 0.0001). The survival of cKO mice was not significantly different whether they were raised with or without siblings (P = 0.4974). (B) Representative 
pictures of P17 control and cKO littermates, illustrating size difference of the mice. (C) Body weight (g) and length (cm) measurements of control (Cre–, 
n = 25; Cre+, n = 8) and cKO (n = 24) mice. No significant difference was observed between Cre– and Cre+ control mice. (D) Skeletal elements of control 
and cKO mice were stained with alizarin red and alcian blue. (E) Length measurements of P17 control and cKO skeletal elements. (n = 5). *P < 0.05.
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Figure 2-5 Postnatal phenotypes in Atrx-cKO mice 
(A) Whole skeletal isosurface images of P17 control and cKO mice were generated using 
microCT. Arrow points to kyphosis. Scale bar: 10 mm. (B) Horizontal view of the cKO 
skull illustrates decreased bone mineralization. Scale bar: 5 mm. (C) Tibial cross section 
shows decreased cortical thickness. Scale bar: 1 mm. (D) Decreased BMD (*P = 0.002), 
trabecular number (**P = 0.002), and cortical thickness (†P = 0.0001) in the cKO mice 
compared with controls. Data were obtained from hind legs using MicroView 3D 
software (n = 3). (E) Picrosirius red staining of P17 control and cKO tibia (representative 
image), femur, and humerus reveals a drastic loss of trabecular bone area in cKO 
compared with control mice (n = 4; *P < 0.05). Scale bar: 200 µm. (F) H&E staining of 
P20 skin cryosections shows loss of subcutaneous fat in cKO compared with control mice 
(n = 3; *P = 0.0002). Dermal thickness was not significantly different (n = 3; *P = 
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mone is more critical than growth hormone in the regulation of 
IGF-1 levels at prepubertal stages of development (62). Genetically 
modified mice that are deficient in thyroid hormone show greater 
than 50% reduction in Igf1 expression in liver and bone, and T4 
treatment can reverse this effect (62). In addition, thyroid hormone 
and its receptor can bind intron 1 of the Igf1 gene and stimulate 
its expression (62). In line with this model, circulating thyroid 
hormone levels were decreased in the Atrx-cKO mice, and several 
thyroid hormone–responsive genes were decreased in the liver. We 
also detected altered expression of several genes involved in IGF-1 
signaling in the liver, including reduced Igfals and increased Igfbp1 
expression. Notably, Ercc1–/– mice exhibit a quite rapid postnatal 
degeneration phenotype similar to that of the Atrx-cKO mice, and 
Thrsp is the most downregulated gene in the Ercc1-null liver, exhib-
iting a 15-fold decrease (63). This suggests that diminished thyroid 
hormone action might be implicated in both models, and it will be 
Figure 5
Postnatal phenotypes in Atrx-cKO mice. (A) Whole skeletal isosurface images of P17 control and cKO mice were generated using microCT. Arrow 
points to kyphosis. Scale bar: 10 mm. (B) Horizontal view of the cKO skull illustrates decreased bone mineralization. Scale bar: 5 mm. (C) Tibial 
cross section shows decreased cortical thickness. Scale bar: 1 mm. (D) Decreased BMD (*P = 0.002), trabecular number (**P = 0.002), and corti-
cal thickness (†P = 0.0001) in the cKO mice compared with controls. Data were obtained from hind legs using MicroView 3D software (n = 3). (E) 
Picrosirius red staining of P17 control and cKO tibia (representative image), femur, and humerus reveals a drastic loss of trabecular bone area in 
cKO compared with control mice (n = 4; *P < 0.05). Scale bar: 200 μm. (F) H&E staining of P20 skin cryosections shows loss of subcutaneous fat 
in cKO compared with control mice (n = 3; *P = 0.0002). Dermal thickness was not significantly different (n = 3; *P = 0.3545). Scale bar: 300 mm. 
sf, subcutaneous fat; d, dermis. (G) Dark field image of P20 control and cKO ocular lenses demonstrates appearance of cataracts (loss of lens 
transparency) in cKO compared with control. (H) Dark field image of P20 control and cKO spleen demonstrates the disproportionally smaller size 
of cKO spleen. Original magnification, ×50 (E and F). See also Supplemental Figure 5.
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0.3545). Scale bar: 300 mm. sf, subcutaneous fat; d, dermis. (G) Dark field image of P20 
control and cKO ocular lenses demonstrates appearance of cataracts (loss of lens 
transparency) in cKO compared with control. (H) Dark field image of P20 control and 
cKO spleen demonstrates the disproportionally smaller size of cKO spleen. Original 
magnification, ×50 (E and F). See also Supplemental Figure 2-12.  
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2.3.8 Endocrine defects in Atrx-cKO mice 
To investigate the mechanism(s) by which ATRX disruption in the CNS could cause such 
drastic postnatal phenotypes, we first wanted to confirm that the skeletal growth 
phenotype was caused by non-cell-autonomous mechanisms. Indeed, tibiae from cKO 
and control mice grew at similar rates in ex vivo organ cultures and had similar growth 
plate length or organization (Figure 2-6a), substantiating that bone growth defects are 
caused by systemic alterations. 
Given the small size of the cKO mice, we suspected that the endocrine system might be 
defective. The insulin-like growth factor 1/growth hormone (IGF-1/GH) somatotroph 
axis has previously been linked to growth, aging, and life span (Niedernhofer et al., 
2006). We observed impairment in IGF-1 levels and signaling in the cKO mice. ELISA 
assays at P17 showed a dramatic reduction of serum and liver IGF-1 levels compared 
with those in control samples (Figure 2-6b). In addition, quantitative RT-PCR (qRT-
PCR) analyses revealed marked transcriptional alterations of key genes for somatotroph 
signaling in the liver (Figure 2-6c). 
Thyroid hormone is an important regulator of Igf1 expression and skeletal growth during 
the prepubertal growth period, while GH effects are limited at that time (Xing et al., 
2012). We observed that circulating thyroxine (T4) levels were dramatically decreased in 
the cKO mice, while the GH level was only slightly diminished, and the difference did 
not reach statistical significance (Figure 2-6d). In addition, expression of several thyroid 
hormone–responsive genes such as Thrsp, Nrp1, Ghr, Prlr was decreased in the liver 
(Figure 2-6e). It is important to note that Atrx transcript and protein levels were normal in 
livers of cKO mice (Supplemental Figure 2-11c and Figure 2-6e), indicating that these 
transcriptional effects are not due to spurious deletion of Atrx in the liver itself. Given 
that hypoglycemia is a feature of several mutant mice displaying segmental progeria 
(Mostoslavsky et al., 2006; van de Ven et al., 2006; van der Pluijm et al., 2007) and that 
thyroid hormone is essential for the maintenance of glucose homeostasis, we measured 
blood glucose and found that it was significantly lower in P20 cKO compared with 
control mice (Figure 2-6f). 
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Figure 2-6 Endocrine defects and hypoglycemia in Atrx-cKO mice 
(A) Longitudinal growth of control and cKO tibia was measured after 7 days (d7) of ex 
vivo culture. Results are expressed as the ratio of length at d7 to that at d0. No difference 
in growth was detected between control and cKO mice (n = 3). Scale bar: 100 µm. (B) 
Serum and liver IGF-1 levels are decreased in cKO mice (n = 3). (C) Expression of 
several IGF-1 pathway genes is altered in cKO liver compared with controls (n = 3). 
Real-time data were normalized to Gapdh expression. (D) Circulating T4 levels are 
significantly decreased in P20 cKO mice compared with controls, while GH levels are 
only mildly affected (n = 3). (E) Thyroid hormone target genes exhibit decreased 
expression in the liver of P20 cKO mice compared with controls (n = 3). Real-time data 
were normalized to Gapdh expression. (F) Glucose levels are reduced in P20 cKO serum 
compared with controls (n = 5). Original magnification, ×50 (A). *P < 0.05.  
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important in the future to examine thyroxine levels in other models 
of progeria. Taken together, our findings suggest that DNA dam-
age incurred in the embryonic anterior pituitary leads to defective 
expression of Tsh postnatally, causing hypothyroidism, decreased 
IGF-1 signaling, and hypoglycemia. Decreased IGF-1 in the serum 
can negatively impact skeletal growth development, trabecular con-
tent, and subsequent mineralization, as seen in our cKO mice (64). 
It should be noted that thyroid hormone can also act directly on 
target tissues such as growth plate chondrocytes, independent of 
liver-derived IGF-1. Reduced bone growth, and possibly other phe-
notypes observed in our mutant mice, might therefore be caused by 
a combinati n of reduc d circulating IGF-1 and reduced thyroid 
hormone receptor activation in the target tissue (65, 66).
Hyperactivity of the p53 tumor suppressor gene shortens 
life span and accelerates aging in mice (67). We had previously 
reported that p53 is activated in the absence of ATRX in the 
embryonic brain and that loss of p53 rescued cell death in the 
ATRX-deficient mouse brain (18). Thus, p53 is required for 
the removal of cells with excessive DNA damage in the Atrx-
null brain, which explains the enhanced accumulation of DNA 
damage we observed upon simultaneous loss of ATRX and p53. 
Decreased telomere stability and length are also key determi-
nants of life span and have been reported in cancer as well as 
several types of segmental progeria syndromes, such as Werner 
syndrome, Cockayne syndrome, dyskeratosis congenita, and 
Hutchinson-Gilford progeria (68–75). If telomeric damage is the 
Figure 6
Endocrine defects and hypoglycemia in Atrx-cKO mice. (A) Longitudinal growth of control and cKO tibia was measured after 7 days (d7) of ex 
vivo culture. Results are expressed as the ratio of length at d7 to that at d0. No difference in growth was detected between control and cKO mice 
(n = 3). Scale bar: 100 μm. (B) Serum and liver IGF-1 levels are decreased in cKO mice (n = 3). (C) Expression of several IGF-1 pathway genes is 
altered in cKO liver compared with controls (n = 3). Real-time data were normalized to Gapdh expression. (D) Circulating T4 levels are significantly 
decreased in P20 cKO mice compared with controls, while GH levels are only mildly affected (n = 3). (E) Thyroid hormone target genes exhibit 
decreased expression in the liver of P20 cKO mice compared with controls (n = 3). Real-time data were normalized to Gapdh expression. (F) 
Glucose levels are reduced in P20 cKO serum compared with controls (n = 5). Original magnification, ×50 (A). *P < 0.05.
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2.3.9 ATRX is deleted and causes DNA damage in the embryonic 
anterior pituitary 
The control of thyroid hormone levels and actions is complex and relies on the 
production of thyroid-releasing hormone (TRH) by the hypothalamus, leading to thyroid-
secreting hormone (TSH) production by the pituitary, which in turn induces T3 and T4 
synthesis by the thyroid gland (Gaitonde et al., 2012). To determine the cause of low 
circulating T4 levels, we first investigated Atrx and Tsh expression levels in the pituitary 
of control and cKO mice. Atrx expression was decreased, as were the levels of Tsh 
transcripts (Figure 2-7a). In addition, several genes responsible for T4 production (Tshr, 
Tpo, Tg, and Slc5a5) were expressed at lower levels in the thyroid of cKO mice 
compared with control mice (Figure 2-7a). These findings suggest that Atrx deletion in 
the pituitary impairs TSH production, leading to decreased signaling to the thyroid and 
low T4 production. ATRX immunofluorescence of P20 pituitary cryosections confirmed 
ATRX expression in the pituitary of control mice and that it was absent in the anterior 
and intermediate pituitary of cKO mice (Figure 2-7b,c). We also observed deletion of 
ATRX in the embryonic anterior pituitary at E13.5 (Figure 2-7d), which corresponded to 
a dramatic increase in γH2AX staining (Figure 2-7e). These results suggest that ATRX is 
deleted early during embryonic development of the anterior pituitary of cKO mice, where 
it causes increased DNA damage and results in abnormal function of the thyrotrophs in 
postnatal cKO mice. 
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Figure 2-7 Loss of ATRX in the developing anterior pituitary causes DNA damage, 
reduced Tsh expression, and altered thyroid function 
(A) Quantitative RT-PCR analysis of P23 control and cKO shows loss of Atrx expression 
in the pituitary (5.9-fold decrease) and thyroid (1.25-fold decrease). Tsha and Tshb 
subunits showed decreased expression in the pituitary, and a number of downstream 
targets of TSH showed decreased expression in the thyroid of cKO mice compared with 
controls (n = 3). (B) H&E staining of P23 control and cKO pituitary. Scale bar: 500 µm. 
(C) Immunofluorescence detection of ATRX expression in P23 control and cKO pituitary 
demonstrates specific loss of ATRX in the anterior and intermediate pituitary. Scale bars: 
500 µm (left panels) and 50 µm (right panels). A, anterior; I, intermediate; P, posterior 
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in ATRX-deficient human cells, such as chromosome missegrega-
tion, anaphase bridges, and micronucleus formation (19). Func-
tions for ATRX in restricting replicative stress, telomere fusions, 
and mitotic defects may also help explain the tumor-suppressive 
roles recently ascribed to the ATRX protein. Mutations in the 
ATRX gene were identified in several types of cancers, including 
pediatric brain tumors (5–7, 9, 10). A common d nominator in 
the majority of Atrx-null tumors was the frequent appearance 
of large telomeric foci, a hallmark of alternative lengthening of 
telomeres (ALT), providing further evidence that ATRX function 
is intimately linked to telomere biology, possibly as a suppressor 
of illegitimate recombination events. The hypersensitivity of Atrx-
key driver of life span, our findings would then suggest that telo-
meric abnormalities confined to specific brain and/or pituitary 
cells are in themselves sufficient to induce several aging-like phe-
notypes prematurely, a provocative idea that would have to be 
confirmed or dis issed in future work.
Problems in replication have been shown to lead to chromo-
some segregation failures in ensuing mit es (76). Similarly, sev-
eral G4-DNA ligands have been demonstrated to cause telomeric 
fusions and telomere aggregate formatio  that eventually lead to 
chromosomal instability, anaphase bridges, and mitotic catas-
trophe (77–81). It is conceivable that replicative damage is the 
underlying cause of mitotic defects that we previously reported 
Figure 7
Loss of ATRX in the developing anterior pituitary causes DNA damage, reduced Tsh expression, and altered thyroid function. (A) Quantitative RT-PCR 
analysis of P23 control and cKO shows loss of Atrx expression in the pituitary (5.9-fold decrease) and thyroid (1.25-fold decrease). Tsha and Tshb 
subunits showed decreased expression in the pituitary, and a number of downstream targets of TSH showed decreased expression in the thyroid 
of cKO mice compared with controls (n = 3). (B) H&E staining of P23 control and cKO pituitary. Scale bar: 500 μm. (C) Immunofluorescence 
detection of ATRX expression in P23 control and cKO pituitary demonstrates specific loss of ATRX in the anterior and intermediate pituitary. 
Scale bars: 500 μm (left panels) and 50 μm (right panels). A, anterior; I, intermediate; P, posterior pituitary. (D) Immunofluorescence detection 
of ATRX in E13.5 control and cKO sagittal embryonic pituitary cryosections shows loss of ATRX expression. Scale bar: 100 μm. Pit, pituitary. (E) 
Immunofluorescence detection of γH2AX in E13.5 sagittal embryonic pituitary cryosections shows increased DNA damage in cKO embryonic 
pituitary compared with control. Scale bar: 100 μm. Original magnification, ×25 (C, left panels); ×100 (C, right panels, and E); ×50 (D). *P < 0.05.
Downloaded from http://www.jci.org on February  8, 2015.   http://dx.doi.org/10.1172/JCI65634
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pituitary. (D) Immunofluorescence detection of ATRX in E13.5 control and cKO sagittal 
embryonic pituitary cryosections shows loss of ATRX expression. Scale bar: 100 µm. Pit, 
pituitary. (E) Immunofluorescence detection of γH2AX in E13.5 sagittal embryonic 
pituitary cryosections shows increased DNA damage in cKO embryonic pituitary 
compared with control. Scale bar: 100 µm. Original magnification, ×25 (C, left panels); 
×100 (C, right panels, and E); ×50 (D). *P < 0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
117 
 
2.4 Discussion 
We have shown that ATRX deficiency causes replicative DNA damage at telomeres and 
pericentromeric heterochromatin and increases the incidence of telomeric fusions. 
Moreover, deletion of the Atrx gene in the embryonic nervous system and anterior 
pituitary attenuates postnatal endocrine and metabolic signaling with concurrent growth 
reduction and progressive progeria-like tissue deterioration. Control experiments 
confirmed that loss of ATRX is restricted to the forebrain and anterior pituitary. 
Furthermore, our previous studies have shown that specific and efficient inactivation of 
the Atrx gene in cartilage does not cause any of the skeletal and growth phenotypes 
described here (Solomon et al., 2009), providing further evidence that these defects are 
non-cell-autonomous. 
We do not yet fully comprehend the mechanisms responsible for the accumulation of 
DNA damage observed in the Atrx-null embryonic forebrain and pituitary. We 
established that loss of ATRX does not prevent DNA repair, since γH2AX foci did no 
persist in the postnatal brain at P7 and Atrx-null cultured NPCs could resolve DSBs 
induced by γ-irradiation. However, we provide evidence that the accumulation of damage 
is partly due to replication stress linked to G4-DNA stability. Telomeres are 
nucleoprotein complexes that protect chromosome ends from degradation and end 
fusions. They consist of repetitive DNA high in guanine and cytosine nucleotide residues 
and have the ability to form G4s when in the single-stranded form (Wang and Patel, 
1992). The presence of these bulky DNA adducts can potentially impede DNA 
replication. We demonstrate that Atrx-null NPCs are hypersensitive to the potent G4 
ligand TMS, suggesting that in the absence of ATRX, cells have difficulty in resolving 
G4-DNA. This conclusion is supported by the demonstration that the ATRX protein can 
bind G4-DNA structures in vitro (Law et al., 2010). Since G4-DNA structures form at 
telomeres, the γH2AX signals we observed at telomeres in Atrx-null NPCs may result 
from a failure to properly resolve G4 structures, leading to telomere uncapping and 
initiation of the DNA damage response. This in turn may explain the increase in telomere 
fusions observed in Atrx-null NPCs due to repeating break-fusion-break cycles. In 
contrast, heterochromatic regions flanking centromeres are AT rich, and a role for ATRX 
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in facilitating replication of G4-DNA structures cannot explain the increased genetic 
damage at these sites. ATRX potentially plays a more general role in heterochromatin 
remodeling/replication during late S phase or may be required to facilitate replication of 
other secondary structures. ATRX is associated with the DAXX histone chaperone and 
was proposed to participate in the incorporation of histone variant H3.3 at highly 
repetitive regions, including pericentric heterochromatin and telomeric chromatin (Drane 
et al., 2010; Lewis et al., 2010). There is evidence that promyelocytic nuclear bodies 
(PML-NBs) are involved in facilitating heterochromatin remodeling/replication in late 
S/G2 phase (Luciani et al., 2006). ATR-X syndrome patient mutations have been shown 
to alter ATRX targeting to PML-NBs, suggesting an important requirement for ATRX at 
these subnuclear domains (Berube et al., 2008). ATRX and DAXX localize to PML-NBs 
during S phase and may be required for remodeling of heterochromatin during 
replication, a process likely to involve nucleosome remodeling and histone variant 
deposition or ejection (Ishov et al., 2004). 
An important and unexpected finding from our studies is that specific loss of ATRX early 
during embryonic brain and pituitary development can influence postnatal health and life 
span. Systemic loss or mutation of several factors required for telomeric stability, 
response to replication stress, or nucleotide excision repair (NER) cause phenotypes that 
resemble premature aging in mice (de Boer et al., 2002; Harada et al., 1999; Jaarsma et 
al., 2011; Murga et al., 2009; Niedernhofer, 2008a, b; O'Driscoll, 2009; van de Ven et al., 
2006; Weeda et al., 1997) and segmental progeria syndromes in humans, including 
XPF/ERCC1 in xeroderma pigmentosum, ERCC6/8 in Cockayne syndrome, and ATR in 
Seckel syndrome (Neveling et al., 2007). 
The link between excessive DNA damage and a suppressed IGF-1 response, although 
reported in many progeria models, has not yet been satisfactorily explained. Here, we 
provide evidence that DNA damage in the embryonic pituitary leads to decreased 
expression of Tsh, with the predictable outcome of low thyroxine production by the 
thyroid. Recent reports have demonstrated that thyroid hormone is more critical than 
growth hormone in the regulation of IGF-1 levels at prepubertal stages of development 
(Wang et al., 2010). Genetically modified mice that are deficient in thyroid hormone 
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show greater than 50% reduction in Igf1 expression in liver and bone, and T4 treatment 
can reverse this effect (Wang et al., 2010). In addition, thyroid hormone and its receptor 
can bind intron 1 of the Igf1 gene and stimulate its expression (Wang et al., 2010). In line 
with this model, circulating thyroid hormone levels were decreased in the Atrx-cKO 
mice, and several thyroid hormone–responsive genes were decreased in the liver. We also 
detected altered expression of several genes involved in IGF-1 signaling in the liver, 
including reduced Igfals and increased Igfbp1 expression. Notably, Ercc1-/- mice exhibit a 
quite rapid postnatal degeneration phenotype similar to that of the Atrx-cKO mice, and 
Thrsp is the most downregulated gene in the Ercc1-null liver, exhibiting a 15-fold 
decrease (Kamileri et al., 2012b). This suggests that diminished thyroid hormone action 
might be implicated in both models, and it will be important in the future to examine 
thyroxine levels in other models of progeria. Taken together, our findings suggest that 
DNA damage incurred in the embryonic anterior pituitary leads to defective expression of 
Tsh postnatally, causing hypothyroidism, decreased IGF-1 signaling, and hypoglycemia. 
Decreased IGF-1 in the serum can negatively impact skeletal growth development, 
trabecular content, and subsequent mineralization, as seen in our cKO mice (Mohan and 
Kesavan, 2012). It should be noted that thyroid hormone can also act directly on target 
tissues such as growth plate chondrocytes, independent of liver-derived IGF-1. Reduced 
bone growth, and possibly other phenotypes observed in our mutant mice, might 
therefore be caused by a combination of reduced circulating IGF-1 and reduced thyroid 
hormone receptor activation in the target tissue (Wit and Camacho-Hubner, 2011; 
Wojcicka et al., 2013). 
Hyperactivity of the p53 tumour suppressor gene shortens life span and accelerates aging 
in mice (Tyner et al., 2002). We had previously reported that p53 is activated in the 
absence of ATRX in the embryonic brain and that loss of p53 rescued cell death in the 
ATRX-deficient mouse brain (Seah et al., 2008). Thus, p53 is required for the removal of 
cells with excessive DNA damage in the Atrx-null brain, which explains the enhanced 
accumulation of DNA damage we observed upon simultaneous loss of ATRX and p53. 
Decreased telomere stability and length are also key determinants of life span and have 
been reported in cancer as well as several types of segmental progeria syndromes, such as 
Werner syndrome, Cockayne syndrome, dyskeratosis congenita, and Hutchinson-Gilford 
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progeria (Batenburg et al., 2012; Benson et al., 2010; Chang et al., 2004; Crabbe et al., 
2007; Damerla et al., 2012; Mitchell et al., 1999; Opresko et al., 2004; Shay and Wright, 
1999). If telomeric damage is the key driver of life span, our findings would then suggest 
that telomeric abnormalities confined to specific brain and/or pituitary cells are in 
themselves sufficient to induce several aging-like phenotypes prematurely, a provocative 
idea that would have to be confirmed or dismissed in future work. 
Problems in replication have been shown to lead to chromosome segregation failures in 
ensuing mitoses (Chan et al., 2009). Similarly, several G4-DNA ligands have been 
demonstrated to cause telomeric fusions and telomere aggregate formation that eventually 
lead to chromosomal instability, anaphase bridges, and mitotic catastrophe (Gauthier et 
al., 2012; Hampel et al., 2013; Incles et al., 2004; Kim et al., 2003; Tahara et al., 2006). It 
is conceivable that replicative damage is the underlying cause of mitotic defects that we 
previously reported in ATRX-deficient human cells, such as chromosome 
missegregation, anaphase bridges, and micronucleus formation (Ritchie et al., 2008). 
Functions for ATRX in restricting replicative stress, telomere fusions, and mitotic defects 
may also help explain the tumour-suppressive roles recently ascribed to the ATRX 
protein. Mutations in the ATRX gene were identified in several types of cancers, 
including pediatric brain tumours (Cheung et al., 2012; Heaphy et al., 2011a; Jiao et al., 
2011; Schwartzentruber et al., 2012; Yachida et al., 2012; Yuan et al., 2014). A common 
denominator in the majority of Atrx-null tumours was the frequent appearance of large 
telomeric foci, a hallmark of alternative lengthening of telomeres (ALT), providing 
further evidence that ATRX function is intimately linked to telomere biology, possibly as 
a suppressor of illegitimate recombination events. The hypersensitivity of Atrx-null 
neuroprogenitors to TMS is an important finding in that regard, as it indicates that Atrx-
null tumours may be susceptible to treatment with G4-DNA binding ligands. 
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2.5 Supplementary Figures 
 
Figure 2-8 DNA damage is not detected in the ATRX-null postnatal brain 
(A) Immunostaining for γH2AX in P7 control and cKO cortical cryosections. Scale bar: 
200 µm. (B) Immunostaining for ATRX in P7 control and cKO cortical cryosections. 
Scale bar: 200 µm. Original magnification, x50 (A and B). 
A
Figure S1
DNA damage is not detected in the ATRX-null postnatal brain. (A) Immunostaining for γH2AX in P7 control 
and cKO cortical cryosections. Scale bar: 200μm. (B) Immunostaining for ATRX in P7 control and cKO 
cortical cryosections. Scale bar: 200μm. Original magnification, x50 (A and B).
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Figure 2-9 DNA damage occurs at major satellite repeats and telomeric repeats in 
ATRX-null NPCs, however there is no difference in chromosome number and 
telomere defects are not restricted to the p or q arms of cKO chromosomes  
(A) Confocal immunoFISH images of γH2AX (red) and major satellite repeats (MajSat-
FISH; green) shows that DNA damage occurs at PCH more frequently in cKO compared 
to control NPCs (γH2AX/MSat-FISH colocalization; 300 nuclei counted, n = 3). (B) 
Since endogenous γH2AX levels are higher in cKO NPCs compared to control, the ratio 
of γH2AX and Tel-FISH or MajSat-FISH colocalization vs. total γH2AX foci per cell 
was calculated to obtain a relative measure of the percentage of γH2AX foci per nucleus 
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that occurred at either telomeres or major satellite repeats (300 nuclei counted, n = 3). 
Scale bar: 10 µm. (C) ImmunoFISH staining of ATRX (red) and telomeres (Tel-FISH; 
green) in control and cKO NPCs demonstrates loss of ATRX staining in cKO NPCs. 
Scale bar: 10 µm. (D) Chromosome number per metaphase spread did not differ between 
control and cKO NPCs (control: 88 metaphases and cKO 108 metaphases, n = 3). (E) 
Telomeric defects quantified in Figure 2-2e were scored for occurring on the P or Q arm 
of chromosomes. Frequency of defects on either arm did not differ in control and cKO 
NPCs (1475 chromosomes counted, n = 3). Original magnification, x1000 (A); x630 (C). 
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Figure 2-10 ATRX deficiency does not influence repair of DSBS, however causes a 
slight decrease in G0/G1-phase NPCs with a concomitant increase in S-phase cells at 
4 days in vitro (D.I.V.) 
(A) Control and cKO NPCs were exposed to 0, 1 and 10 Gy doses of γ-irradiation to 
induce DSBs. γH2AX signal was assessed at 0h, 3h and 6h post-irradiation. DSBs 
induced by γ-irradiation were largely repaired by 6h post-treatment in both control and 
cKO NPCs, as evidenced by the resolution of γH2AX foci. Scale bars: 100 µm. (B) 
Actively proliferating control and cKO NPCs were pulse-labeled with BrdU at 2 and 4 
D.I.V., processed for flow cytometry, and analyzed for propidium iodide (PI) and BrdU 
staining. The proportion of cells in each phase of the cell cycle is indicated (n = 3). 
Original magnification, x200 and x100 (A). 
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Figure S3
ATRX deficiency does not influence repair of DSBs, however caus s a slight decrease in G0 /G1/-phase NPCs with a
concomitant increase in S-phase cells at 4 days in vitro (D.I.V.). (A) Control and cKO NPCs were exposed to 0, 1 and 
5 Gy doses of γ-irradiation to induce DSBs. γH2AX signal was assessed at 0h, 3h and 6h post-irradiation. DSBs 
induced by γ-irradiation were largely repaired by 6h post-treatment in both control and cKO NPCs, as evidenced by 
the resolution of γH2AX foci. Scale bars: 100μm. (B) Actively proliferating control and cKO NPCs were pulse-labeled 
with BrdU at 2 and 4 D.I.V., processed for flow cytometry, and analyzed for propidium iodide (PI) and BrdU staining. 
The proportion of cells in each phase of the cell cycle is indicated (n = 3). Original magnification, x200 
(A).
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Figure 2-11 ATRX is specifically deleted in the forebrain 
(A) Western blot analysis of ATRX expression using nuclear protein extracts obtained 
from P0.5, P10, and P20 control and cKO telencephalon (n = 3). (B) Quantitative RT-
PCR analysis of Atrx expression in P20 control and cKO organs. Forebrain and liver (n = 
3); heart, thymus, spleen, and testes (n = 1). Real-time data is normalized to Gapdh 
expression. (C) Western blot analysis of ATRX expression using nuclear protein extracts 
obtained from P20 control and cKO liver. (D) Immunohistochemistry detection of ATRX 
in P20 control and cKO tibia paraffin-embedded sections. Scale bar: 100 µm. Original 
magnification, x50 (D). 
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Figure 2-12 Worsening postnatal phenotypes in ATRX cKO mice 
Figure S5 
Worsening postnatal phenotypes in ATRX cKO mice. ( ) Quantification of Picrosirius Red staining in 
tibia, femur and humerus reveals trabecular bone area is not significantly different between control and 
cKO until approximately P10 (n = 3 at both time points). (B) H&E staining of skin cryosections from P10 
and P14 shows decreased subcutaneous fat thickness as early as P10 in cKO mice compared to 
controls (P10, n = 3; P14 n = 1). Scale bar: 200μm. (C) Subcutaneous fat thickness in the Atrx cKO 
at different developmental time points shows cKO mice develop subcutaneous fat (P10), which is 
gradually reduced in thickness by P20 (n = 3 at P10 and P20; *P = 0.0409). (D) Organ weight (g) relative 
to total body weight at P10 and P20. Representative dark field images of organs from control and cKO 
mice at the indicated time points. 
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(A) Quantification of Picrosirius Red staining in tibia, femur and humerus reveals 
trabecular bone area is not significantly different between control and cKO until 
approximately P10 (n = 3 at both time points). (B) H&E staining of skin cryosections 
from P10 and P14 shows decreased subcutaneous fat thickness as early as P10 in cKO 
mice compared to controls (P10, n = 3; P14, n = 1). Scale bar: 200 µm. (C) Subcutaneous 
fat thickness in the Atrx cKO at different developmental time points shows cKO mice 
develop subcutaneous fat (P10), which is gradually reduced in thickness by P20 (n = 3 at 
P10 and P20; *P = 0.0409). (D) Organ weight (g) relative to total body weight at P10 and 
P20. Representative dark field images of organs from control and cKO mice at the 
indicated time points. Original magnification, x50 (B). 
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Chapter 3 
3 Dual effect of CTCF loss on neuroprogenitor 
differentiation and survival 
This study was the first to investigate the functions of CTCF in brain development. Prior 
to this study virtually nothing was known regarding CTCF activities in the brain, or in a 
general physiological context. This chapter investigates the consequences of CTCF loss-
of-function to embryonic brain development by primarily focusing on neocortical 
neurogenesis, which is particularly relevant to understanding the significance of human 
CTCF mutations that cause intellectual disability. 
This chapter was previously published as (Watson et al., 2014). The Journal of 
Neuroscience does not require permissions for reproduction. 
3.1 Introduction 
CTCF is a multifunctional DNA binding protein that regulates higher-order chromatin 
structure to influence transcriptional regulation, genomic imprinting, X chromosome 
inactivation, and chromatin insulation (Holwerda and de Laat, 2013). It binds to a variety 
of highly divergent target sequences throughout the genome using a combination of its 11 
zinc finger motifs (Nakahashi et al., 2013). CTCF partners with a number of chromatin-
related proteins such as the cohesin complex (Parelho et al., 2008; Wendt and Peters, 
2009), nucleophosmin, and CTCF itself (Yusufzai and Felsenfeld, 2004; Yusufzai et al., 
2004). These interactions may allow CTCF sites to contact one another and/or to be 
tethered to subnuclear domains. CTCF-mediated chromatin interactions detected by 
Chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) correlate with 
approximately 10% of all CTCF binding sites (CBSs), however, indicating that CTCF 
likely plays additional roles within the cell (Handoko et al., 2011). 
De novo mutations in CTCF have been identified previously in patients with varying 
degrees of intellectual disability and microcephaly (Gregor et al., 2013), highlighting the 
importance of chromatin organization for the normal development and function of the 
CNS. Whereas CTCF function has been studied extensively in cell culture systems, its 
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function in an in vivo context remains to be completely resolved (Ohlsson et al., 2010a). 
Ubiquitous deletion of CTCF in the mouse leads to lethality before embryonic day 3.5 
(E3.5), suggesting that it is essential for early developmental processes (Fedoriw et al., 
2004; Heath et al., 2008; Moore et al., 2012). Conditional deletion of Ctcf in specific 
tissues causes either reduced proliferation or apoptotic cell death, depending on the tissue 
targeted for Cre recombination. For example, deletion of Ctcf in thymocytes resulted in 
increased p21 and p27 expression and cell cycle arrest, whereas reduced CTCF in mouse 
oocytes induced meiotic and mitotic defects and apoptotic cell death before the blastocyst 
stage (Fedoriw et al., 2004; Heath et al., 2008; Wan et al., 2008). Deletion of Ctcf in the 
developing limb bud resulted in massive apoptosis and near-complete loss of limb 
structures, accompanied by increased p53 upregulated modulator of apoptosis (PUMA), a 
known activator of caspase-mediated apoptosis (Nakano and Vousden, 2001; Soshnikova 
et al., 2010; Yu et al., 2001). In human cancer cells, CTCF binds to the Puma gene, and 
its depletion results in increased Puma transcript and rapid apoptosis, indicating that 
Puma transcription can be directly influenced by the presence or absence of CTCF 
(Gomes and Espinosa, 2010a, b). 
Given the deleterious effects of CTCF mutations in the human CNS, we specifically 
inactivated Ctcf in the developing mouse brain. CTCF loss of function using two different 
Cre driver lines in mice triggered apoptosis in dividing neuroprogenitor cells (NPCs) of 
the forebrain. Despite prevention of apoptosis by Puma deletion, rescued Ctcf/Puma 
double-null apical and outer radial glia (oRG) progenitors exhibited decreased 
proliferative capacity. Furthermore, loss of CTCF caused premature neurogenesis, 
resulting in depletion of the progenitor pool and a microcephaly phenotype at birth. These 
findings highlight the complexity of CTCF activities during neurogenesis. 
3.2 Materials and Methods 
3.2.1 Mouse husbandry and genotyping 
Mice were exposed to 12 h light/dark cycles and fed tap water and regular chow ad 
libitum. The CtcfloxP mice, in which loxP sites flank exons 3–12, have been described 
previously (Heath et al., 2008). Mice conditionally deficient in CTCF were generated by 
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crossing CtcfloxP/+ females (C57BL/6 background) with heterozygous Foxg1Cre knock-in 
male mice (129/sv background) or with NestinCre heterozygous male mice (C57BL/6 
background; (Berube et al., 2005; Hebert and McConnell, 2000). To account for 
decreased Foxg1 expression due to knock-in of the Cre recombinase gene, Cre+ males 
were used as controls (Ctcf+/+Foxg1-cre+/−) unless stated otherwise. Using the NestinCre 
driver line, CtcfloxP/loxP mice were crossed with CtcfloxP/+;Nestin+ mice to generate Ctcflox/P/loxP 
or CtcfloxP/+ (controls) and CtcfloxP/loxP;Nestin+ (CtcfNes-cre). Puma−/− (Bbc3tm1Ast) mice were 
obtained from The Jackson Laboratory (stock #011067; (Villunger et al., 2003). DNA 
from tail biopsies of newborn pups or yolk sac from embryos was genotyped by PCR. 
Primer sequences are provided in Table 1. 
3.2.2 Immunostaining and histology 
For immunofluorescence staining, cryosections were incubated with the primary antibody 
overnight at 4°C, washed in PBS/0.3% Triton-X 100, and incubated with the secondary 
antibody for 1 h. Sections were counterstained with DAPI (Sigma-Aldrich) and mounted 
in SlowFade Gold (Invitrogen). Primary antibodies used were as follows: rabbit anti-
CTCF (1:400; Cell Signaling Technology), rabbit anti-cleaved caspase 3 (AC3; Asp175; 
1:400; Cell Signaling Technology), mouse anti-BrdU (1:50; BD Biosciences), rabbit anti-
PUMA (1:200; Cell Signaling Technology), rabbit anti-TBR2 (1:200; Abcam), goat anti-
SOX2 (1:400; Santa Cruz Biotechnology), goat anti-PAX6 (1:200; Santa Cruz 
Biotechnology), rabbit anti-SOX2 (1:100; Millipore Bioscience Research Reagents), 
rabbit anti-Ki67 (1:200; Abcam), rabbit anti-TBR1 (1:200; Abcam), mouse anti-SATB2 
(1:200; Abcam), and rabbit anti-CTIP2 (1:200; Abcam). Secondary antibodies used were 
as follows: goat-anti-rabbit Alexa 594 (1:800; Invitrogen), goat-anti-mouse Alexa 488 
(1:800; Invitrogen), donkey-anti-sheep Alexa 594 (1:800; Invitrogen), and donkey-anti-
mouse Alexa 488 (1:800; Invitrogen). Sections were subjected to antigen retrieval 
(incubated in 0.1 mM sodium citrate, pH 6.0, heated to ∼95°C and microwaved on low 
for 10 min) before overnight incubation (for BrdU, SOX2, PAX6, TBR2, STAB2, TBR1, 
and CTIP2). Terminal deoxynucleotidyl nick end labeling (TUNEL) was performed 
according to the manufacturer's instructions (Roche). For histological studies, slides were 
stained with hematoxylin and eosin (H&E). 
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3.2.3 BrdU labeling 
Pregnant mice were injected intraperitoneally with cell proliferation labeling reagent [10 
mM bromodeoxyuridine (BrdU) and 1 mM fluorodeoxyuridine (FdU) in H2O] at 1 
ml/100 g body weight, or 0.3 mg/g body weight (GE Healthcare Life Sciences). Animals 
were killed after 1 h by CO2 asphyxiation, and the embryos were recovered in ice-cold 
PBS, pH 7.4, and were fixed in 4% paraformaldehyde. Tissue was equilibrated in 30% 
sucrose/PBS and frozen in OCT (Tissue Tek). For cell cycle exit analysis, pregnant 
female mice (E13) were injected with cell proliferation labeling reagent at 1 ml/100 g 
body weight (GE Healthcare Life Sciences), and embryos were collected and processed 
for immunofluorescence analysis 24 h later. Before immunofluorescence analysis, 
cryosections (8 µm) were treated with 2N HCl to denature the DNA, and neutralized with 
0.1 M Na2B4O7, pH 8.5. 
3.2.4 Primary NPC cultures and manipulation 
Cortical progenitor cultures were prepared as described previously (Gloster et al., 1999; 
Slack et al., 1998; Watson et al., 2013) using cortices dissected from E12.5 embryos. 
Cells were seeded on polyornithine-coated (Sigma-Aldrich) plastic plates or glass 
coverslips. Cells were fixed in 4% paraformaldehyde for 10 min, washed in PBS, and 
processed for immunofluorescence. Cell viability was measured using the trypan blue dye 
exclusion method. Cell counts were determined with a hemacytometer. 
3.2.5 Western blot analysis 
Nuclear protein was extracted from the E16.5 telencephalon using a standard extraction 
kit (Thermo Scientific) and quantified using the Bradford assay. Protein (20 µg) was 
resolved on a 6% SDS-polyacrylamide gel and transferred onto a nitrocellulose 
membrane (Bio-Rad). The membrane was probed with rabbit anti-p53 (1:500; Santa Cruz 
Biotechnology) and rabbit anti-inner centromere protein (INCENP) (1:10000; Sigma 
Aldrich) antibodies followed by the appropriate horseradish peroxidase-conjugated 
secondary antibodies (1:4000; GE Healthcare Life Sciences). The membrane was 
incubated in ECL before exposure to x-ray film. Densitometry analysis was performed 
using ImageJ software (version 1.47). 
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3.2.6 Real-time PCR 
Total RNA was isolated using the RNeasy Mini kit (Qiagen). First-strand cDNA was 
synthesized from 1 µg of total RNA using the SuperScriptTM II Reverse Transcriptase 
kit (Invitrogen) with deoxyribonucleotide triphosphates (dNTPs) (1 mM final 
concentration; GE Healthcare), porcine RNAguard (GE Healthcare), and 0.3 µg random 
primers (GE Healthcare). Amplification was performed using a Chromo-4 Continuous 
Fluorescence Detector (Bio-Rad) in the presence of iQ SYBR Green supermix (Bio-Rad) 
and recorded using Opticon Monitor 3 software (Bio-Rad). Results were normalized to β-
actin expression, and relative gene expression levels were calculated using GeneX 
software (Bio-Rad). Samples were amplified as follows: 95°C for 10 s, annealed for 20 s, 
72°C for 30 s. After amplification, a melting curve was generated, and samples were 
resolved on a 1.5% agarose gel (75 V for 1 h) to verify amplicon purity. Primer oligomers 
were designed using Primer3 software (http://bioinfo.ut.ee/primer3-0.4.0/primer3/) and 
were obtained from Integrated DNA Technologies. Sequences are provided in Table 1. 
3.2.7 Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) experiments were performed as described 
previously (Kernohan et al., 2010). Briefly, mouse forebrain tissue was dissected and 
processed to single-cell suspension. Cells were cross-linked in 1% formaldehyde, lysed in 
SDS buffer and sonicated. Immunoprecipitation was performed with a rabbit anti-CTCF 
antibody (Cell Signaling Technology) and a rabbit anti-p53 antibody (Santa Cruz 
Biotechnology). Input samples represent 1/25 of total chromatin input. ChIP products 
were amplified in duplicate with iQ SYBR Green Master Mix (Bio-Rad) on a Chromo-4 
thermocycler under the following conditions: 95°C for 5 min, followed by 35 cycles of 
95°C for 10 s, 55°C for 20 s, 72°C for 30 s, and a final melting curve generated from 
55°C to 95°C in increments of 1°C per plate read. Fold change and percent input 
formulas were adapted from (Mukhopadhyay et al., 2004) as follows: percent input = 100 
* [2(ΔCtInput − ΔCtInput) − (ΔCtInput − ΔCtAb)]/25. Error bars represent the SEM. 
Primer sequences are provided in Table 1. 
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3.2.8 Microscopy 
Images were captured with a digital camera (ORCA-ER; Hamamatsu) using an inverted 
microscope (DMI 6000b; Leica). Openlab imaging software (PerkinElmer) was used for 
manual image capture, and processing was performed using Volocity software 
(PerkinElmer). For quantification of AC3+ cells per area, AC3+ cells were counted in a 
defined area in at least six serial cortical cryosections, and the ratio of AC3+ cells to area 
(square millimeters) was calculated. For BrdU, SOX2, TBR2, BrdU/Ki67, TBR1, 
SATB2, and CTIP2 quantification, at least two serial cortical cryosections were assessed 
for positive cells within the indicated regions per embryo. DAPI morphology was used to 
bin cortex into the ventricular/subventricular zone (VZ/SVZ), intermediate zone (IZ), and 
cortical plate (CP). 
3.2.9 Statistical analyses 
Statistical analysis was performed using GraphPad Prism software (GraphPad Software; 
version 4.02), and all results are expressed as the mean ± SEM. Unless indicated 
otherwise, p values were generated using Student's t test (unpaired, two-tailed) to 
compare between two independent data sets. Genotype ratios (Figure 3-1a, 3-2a) were 
compared using a χ2 test. To compare cell viability data (see Figure 3-4e), a one-way 
ANOVA was used with Dunnett's multiple comparison post-test to compare the cell 
viability of each genotype (CtcfNes-cre, CtcfNes-cre;Puma−/−, and Puma−/−) to control. 
3.2.10 Study approval 
All procedures involving animals were conducted in accordance with the regulations of 
the Animals for Research Act of the Province of Ontario and approved by the University 
of Western Ontario Animal Care and Use Committee. 
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Puma transcript and rapid apoptosis, indicating that Puma tran-
scription can be directly influenced by the presence or absence of
CTCF (Gomes and Espinosa, 2010a,b).
Given the deleterious effects ofCTCFmutations in the human
CNS, we specifically inactivated Ctcf in the developing mouse
brain. CTCF loss of function using two different Cre driver lines
in mice triggered apoptosis in dividing neuroprogenitor cells
(NPCs) of the forebrain. Despite prevention of apoptosis by
Puma deletion, rescued Ctcf/Puma double-null apical and outer
radial glia (oRG) progenitors exhibited decreased proliferative
capacity. Furthermore, loss of CTCF caused premature neuro-
genesis, resulting in depletion of the progenitor pool and a mi-
crocephaly phenotype at birth. These findings highlight the
complexity of CTCF activities during neurogenesis.
Materials andMethods
Mouse husbandry and genotyping. Mice were exposed to 12 h light/dark
cycles and fed tap water and regular chow ad libitum. The Ctcf loxP mice,
in which loxP sites flank exons 3–12, have been described previously
(Heath et al., 2008).Mice conditionally deficient inCTCFwere generated
by crossingCtcf loxP/! females (C57BL/6 background) with heterozygous
Foxg1Cre knock-in male mice (129/sv background) or with NestinCre
heterozygous male mice (C57BL/6 background; He´bert andMcConnell,
2000; Be´rube´ et al., 2005). To account for decreased Foxg1 expression due
to knock-in of the Cre recombinase gene, Cre!males were used as con-
trols (Ctcf!/!Foxg1-cre!/") unless stated otherwise. Using theNestinCre
driver line, Ctcf loxP/loxP mice were crossed with Ctcf loxP/!;Nestin! mice
to generate Ctcf lox/P/loxP or Ctcf loxP/! (controls) and Ctcf loxP/loxP;Nestin!
(CtcfNes-cre). Puma"/" (Bbc3tm1Ast) mice were obtained from The Jack-
son Laboratory (stock #011067; Villunger et al., 2003). DNA from tail
biopsies of newborn pups or yolk sac from embryos was genotyped by
PCR. Primer sequences are provided in Table 1.
Immunostaining and histology. For immunofluorescence staining,
cryosections were incubated with the primary antibody overnight at 4°C,
washed in PBS/0.3% Triton-X 100, and incubated with the secondary
antibody for 1 h. Sections were counterstained with DAPI (Sigma-
Aldrich) andmounted in SlowFade Gold (Invitrogen). Primary antibod-
ies used were as follows: rabbit anti-CTCF (1:400; Cell Signaling
Technology), rabbit anti-cleaved caspase 3 (AC3; Asp175; 1:400; Cell
Signaling Technology), mouse anti-BrdU (1:50; BD Biosciences), rabbit
anti-PUMA(1:200; Cell SignalingTechnology), rabbit anti-TBR2 (1:200;
Abcam), goat anti-SOX2 (1:400; Santa Cruz Biotechnology), goat anti-
PAX6 (1:200; Santa Cruz Biotechnology), rabbit anti-SOX2 (1:100; Mil-
lipore Bioscience Research Reagents), rabbit anti-Ki67 (1:200; Abcam),
rabbit anti-TBR1 (1:200; Abcam), mouse anti-SATB2 (1:200; Abcam),
and rabbit anti-CTIP2 (1:200; Abcam). Secondary antibodies used were
as follows: goat-anti-rabbit Alexa 594 (1:800; Invitrogen), goat-anti-
mouse Alexa 488 (1:800; Invitrogen), donkey-anti-sheep Alexa 594 (1:
800; Invitrogen), and donkey-anti-mouse Alexa 488 (1:800; Invitrogen).
Sections were subjected to antigen retrieval (incubated in 0.1mM sodium
citrate, pH 6.0, heated to #95°C and microwaved on low for 10 min)
before overnight incubation (for BrdU, SOX2, PAX6, TBR2, STAB2,
TBR1, and CTIP2). Terminal deoxynucleotidyl nick end labeling
(TUNEL) was performed according to the manufacturer’s instructions
(Roche). For histological studies, slides were stained with hematoxylin
and eosin (H&E).
BrdU labeling. Pregnant mice were injected intraperitoneally with cell
proliferation labeling reagent [10 mM bromodeoxyuridine (BrdU) and 1
mM fluorodeoxyuridine (FdU) in H2O] at 1ml/100 g body weight, or 0.3
mg/g body weight (GE Healthcare Life Sciences). Animals were killed
after 1 h by CO2 asphyxiation, and the embryos were recovered in ice-
cold PBS, pH 7.4, and were fixed in 4% paraformaldehyde. Tissue was
equilibrated in 30% sucrose/PBS and frozen in OCT (Tissue Tek). For
cell cycle exit analysis, pregnant femalemice (E13) were injected with cell
proliferation labeling reagent at 1 ml/100 g body weight (GE Healthcare
Life Sciences), and embryos were collected and processed for immuno-
fluorescence analysis 24 h later. Before immunofluorescence analysis,
cryosections (8!m)were treated with 2NHCl to denature theDNA, and
neutralized with 0.1 M Na2B4O7, pH 8.5.
Primary NPC cultures and manipulation. Cortical progenitor cultures
were prepared as described previously (Slack et al., 1998; Gloster et al.,
1999; Watson et al., 2013) using cortices dissected from E12.5 embryos.
Cells were seeded onpolyornithine-coated (Sigma-Aldrich) plastic plates
or glass coverslips. Cells were fixed in 4% paraformaldehyde for 10 min,
washed in PBS, andprocessed for immunofluorescence. Cell viabilitywas
measured using the trypan blue dye exclusion method. Cell counts were
determined with a hemacytometer.
Western blot analysis. Nuclear protein was extracted from the E16.5
telencephalon using a standard extraction kit (Thermo Scientific) and
quantified using the Bradford assay. Protein (20 !g) was resolved on a
6% SDS-polyacrylamide gel and transferred onto a nitrocellulose mem-
brane (Bio-Rad). Themembranewas probedwith rabbit anti-p53 (1:500;
Santa Cruz Biotechnology) and rabbit anti-inner centromere protein
(INCENP) (1:10000; Sigma Aldrich) antibodies followed by the appro-
priate horseradish peroxidase-conjugated secondary antibodies (1:4000;
GE Healthcare Life Sciences). The membrane was incubated in ECL be-
fore exposure to x-ray film. Densitometry analysis was performed using
ImageJ software (version 1.47).
Real-time PCR. Total RNA was isolated using the RNeasy Mini kit
(Qiagen). First-strand cDNA was synthesized from 1 !g of total RNA
using the SuperScriptTM II Reverse Transcriptase kit (Invitrogen) with
deoxyribonucleotide triphosphates (dNTPs) (1 mM final concentration;
GE Healthcare), porcine RNAguard (GE Healthcare), and 0.3 !g ran-
dom primers (GE Healthcare). Amplification was performed using a
Chromo-4 Continuous Fluorescence Detector (Bio-Rad) in the presence of
iQSYBRGreen supermix (Bio-Rad) and recordedusingOpticonMonitor 3
software (Bio-Rad). Results were normalized to"-actin expression, and rel-
ativegeneexpression levelswere calculatedusingGeneXsoftware (Bio-Rad).
Samples were amplified as follows: 95°C for 10 s, annealed for 20 s, 72°C for
30 s. After amplification, a melting curve was generated, and samples were
resolved on a 1.5% agarose gel (75 V for 1 h) to verify amplicon purity.
Primer oligomers were designed using Primer3 software (http://bioinfo.ut.
ee/primer3-0.4.0/primer3/) andwere obtained from IntegratedDNATech-
nologies. Sequences are provided in Table 1.
Chromatin immunoprecipitation. Chromatin immunoprecipitation
(ChIP) experiments were performed as described previously (Kernohan
et al., 2010). Briefly, mouse forebrain tissue was dissected and processed
to single-cell suspension. Cells were cross-linked in 1% formaldehyde,
lysed in SDS buffer and sonicated. Immunoprecipitation was performed
with a rabbit anti-CTCF antibody (Cell Signaling Technology) and a
rabbit anti-p53 antibody (Santa Cruz Biotechnology). Input samples
represent 1/25 of total chromatin input. ChIP products were amplified in
duplicate with iQ SYBR Green Master Mix (Bio-Rad) on a Chromo-4
thermocycler under the following conditions: 95°C for 5 min, followed
by 35 cycles of 95°C for 10 s, 55°C for 20 s, 72°C for 30 s, and a final
Table 1. Primer sequences used for genotyping, gene expression, and qChIP
analyses
Primer Name Forward sequence (5$-3$) Reverse sequence (5$-3$)
Ctcf CTAGGAGTGTAGTTCAGTGAGGCC GCTCTAAAGAAGGTTGTGAGTTC
NestinCre TGACCAGAGTCATCCTTAGCG AATGCTTCTGTCCGTTTGCC
Sry GCAGGTGGAAAAGCCTTACA AAGCTTTGCTGGTTTTTGGA
Puma genotyping WT AGGCTGTCCCTGCGGTCATCC GGACTGTCGCGGGCTAGACCCTCTA
Puma genotyping KO AGGCTGTCCCTGCGGTCATCC ACCGCGGGCTCCGAGTAGC
Ctcf expression CGATATGCTCTCATCCAGCA TCCCACACTTGGAACAGACA
Puma expression CGTGTGGAGGAGGAGGAGT GGAGGAGTCCCATGAAGAGA
"-actin expression CTGTCGAGTCGCGTCCACCC ACATGCCGGAGCCGTTGTCG
5$ 5 kb Puma CBS ACCCTCGTGTTTGGAGTGAC CTCCTGCCTTGTGCCTAAAG
Puma CBS1 GCTCCTCCCAGGTCTCACTA CAGCTTTCATCACTGGGACT
Puma CBS2 AGGAATGGATCTGCTGGATG GTTGCTGACTCACCGGCTAT
3$ 5 kb Puma CBS GAGCCCCTGCCTAGTAGGAT TAGTCCCTGTGTGTGCTTGC
5$ 1 kb p53BS AAAAATGGGCTTGGAGAGC CCACCACTGTCCAGCTTGTT
Puma p53BS CTGTCCCCACGCTGC GCTTGCTTGCTGGTGTCG
3$ 1 kb p53BS AGCCAGGGCTACACAGAGAA CTGAGCCATCTCTCCAGTCC
KO, Knock-out; WT, wild type.
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3.3 Results 
3.3.1 CtcfFoxg1-cre mice exhibit widespread apoptosis and profound 
loss of telencephalic and anterior retinal tissue 
To study the function of CTCF in the embryonic brain, Ctcf floxed mice were 
intercrossed with the previously characterized Foxg1Cre mice (Berube et al., 2005; Heath 
et al., 2008; Hebert and McConnell, 2000). Foxg1 expression is first detected between E8 
and E9 in the telencephalic neuroepithelium, the basal ganglia, the olfactory bulbs, and 
the anterior retina (Dou et al., 1999). Foxg1-cre+ CtcfloxP/loxP progeny resulting from this 
cross are Ctcf null in the anterior retina and forebrain, and will be referred to as CtcfFoxg1-
cre throughout this text. 
We failed to recover live CtcfFoxg1-cre pups at birth (Figure 3-1a). At E13.5, the size of 
telencephalic and retinal structures was greatly diminished in mutant embryos (Figure 3-
1b,c). At E11.5, the telencephalon of mutant embryos was already noticeably smaller 
compared to littermate-matched controls (Figure 3-1d, hatched circle). CTCF 
immunostaining demonstrated nuclear expression of the protein throughout the forebrain 
in control tissue and its absence in mutant embryos (Figure 3-1e). To determine the 
underlying cause of cell loss, we measured levels of proliferation and cell death in E11.5 
CtcfFoxg1-cre and control embryos. Acute (1 h) BrdU labeling of control and CtcfFoxg1-cre 
embryos revealed that the percentage of cells in S phase does not vary significantly 
between mutant and control forebrain tissue (Figure 3-1f,g). To measure apoptosis, we 
stained sections with an antibody against activated caspase-3 as a marker of cell death 
(Figure 3-1h). Quantification of the results revealed a large increase in the proportion of 
cells undergoing apoptotic cell death in CtcfFoxg1-cre embryos compared to littermate-
matched controls (Figure 3-1i). TUNEL also showed increased apoptosis in CtcfFoxg1-cre 
embryos compared to control (Figure 3-1j). Since we already observed profound cell loss 
by E11.5, we wanted to analyze whether a similar mechanism was occurring earlier in 
this system. We observed increased AC3 immunostaining in CtcfFoxg1-cre forebrain 
cryosections at E10.5, confirming that cell death occurs at this earlier time point (data not 
shown). We conclude that deletion of Ctcf in the mouse forebrain at approximately E8.5 
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causes extensive apoptosis resulting in profound loss of telencephalic and anterior retinal 
tissue by E13.5. 
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Figure 3-1 Foxg1Cre-mediated deletion of Ctcf results in a massive increase in 
apoptosis 
(A) Table of genotypes obtained during the embryonic and postnatal periods. Ratios at 
each time point were analyzed using a χ2 test. Het, Ctcfflox/WT;Foxg1-cre+/-. (B) Dark-field 
images of control and CtcfFoxg1-cre embryos at E13.5. (Please note limbs were taken for 
genotyping). (C) H&E staining of E13.5 sagittal cryosections demonstrates complete loss 
of cortex (Ctx), hippocampal hem (H), basal ganglia (BG), lens (L), and anterior retina 
(AR), but not the posterior retina (PR), in CtcfFoxg1-cre embryos. (D) Dark-field images of 
control and CtcfFoxg1-cre embryos at E11.5. The dashed circle outlines the telencephalon, 
which is visibly reduced in size in the CtcfFoxg1-cre embryos compared to littermate 
controls. (E) Immunodetection of CTCF (red) in E11.5 sagittal cryosections confirms 
specific loss of CTCF expression in the forebrain neuroepithelium of CtcfFoxg1-cre 
embryos. (F) Pregnant females were subjected to a 1 h BrdU pulse before being killed. 
Immunodetection of BrdU in E11.5 control and CtcfFoxg1-cre cortical neuroepithelium is 
shown. (G) BrdU+ cells were counted and expressed as a percentage of the total number 
melting curve generated from55°C to 95°C in increments of 1°Cper plate
read. Fold change and percent input formulas were adapted from (Muk-
hopadhyay et al., 2008) as follows: percent input! 100 * [2("CtInput#
"CtInput) # ("CtInput # "CtAb)]/25. Error bars represent the SEM.
Primer sequences are provided in Table 1.
Microscopy. Images were captured with a digital camera (ORCA-ER;
Hamamatsu) using an inverted microscope (DMI 6000b; Leica . Open-
lab imaging software (PerkinElmer) was used for manual image capture,
and processing was performed using Volocity software (PerkinElmer).
For quantification of AC3$ cells per area, AC3$ cells were counted in a
defined area in at least six serial cortical cryosections, and the ratio of
AC3$ cells to area (squaremillimeters) was calculated. For BrdU, SOX2,
TBR2, BrdU/Ki67, TBR1, SATB2, and CTIP2 quantification, at least two
serial cortical cryosections were assessed for positive cells within the in-
dicated regions per embryo. DAPI morphology was used to bin cortex
into the ventricular/subventricular zone (VZ/SVZ), intermediate zone
(IZ), and cortical plate (CP).
Statistical analyses. Statistical analysis was performed using GraphPad
Prism software (GraphPad Software; version 4.02), and all results are
expressed as the mean% SEM. Unless indicated otherwise, p values were
generated using Student’s t test (unpaired, two-tailed) to compare be-
tween two independent data sets. Genotype ratios (Figs. 1A, 2A) were
compared using a ! 2 test. To compare cell viability data (see Fig. 4E), a
one-way ANOVA was used with Dunnett’s multiple comparison post-
test to compare the cell viability of each genotype (CtcfNes-cre, CtcfNes-cre;
Puma#/#, and Puma#/#) to control.
Study approval. All procedures involving animals were conducted in
accordance with the regulations of the Animals for Research Act of the
Province of Ontario and approved by the University of Western Ontario
Animal Care and Use Committee.
Results
CtcfFoxg1-cremice exhibit widespread apoptosis and profound
loss of telencephalic and anterior retinal tissue
To study the function of CTCF in the embryonic brain, Ctcf
floxed mice were intercrossed with the previously characterized
Foxg1Cremice (He´bert andMcConnell, 2000; Be´rube´ et al., 2005;
Heath et al., 2008). Foxg1 expression is first detected between E8
and E9 in the telencephalic neuroepithelium, the basal ganglia,
the olfactory bulbs, and the anterior retina (Dou et al., 1999).
Foxg1-cre$ Ctcf loxP/loxP progeny resulting from this cross are Ctcf
Figure1. Foxg1Cre-mediateddeletionof Ctcf results in amassive increase in apoptosis.A, Table of genotypes obtainedduring the embryonic andpostnatal periods. Ratios at each timepointwere
analyzed using a! 2 test. Het, Ctcf flox/WT;Foxg1-cre$/#. B, Dark-field images of control and Ctcf Foxg1-cre embryos at E13.5. (Please note limbs were taken for genotyping). C, H&E staining of E13.5
sagittal cryosections demonstrates complete loss of cortex (Ctx), hippocampal hem (H), basal ganglia (BG), lens (L), and anterior retina (AR), but not the posterior retina (PR), in Ctcf Foxg1-cre embryos.
D, Dark-field images of control and Ctcf Foxg1-cre embryos at E11.5. The dashed circle outlines the telencephalon, which is visibly reduced in size in the Ctcf Foxg1-cre embryos compared to littermate
controls. E, Immunodetection of CTCF (red) in E11.5 sagittal cryosections confirms specific loss of CTCF expression in the forebrain neuroepitheliumof Ctcf Foxg1-cre embryos. F, Pregnant femaleswere
subjected to a 1 h BrdU pulse before being killed. Immunodetection of BrdU in E11.5 control and Ctcf Foxg1-cre cortical neuroepithelium is shown. G, BrdU$ cells were counted and expressed as a
percentage of the total number of DAPI$ cells (n! 3).H, Immunodetection of activated caspase-3 (red) in control and Ctcf Foxg1-cre cortical neuroepithelium at E11.5. I, AC3$ cells were counted
and expressed as a percentage of the total number of DAPI$ cells (n! 3). J, TUNEL (green) det ction in E11.5 control and Ctcf Foxg1-cre cortical neuroepith lium. Error bars represent the SEM.
Original magnification: C, 25&; E, 50&; F, H, J, 200&. Scale bars: C, top, 1 mm; bottom, 400"m; E, 200"m; F, H, 50"m; J, 100"m.
2862 • J. Neurosci., February 19, 2014 • 34(8):2860–2870 Watson et al. • CTCF Loss Affects Neuroprogenitor Differentiation/Survival
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of DAPI+ cells (n = 3). (H) Immunodetection of activated caspase-3 (red) in control and 
CtcfFoxg1-cre cortical neuroepithelium at E11.5. (I) AC3+ cells were counted and expressed 
as a percentage of the total number of DAPI+ cells (n = 3). (J) TUNEL (green) detection 
in E11.5 control and CtcfFoxg1-cre cortical neuroepithelium. Error bars represent the SEM. 
Original magnification: (C) x25; (E) x50; (F, H, J) x200. Scale bars: (C) top, 1 mm; 
bottom, 400 µm; (E) 200 µm; (F, H) 50 µm; (J) 100 µm. 
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3.3.2 NestinCre-driven inactivation of Ctcf decreases cell survival 
To determine the outcome of Ctcf deletion at a later embryonic time point in the 
telencephalon, we mated Ctcfflox/flox mice to the previously characterized NestinCre 
transgenic mice (Berube et al., 2005; Heath et al., 2008). The resulting mutant is hereafter 
referred to as CtcfNes-cre for simplicity. Cre is expressed after preplate formation in this 
system, resulting in specific deletion of Ctcf in neural progenitor cells at approximately 
E11 (Bérubé et al., 2005). We obtained the expected ratio of CtcfNes-cre mice at birth; 
however, almost all mutant pups were already dead and blue in color (Figure 3-2a). One 
live CtcfNes-cre pup was found struggling to breathe, appeared weak, and was killed. We 
conclude that neonatal lethality of CtcfNes-cre mice is likely due to asphyxiation at birth. 
We first established that the CTCF protein was lost in the basal ganglia and many cells of 
the cortex at E12.5 (Figure 3-2b), and expression was undetectable in the E14 CtcfNes-cre 
cortex, basal ganglia, and hippocampal hem (Figure 3-2c). To determine whether 
NestinCre-mediated deletion of Ctcf also induces apoptosis, we analyzed CtcfNes-cre 
forebrain cryosections at E12.5–E15.5 for evidence of AC3. At E12.5, we observed no 
increase in apoptotic cells in the mutant telencephalon (Figure 3-2d). However, at E14, 
we detected an increase in AC3+ cells in the CtcfNes-cre cortex, basal ganglia, and 
hippocampal hem compared to controls (Figure 3-2d). The increase in caspase activation 
was also observed at E15.5 in all three forebrain regions, with the highest level of AC3+ 
cells in the basal ganglia (Figure 3-2d,e). Increased apoptotic cell death was also 
observed in vitro in primary cortical progenitor cultures established from E12.5 control 
and Ctcf-null telencephalon. Levels of AC3 staining were low in both control and Ctcf-
null NPCs after 2 d in vitro (DIV), and we only observed a detectable increase in staining 
at 4 DIV (Figure 3-2f). Together, the data suggest that when using the NestinCre driver 
line of mice, Ctcf deficiency does trigger the activation of caspase-mediated apoptosis in 
NPCs, but the effect is delayed and less severe than that observed in the CtcfFoxg1-cre 
embryos, suggesting that early neuroepithelial cells are more sensitive to CTCF loss than 
the neuroprogenitors present slightly later in development. 
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null in the anterior retina and forebrain, and will be referred to as
CtcfFoxg1-cre throughout this text.
We failed to recover liveCtcfFoxg1-cre pups at birth (Fig. 1A). At
E13.5, the size of telencephalic and retinal structures was greatly
diminished in mutant embryos (Fig. 1B,C). At E11.5, the telen-
cephalon of mutant embryos was already noticeably smaller
compared to littermate-matched controls (Fig. 1D, hatched cir-
cle). CTCF immunostaining demonstrated nuclear expression of
the protein throughout the forebrain in control tissue and its
absence in mutant embryos (Fig. 1E). To determine the underly-
ing cause of cell loss, we measured levels of proliferation and cell
death in E11.5 CtcfFoxg1-cre and control embryos. Acute (1 h)
BrdU labeling of control and CtcfFoxg1-cre embryos revealed that
the percentage of cells in S phase does not vary significantly be-
tween mutant and control forebrain tissue (Fig. 1F,G). To mea-
sure apoptosis, we stained sections with an antibody against
activated caspase-3 as a marker of cell death (Fig. 1H). Quantifi-
cation of the results revealed a large increase in the proportion of
cells undergoing apoptotic cell death in CtcfFoxg1-cre embryos
compared to littermate-matched controls (Fig. 1I). TUNEL also
showed increased apoptosis in CtcfFoxg1-cre embryos compared to
control (Fig. 1J). Since we already observed profound cell loss by
E11.5, we wanted to analyze whether a similar mechanism was
occurring earlier in this system. We observed increased AC3 im-
munostaining in CtcfFoxg1-cre forebrain cryosections at E10.5,
confirming that cell death occurs at this earlier time point (data
not shown). We conclude that deletion of Ctcf in the mouse
forebrain at approximately E8.5 causes extensive apoptosis re-
sulting in profound loss of telencephalic and anterior retinal tis-
sue by E13.5.
NestinCre-driven inactivation of Ctcf decreases cell survival
To determine the outcome of Ctcf deletion at a later embryonic
time point in the telencephalon, we mated Ctcf flox/floxmice to the
previously characterized NestinCre transgenic mice (Be´rube´ et
al., 2005; Heath et al. 2008). The resulting mutant is hereafter
referred to as CtcfNes-cre for simplicity. Cre is expressed after pre-
plate formation in this system, resulting in specific deletion of
Ctcf in neural progenitor cells at approximately E11 (Be´rube´ et
al., 2005). We obtained the expected ratio of CtcfNes-cre mice at
birth; however, almost all mutant pups were already dead and
blue in color (Fig. 2A). One live CtcfNes-cre pup was found strug-
gling to breathe, appearedweak, andwas killed.We conclude that
neonatal lethality of CtcfNes-cre mice is likely due to asphyxiation
at birth.
We first established that theCTCFproteinwas lost in the basal
ganglia and many cells of the cortex at E12.5 (Fig. 2B), and ex-
pression was undetectable in the E14CtcfNes-cre cortex, basal gan-
glia, and hippocampal hem (Fig. 2C). To determine whether
NestinCre-mediated deletion of Ctcf also induces apoptosis, we
analyzed CtcfNes-cre forebrain cryosections at E12.5–E15.5 for ev-
idence of AC3. At E12.5, we observed no increase in apoptotic
cells in the mutant telencephalon (Fig. 2D). However, at E14, we
detected an increase in AC3! cells in the CtcfNes-cre cortex, basal
ganglia, and hippocampal hem compared to controls (Fig. 2D).
The increase in caspase activationwas also observed at E15.5 in all
three forebrain regions, with the highest level of AC3! cells in the
basal ganglia (Fig. 2D,E). Increased apoptotic cell death was also
observed in vitro in primary cortical progenitor cultures estab-
lished from E12.5 control and Ctcf-null telencephalon. Levels of
AC3 staining were low in both control and Ctcf-null NPCs after
2 d in vitro (DIV), and we only observed a detectable increase in
staining at 4 DIV (Fig. 2F). Together, the data suggest that when
using the NestinCre driver line of mice, Ctcf deficiency does
trigger the activation of caspase-mediated apoptosis in NPCs,
but the effect is delayed and less severe than that observed in
the Ctcf Foxg1-cre embryos, suggesting that early neuroepithelial
Figure 2. NestinCre-mediated deletion of CTCF results in activation of caspase-mediated
apoptosis. A, Table of genotype ratios obtained during the embryonic period. Ratios at each
time point were analyzed by a ! 2 test. B, Immunodetection of CTCF in E12.5 control and
Ctcf Nes-cre coronal forebrain sections. C, Immunodetection of CTCF in E14 control and Ctcf Nes-cre
coronal forebrain sections. D, Quantification of AC3 immunostaining in E12.5, E14, and E15.5
forebrain tissue (n" 3). AC3! cells were counted and expressed per unit area (square milli-
meter). E, Immunodetection of AC3 in E15.5 control and Ctcf Nes-cre basal ganglia. F, Immuno-
detection of AC3 in control and Ctcf Nes-cre at 4 DIV. Het, Ctcf flox/WT;Nestin-cre; Ctx, cortex; BG,
basal ganglia; H, hippocampal hem. Error bars represent the SEM. Original magnification: B, C,
50#; D, 100#; E, 200#. Scale bars: B, 220"m; C, 300"m; E, 100"m; F, 25"m.
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Figure 3-2 NestinCre-mediated deletion of CTCF results in activation of caspase-
mediated apoptosis  
(A) Table of genotype ratios obtained during the embryonic period. Ratios at each time 
point were analyzed by a χ2 test. (B) Immunodetection of CTCF in E12.5 control and 
CtcfNes-cre coronal forebrain sections. Scale bar: 220 µm.  (C) Immunodetection of CTCF 
in E14 control and CtcfNes-cre coronal forebrain sections. Scale bar: 300 µm. (D) 
Quantification of AC3 immunostaining in E12.5, E14, and E15.5 forebrain tissue (n = 3). 
AC3+ cells were counted and expressed per unit area (square millimeter). (E) 
Immunodetection of AC3 in E15.5 control and CtcfNes-cre basal ganglia. Scale bar: 100 µm 
(F) Immunodetection of AC3 in control and CtcfNes-cre at 4 DIV. Scale bar: 25 µm. Het, 
Ctcfflox/WT; Nestin-cre+; Ctx, cortex; BG, basal ganglia; H, hippocampal hem. Error bars 
represent the SEM. Original magnification: (B, C) x50; (D) x100; (E) x200.  
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3.3.3 Increased p53 and PUMA levels in the Ctcf-null telencephalon 
Both the Foxg1Cre and NestinCre models of CTCF loss exhibit increased levels of 
apoptosis, although the timing of onset differs between the two mutants. To investigate 
the molecular mechanism responsible for neuronal cell death due to CTCF loss, we 
assessed activation of the p53/PUMA pathway. Using Western blot analysis, we found 
that neuronal cell death correlated with an increase in p53 protein levels in the CtcfNes-cre 
forebrain compared to control, suggesting activation and stabilization of the protein (Fig. 
3A). We next investigated the levels of PUMA, which has been demonstrated previously 
to mediate NPC death downstream of p53 (Jeffers et al., 2003). Moreover, Puma is one 
of the most upregulated genes in response to CTCF loss in the limb bud (Soshnikova et 
al., 2010). CTCF binding sites in the Puma gene demarcate an intragenic chromatin 
boundary that is abolished upon CTCF knockdown in human cells, resulting in increased 
PUMA expression (Gomes and Espinosa, 2010b). To determine whether PUMA is 
involved caspase-mediated cell death in the Ctcf mutant embryos, we examined PUMA 
protein levels in the CtcfFoxg1-cre and CtcfNes-cre mice. In the E11.5 CtcfFoxg1-cre forebrain, 
we observed an increase in PUMA immunostaining compared to littermate controls, 
corresponding to the high levels of AC3 staining in these embryos (Figure 3-3b). In the 
CtcfNes-cre embryos, PUMA was increased in the E15.5 basal ganglia, again correlating 
with the highest levels of cell death (Figure 3-3c). In primary cultures, Ctcf-null NPCs 
exhibited increased PUMA immunostaining at 4 DIV when compared to control NPCs 
obtained from littermate embryos (Figure 3-3d). We also quantified Puma transcript 
levels by quantitative reverse-transcriptase PCR and observed a significant increase in the 
E16.5 CtcfNes-cre forebrain compared to controls (Figure 3-3e). These observations 
demonstrate that increased PUMA transcript and proteins levels occur as a consequence 
of CTCF loss in NPCs and correlate with p53 activation and the onset of caspase-
mediated cell death. 
PUMA upregulation in the Ctcf-deficient embryonic brain could result from decreased 
CTCF occupancy within the Puma gene body, or because of p53-dependent activation of 
the gene. To investigate these possibilities further, we performed quantitative CTCF and 
p53 ChIP using E16.5 telencephalon isolated from control and CtcfNes-cre embryos (Figure 
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3-3f-h). ChIP analysis confirmed CTCF binding sites found downstream of Puma exon 1 
(CBS1) and exon 3 (CBS2) at the Puma gene in control tissue, similar to the binding 
profile of CTCF in human cancer cells (Figure 3-3g; (Gomes and Espinosa, 2010a). As 
expected, CTCF binding was diminished in the CtcfNes-cre tissue (Figure 3-3g). ChIP for 
p53 demonstrated specific enrichment of the protein at the Puma promoter in CtcfNes-cre 
forebrain compared to control in E16.5 tissue (Figure 3-3h). Together, loss of CTCF in 
NPCs causes increased Puma transcription and protein levels due to increased p53-
dependent transcriptional activation, likely combined with the loss of CTCF-dependent 
repression. 
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Figure 3-3 Loss of CTCF causes p53-dependent transcriptional activation of Puma 
(A) Western blot analysis of nuclear protein extracts obtained from E16.5 control and 
CtcfNes-cre telencephalon. Densitometry analysis of blots revealed a 2.3-fold increase in 
CtcfNes-cre p53 levels compared to control. INCENP was used as a loading control. (B, C) 
Immunodetection of PUMA in E11.5 control and CtcfFoxg1-cre cortical neuroepithelium 
(B), E15.5 control and CtcfNes-cre forebrain (C), and control and Ctcf-null NPCs (D) at 4 
DIV. Scale bars: 50 µm (B, C); 25 µm (D). (E) Quantitative real-time PCR analysis of 
Ctcf and Puma expression in control and CtcfNes-cre E16.5 forebrain using primers 
spanning Puma exons 3– 4 (n = 3). β-actin was used as an internal control. (F) Schematic 
representation of the mouse Puma gene. PCR products used to detect sites of CTCF 
binding (CBS1 and CBS2) and p53 binding (p53BS) are shown. (G) Quantitative 
chromatin immunoprecipitation of CTCF at the Puma gene in E16.5 control and CtcfNes-
cre telencephalon tissue (n = 3). Primer pairs 5 kb upstream and downstream of binding 
sites were used as negative controls. (H) Quantitative chromatin immunoprecipitation of 
p53 at the Puma gene in E16.5 control and CtcfNes-cre telencephalon tissue shows 
increased p53 occupancy at the Puma promoter in the CtcfNes-cre telencephalon (n = 3). 
Primer pairs 1 kb upstream and downstream of the binding site were used as negative 
controls. Error bars represent SEM. Original magnification: (A, C) x200; (B) x100.  
 
cells are more sensitive to CTCF loss than the neurop geni-
tors present slightly later in development.
Increased p53 and PUMA levels in the Ctcf-null telencephalon
Both the Foxg1Cre and NestinCre models of CTCF loss exhibit
increased levels of apoptosis, although the timing of onset differs
between the two mutants. To investigate the molecular mecha-
nism responsible for neuronal cell death due to CTCF loss, we
assessed activation of the p53/PUMA pathway. Using Western
blot analysis, we found that neuronal cell death correlatedwith an
increase in p53 protein levels in the CtcfNes-cre forebrain com-
pared to control, suggesting activation and stabilization of the
protein (Fig. 3A). We next investigated the levels of PUMA,
which has been demonstrated previ usly to mediate NPC d ath
downstream of p53 (Jeffers et al., 2003). Moreover, Puma is one
of the most upregulated genes in response to CTCF loss in the
limb bud (Soshnikova et al., 2010). CTCF binding sites in the
Puma gene demarcate an intragenic chromatin boundary that is
abolished upon CTCF knockdown in human cells, resulting in
increased PUMA expression (Gomes and Espinosa, 2010b). To
determine whether PUMA is involved caspase-mediated cell
death in the Ctcf mutant embryos, we examined PUMA protein
levels in theCtcfFoxg1-cre andCtcfNes-cremice. In theE11.5CtcfFoxg1-cre
forebrain, we observed an increase in PUMA immunostaining
compared to littermate controls, corresponding to the high levels
of AC3 staining in these embryos (Fig. 3B). In the CtcfNes-cre em-
bryos, PUMA was increased in the E15.5 basal gangli , again
correlating with the highest levels of cell death (Fig. 3C). In pri-
mary cultures,Ctcf-null NPCs exhibited increased PUMA immu-
nostaining at 4 DIV when compared to control NPCs obtained
from littermate embryos (Fig. 3D). We also quantified Puma
transcript levels by quantitative reverse-transcriptase PCR and
observed a significant increase in the E16.5 CtcfNes-cre forebrain
compared to controls (Fig. 3E). These observations demonstrate
that increased PUMA transcript and proteins levels occur as a
consequence of CTCF loss in NPCs and correlat wit p53 acti-
vation and the onset of caspase-mediated cell death.
PUMA upregulation in the Ctcf-deficient embryonic brain
could result from decreased CTCF occupancy within the Puma
gene body, or because of p53-dependent activation of the gene.
To investigate these possibilities further, we performed quantita-
tive CTCF and p53ChIP using E16.5 telencephalon isolated from
control and CtcfNes-cre embryos (Fig. 3F--H). ChIP analysis con-
firmed CTCF binding sites found downstream of Puma exon 1
(CBS1) and exon 3 (CBS2) at the Puma gene in control tissue,
similar to the binding profile of CTCF in human cancer cells (Fig.
3G; Gomes and Espinosa, 2010a). As expect d, CTCF binding
was diminished in the CtcfNes-cre tissue (Fig. 3G). ChIP for p53
demonstrated specific enrichment of the protein at the Puma
promoter in CtcfNes-cre forebrain compared to control in E16.5
tissue (Fig. 3H). Together, loss of CTCF inNPCs causes increased
Puma transcription and protein levels due to increased p53-
dependent transcriptional activation, likely combined with the
loss of CTCF-dependent repression.
Deletion of Puma in a Ctcf-null context rescues cell death, but
does not improve viability or brain defects at birth
To investigate whether increased PUMA levels cause cell death in
the Ctcf-deficient embryonic brain, we introduced a mutant
Puma allele (Bbc3tm1Ast) in the Ctcf loxP and NestinCre mice to
generate mice that lack both Ctcf and Puma expression in the
brain (hereafter referred to as CtcfNes-cre;Puma!/!). Histological
analysis of E16.5 CtcfNes-cre cryosections showed thinning of the
VZ/SVZ, hypocellularity of the intermediate zone, and a dra-
matic reduction in the size of the hippocampal hem (Fig. 4A).
CtcfNes-cre;Puma!/! embryos at E16.5 showed rescue in the VZ/
Figure 3. Loss of CTCF causes p53-dependent transcriptional activation of Puma. A, Western blot analysis of nuclear protein extracts obtained from E16.5 control and Ctcf Nes-cre telencephalon.
Densitometry analysis of blots revealed a 2.3-fold increase in Ctcf Nes-cre p53 levels compared to control. B, C, INCENP was used as a loading control. Immunodetection of PUMA in E11.5 control and
Ctcf Foxg1-cre cortical neuroepithelium (B), E15.5 control and Ctcf Nes-cre forebrain (C), and control and Ctcf-null NPCs (D) at 4 DIV. E, Quantitative real-time PCR analysis of Ctcf and Puma expression in
control and Ctcf Nes-cre E16.5 forebrain using primers spanning Puma exons 3–4 (n" 3).!-actinwas used as an internal control. F, Schematic representation of themouse Puma gene. PCR products
used to detect sites of CTCF binding (CBS1 and CBS2) and p53 binding (p53BS) are shown. G, Quantitative chromatin immunoprecipitation of CTCF at the Puma gene in E16.5 control and Ctcf Nes-cre
telencephalon tissue (n" 3). Primer pairs 5 kb upstreamand downstreamof binding siteswere used as negative controls.H, Quantitative chromatin immunoprecipitation of p53 at the Puma gene
in E16.5 control and Ctcf Nes-cre telencephalon tissue shows increased p53 occupancy at the Puma promoter in the Ctcf Nes-cre telencephalon (n" 3). Primer pairs 1 kb upstream and downstream of
the binding site were used as negative controls. Error bars represent SEM. Original magnification: A, C, 200#; B, 100#. Scale bars: B, C, 50"m; D, 25"m.
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3.3.4 Deletion of Puma in a Ctcf-null context rescues cell death, but 
does not improve hypocellularity at birth 
To investigate whether increased PUMA levels cause cell death in the Ctcf-deficient 
embryonic brain, we introduced a mutant Puma allele (Bbc3tm1Ast) in the CtcfloxP and 
NestinCre mice to generate mice that lack both Ctcf and Puma expression in the brain 
(hereafter referred to as CtcfNes-cre;Puma−/−). Histological analysis of E16.5 CtcfNes-cre 
cryosections showed thinning of the VZ/SVZ, hypocellularity of the intermediate zone, 
and a dramatic reduction in the size of the hippocampal hem (Figure 3-4a). CtcfNes-
cre;Puma−/− embryos at E16.5 showed rescue in the VZ/SVZ thickness, as well as 
hippocampal size (Figure 3-4a). We confirmed these observations by partitioning the 
E16.5 cortex into the CP, IZ, and VZ/SVZ based on cytoarchitecture and quantifying the 
number of DAPI+ cells per region (Figure 3-4b,c). We observed a restoration in the 
number of IZ cells and partial restoration in the number of VZ/SVZ cells in the CtcfNes-cre; 
Puma−/− compared to CtcfNes-cre cortex (Figure 3-4c). There was no significant difference 
in the number of CP cells between genotypes at E16.5 (Figure 3-4c). 
We performed AC3 immunostaining in E16.5 brain sections to investigate whether 
apoptotic cell death was rescued in the double mutant brain. AC3+ cells were elevated in 
the CtcfNes-cre cortex, basal ganglia, and hippocampal hem compared to control (Figure 3-
4b,d). AC3+ cells were largely localized to the ventricular zone of the neocortex, 
indicating that Ctcf-null proliferating cells are more susceptible to caspase-dependent cell 
death than differentiated cells of the cortical plate. Deletion of Puma in the CtcfNes-cre 
mouse was sufficient to abolish apoptotic cell death, indicating that PUMA mediates 
increased caspase-dependent cell death in Ctcf-null neuroprogenitor cells (Figure 3-4b,d). 
Together, these data indicate a specific decrease in intermediate zone cellularity in the 
E16.5 CtcfNes-cre cortex that is fully restored upon inhibition of cell death. The number of 
cells in the ventricular/subventricular zone is only partially restored, suggesting that loss 
of cells cannot completely be explained by increased cell death. 
To further confirm that cell viability is rescued by deletion of Puma in a Ctcf-null 
context, we established primary cortical progenitor cultures from E12.5 control, CtcfNes-
cre, CtcfNes-cre;Puma−/−, and Puma−/− telencephalon and measured viability via trypan blue 
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dye exclusion at 2–5 DIV. Each time point was analyzed by a one-way ANOVA 
followed by Dunnett's multiple comparisons post-test to determine which genotypes had 
a mean percentage of viability that was significantly different from control. No difference 
in viability was observed at 2 and 3 DIV; however, at 4 and 5 DIV, CtcfNes-cre NPCs 
exhibited a marked reduction in viability, correlating with increased levels of AC3 
(Figure 3-4e). NPCs obtained from CtcfNes-cre;Puma−/− embryos did not show a significant 
decrease in viability at any of the time points analyzed (Figure 3-4e). 
Since we observed a rescue in caspase-mediated cell death in the embryonic CtcfNes-
cre;Puma−/− brain, we predicted that the brain size at birth would also be recovered and 
that the mice would survive into the postnatal period, allowing for more extended 
analyses. Surprisingly, we failed to recover live CtcfNes-cre;Puma−/− mice at birth. 
Histological staining of postnatal day 0.5 (P0.5) CtcfNes-cre;Puma−/− sections demonstrated 
severe hypocellularity and disorganization of the cortical plate and hippocampus, and an 
overall similarity to the CtcfNes-cre neonatal brain (Figure 3-5a). Histological cell counts 
confirmed that there are fewer cells in CtcfNes-cre and CtcfNes-cre;Puma−/− cortical plate 
compared to controls; however, no significant difference in cell number was detected 
between CtcfNes-cre and CtcfNes-cre;Puma−/− (Figure 3-5b). These findings indicate that 
although deletion of Puma prevents Ctcf-null cells from undergoing apoptosis, other 
factors come into play to prevent cortical size expansion in the double mutant brain. 
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Figure 3-4 Apoptosis is abolished upon deletion of PUMA in the Ctcf-deficient 
embryonic brain 
(A) H&E staining of E16.5 control, CtcfNes-cre and CtcfNes-cre;Puma-/- coronal cortical 
cryosections. Skin and skull cap were not dissected from CtcfNes-cre brain. Scale bar: 
200 µm. (B) AC3 immunostaining in E16.5 control, CtcfNes-cre, and CtcfNes-cre;Puma-/- 
neocortex. Sclae bar: 100 µm. (C) DAPI+ cells were quantified in 200 µm-wide regions of 
the control, CtcfNes-cre (conditional knock-out), and CtcfNes-cre;Puma-/- (double knock-out) 
CP, IZ, and VZ/SVZ (n = 3). (D) AC3+ cells were quantified per unit area in the cortex 
(Ctx), basal ganglia (BG), and hippocampal hem (H; n = 3). (E) Cell viability of NPC 
cultures was measured by trypan blue dye exclusion after 2–5 DIV (n = 3). Data were 
analyzed by a one-way ANOVA followed by Dunnett’s multiple comparisons test to 
determine which means were significantly different from the control. No significant 
difference in cell viability was found at 2 and 3 DIV (P = 0.2122 and 0.2062, 
SVZ thickness, as well as hippocampal size (Fig. 4A). We con-
firmed these observations by partitioning the E16.5 cortex into
the CP, IZ, and VZ/SVZ based on cytoarchitecture and quantify-
ing the number of DAPI! cells per region (Fig. 4B,C). We ob-
served a restoration in the number of IZ cells and partial
restoration in the number of VZ/SVZ cells in the CtcfNes-cre;
Puma"/" compared to CtcfNes-cre cortex (Fig. 4C). There was no
significant difference in the number of CP cells between geno-
types at E16.5 (Fig. 4C).
We performed AC3 immunostaining in E16.5 brain sections
to investigate whether apoptotic cell death was rescued in the
double mutant brain. AC3! cells were elevated in the CtcfNes-cre
cortex, basal ganglia, and hippocampal hem compared to control
(Fig. 4B,D). AC3! cells were largely localized to the ventricular
zone of the neocortex, indicating thatCtcf-null proliferating cells
are more susceptible to caspase-dependent cell death than differ-
entiated cells of the cortical plate. Deletion ofPuma in theCtcfNes-
cremouse was sufficient to abolish apoptotic cell death, indicating
that PUMA mediates increased caspase-dependent cell death in
Ctcf-null neuroprogenitor cells (Fig. 4B,D). Together, these data
indicate a specific decrease in intermediate zone cellularity in the
E16.5 CtcfNes-cre cortex that is fully restored upon inhibition of
cell death. The number of cells in the ven-
tricular/subventricular zone is only par-
tially restored, suggesting that loss of cells
cannot completely be explained by in-
creased cell death.
To further confirm that cell viability is
rescued by deletion of Puma in a Ctcf-null
context, we established primary cortical
progenitor cultures from E12.5 control,
CtcfNes-cre,CtcfNes-cre;Puma"/", andPuma"/"
telencephalon and measured viability via
trypan blue dye exclusion at 2–5 DIV.
Each time point was analyzed by a one-
way ANOVA followed by Dunnett’s mul-
tiple comparisons post-test to determine
which genotypes had a mean percentage
of viability that was significantly different
from control. No difference in viability
was observed at 2 and 3DIV; however, at 4
and 5 DIV, CtcfNes-cre NPCs exhibited a
marked reduction in viability, correlating
with increased levels of AC3 (Fig. 4E).
NPCs obtained from CtcfNes-cre;Puma"/"
embryos did not show a significant de-
crease in viability at any of the time points
analyzed (Fig. 4E).
Since we observed a rescue in caspase-
mediated cell death in the embryonic
CtcfNes-cre;Puma"/" brain, we predicted
that the brain size at birth would also be
recovered and that themicewould survive
into the postnatal period, allowing for
more extended analyses. Surprisingly, we
failed to recover live CtcfNes-cre;Puma"/"
mice at birth. Histological staining of
postnatal day 0.5 (P0.5) CtcfNes-cre;Pu-
ma"/" sections demonstrated severe hy-
pocellularity and disorganization of the
cortical plate and hippocampus, and an
overall similarity to the CtcfNes-cre neona-
tal brain (Fig. 5A). Histological cell counts
confirmed that there are fewer cells in CtcfNes-cre and CtcfNes-cre;
Puma"/" cortical plate compared to controls; however, no sig-
nificant difference in cell numberwas detected betweenCtcfNes-cre
and CtcfNes-cre;Puma"/" (Fig. 5B). These findings indicate that
although deletion of Puma prevents Ctcf-null cells from under-
going apoptosis, other factors come into play to prevent cortical
size expansion in the doubl mutant brain.
Ctcf-null apical and oRG progenitors rescued from death by
Puma deletion fail to proliferate
Given that cell death at E16.5 was rescued in the double mutant
embryos but the brain hypocellularity at birth was not, we spec-
ulated that the cells rescued from apoptosis might become ar-
rested in the cell cycle, resulting in decreased proliferation. To test
this hypothesis, we performed acute BrdU labeling at E16.5 and
quantified the proportion of cells in S phase by BrdU immuno-
staining. To compare the cortical distribution and number of
NPCs in S phase, the E16.5 cortexwas partitioned into the CP, IZ,
and VZ/SVZ based on cytoarchitecture (Fig. 6A). The number
of BrdU! cells was significantly reduced in the CtcfNes-cre and
CtcfNes-cre;Puma"/" intermediate zones and ventricular zone/
subventricular zones compared to control (Fig. 6A,B). Despite
Figure 4. Apoptosis is abolished upon deletion of PUMA in the Ctcf-deficient embryonic brain.A, H&E staining of E16.5 control,
Ctcf Nes-cre, and Ctcf Nes-cre;Puma"/" coronal cortical cryosections. Skin and skull cap were not dissected from Ctcf Nes-cre brain. B,
AC3 immunostaining in E16.5 control, Ctcf Nes-cre, and Ctcf Nes-cre;Puma"/" neocortex. C, DAPI! cells were quantified in 200-!m-
wide regions of the control, Ctcf Nes-cre (conditional knock-out), and Ctcf Nes-cre;Puma"/" (double knock-out) CP, IZ, and VZ/SVZ
(n# 3). D, AC3! cells were quantified per unit area in the cortex (Ctx), basal ganglia (BG), and hippocampal hem (H; n# 3). E,
Cell viability of NPC cultures was measured by trypan blue dye exclusion after 2–5 DIV (n# 3). Data were analyzed by a one-way
ANOVA followed by Dunnett’s multiple comparisons test to determine which means were significantly different from the control.
No significant difference in cell viability was found at 2 and 3 DIV ( p# 0.2122 and 0.2062, respectively); however, viability was
significantly different between Ctcf Nes-cre and control at 3 and 4DIV ( p$ 0.01), but not between Ctcf Nes-cre;Puma"/" and control
or Puma"/" and control ( p% 0.05). Error bars represent SEM. Original magnification: A, 100&; C, 50&. Scale bars: A, 200!m;
B, 100!m.
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respectively); however, viability was significantly different between CtcfNes-cre and control 
at 3 and 4 DIV (P = 0.01), but not between CtcfNes-cre;Puma-/- and control or Puma-/- and 
control (P > 0.05). Error bars represent SEM. Original magnification: (A) x100; (C) x50.  
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Figure 3-5 Puma deletion in the Ctcf-deficient brain fails to restore hippocampal size 
or hypocellularity of the cortical plate 
(A) H&E staining of neonatal (P0.5) control, CtcfNes-cre, and CtcfNes-cre;Puma-/- cortex and 
hippocampus. Scale bars: top, 800 μm; bottom, 200 μm. (B) Graph depicting cortical 
plate cell counts as a percentage of control (n = 3). Error bars represent SEM. Original 
magnification, (A) x25. 
 
 
 
substantial rescue in cellularity of the
CtcfNes-cre;Puma!/! cortex compared to
CtcfNes- cre at E16.5, the proliferative ca-
pacity of progenitors was not significantly
different (Fig. 6A,B). Our results demon-
strate that Puma deletion rescues cell
death in the Ctcf-null brain, but that the
rescued cells display reduced proliferative
capacity.
Three NPC subtypes exist in the em-
bryonic cortex: apical radial glia (apical
progenitors), basal progenitors, and outer
radial glia. Apical progenitors can be iden-
tified by their expression of SOX2 and
PAX6 transcription factors (Go¨tz et al.,
1998; Tarabykin et al., 2001; Bani-
Yaghoub et al., 2006; Shitamukai and
Matsuzaki, 2012). They undergo interki-
netic nuclear migration and divide at the
ventricular surface to either self-renew or
differentiate into basal progenitors, outer
radial glia, or cortical neurons (Shitamu-
kai et al., 2011; Shitamukai and Matsu-
zaki, 2012). Basal progenitors reside in the
subventricular zone and uniquely express
the T-box transcription factor TBR2 (En-
glund et al., 2005). They are reported to
have the potential to self-renew; however,
the majority of their divisions are neuro-
genic (Haubensak et al., 2004; Miyata et
al., 2004; Noctor et al., 2004). Outer radial
glia are similar to radial glia in that they
have a basal process and express SOX2
and PAX6; however, oRG cells are located
outside of the VZ in the outer SVZ. They
are able to divide asymmetrically, producing one oRG and one
neuron-committed cell with each division (Reillo et al., 2011;
Shitamukai et al., 2011; Wang et al., 2011a,b; Shitamukai and
Matsuzaki, 2012).We performed acute BrdU-labeling for 1 h and
coimmunostained E16.5 cortical sections with antibodies against
BrdU and TBR2 or SOX2 to examine the behavior of different
progenitor subtypes after loss of CTCF (Figs. 7, 8).
The total number of TBR2" basal progenitor cells was re-
duced in the CtcfNes-cre cortex compared to control (Fig. 7A,B).
The number of basal progenitors was restored to control levels in
the CtcfNes-cre;Puma!/! cortex, and most rescued cells were still
able to enter S phase (Fig. 7A,C). Despite the correct overall
number of TBR2" cells in the CtcfNes-cre;Puma!/! cortex, the
localization of basal progenitors appeared to be shifted apically
compared to control (Fig. 7A,B). This is perhaps due to an in-
ability of the rescued basal progenitors to correctly delaminate
from the ventricular surface.
Quantification of SOX2" cells indicated a dramatic reduction
in the number of apical progenitors and oRGs in the CtcfNes-cre
cortex (Fig. 8A,B). The number of SOX2" apical progenitorswas
only partially rescued in the CtcfNes-cre;Puma!/! cortex, indicating
that CTCF may control the size of the apical progenitor pool
independently of apoptosis (Fig. 8A,B). Conversely, oRG
(SOX2" cells in the intermediate zone) numberswere restored to
control levels in the CtcfNes-cre;Puma!/! cortex, indicating that
these cells are lost via Puma-mediated apoptotic cell death upon
deletion of Ctcf (Fig. 8A,B). The proliferative capacity of apical
progenitors (SOX2"/BrdU" cells in the VZ/SVZ) was severely
diminished in the CtcfNes-cre cortex compared to control, and was
not restored in theCtcfNes-cre;Puma!/! cortex (Fig. 8A,C). Similarly,
BrdU incorporation in the rescuedCtcfNes-cre;Puma!/!oRG cells was
extremely low, indicating that they are likely arrested in the cell
cycle and fail to correctly enter S phase (Fig. 8A,C). To confirm
that these cells are oRG progenitors, we performed SOX2 and
PAX6 coimmunostaining and indeed observed a decreased num-
ber of SOX2"PAX6" cells in the intermediate zone of CtcfNes-cre
embryos compared to control and CtcfNes-cre;Puma!/! at E16.5
(Fig. 8D).
Ctcf loss causes premature differentiation of apical
progenitors
Incomplete restoration of the apical progenitor population in the
CtcfNes-cre;Puma!/! cortex suggests that loss of CTCF leads to an
apoptosis-independent reductionof these cells (Fig. 8A,B).To iden-
tify the cause of reduced apical cell numbers, we analyzed the pro-
genitor pool composition, cell cycle exit indices, and postmitotic
projection neuron subtypes in control andCtcfNes-cre cortex at E14.
Apical progenitors begin to produce projection neurons at
approximately E11.5. At the same time, they generate neuron-
committed basal progenitors and oRGprogenitors. Since thema-
jority of basal progenitor divisions are terminal and result in the
production of two neurons, this would result in increased gener-
ation of neurons at the expense of the progenitor pool (Hauben-
sak et al., 2004; Miyata et al., 2004; Noctor et al., 2004). The
relative abundance of TBR2" basal progenitors was significantly
increased in the E14 CtcfNes-cre cortex compared to control,
whereas the number of SOX2" apical progenitors was not af-
Figure 5. Puma deletion in the Ctcf-deficient brain fails to restore hippocampal size or hypocellularity of the cortical plate. A,
H&E staining of neonatal (P0.5) control, Ctcf Nes-cre, and Ctcf Nes-cre;Puma!/! cortex and hippocampus. Scale bars: top, 800!m;
bottom, 200!m. Original magnification, 25#. B, Graph depicting cortical plate cell counts as a percentage of control (n$ 3).
Error bars represent SEM.
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3.3.5 Ctcf-null apical and oRG progenitors rescued from death by 
Puma deletion fail to proliferate 
Given that cell death at E16.5 was rescued in the double mutant embryos but the brain 
hypocellularity at birth was not, we speculated that the cells rescued from apoptosis 
might become arrested in the cell cycle, resulting in decreased proliferation. To test this 
hypothesis, we performed acute BrdU labeling at E16.5 and quantified the proportion of 
cells in S phase by BrdU immunostaining. To compare the cortical distribution and 
number of NPCs in S phase, the E16.5 cortex was partitioned into the CP, IZ, and 
VZ/SVZ based on cytoarchitecture (Figure 3-6a). The number of BrdU+ cells was 
significantly reduced in the CtcfNes-cre and CtcfNes-cre;Puma−/− intermediate zones and 
ventricular zone/subventricular zones compared to control (Figure 3-6a,b). Despite 
substantial rescue in cellularity of the CtcfNes-cre;Puma−/− cortex compared to CtcfNes-cre at 
E16.5, the proliferative capacity of progenitors was not significantly different (Figure 3-
6a,b). Our results demonstrate that Puma deletion rescues cell death in the Ctcf-null 
brain, but that the rescued cells display reduced proliferative capacity. 
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Figure 3-6 Ctcf deficient cells that are rescued from apoptotic death display reduced 
proliferative capacity 
Pregnant females were subjected to a 1 h BrdU pulse before being killed. (A) BrdU 
(green) immunostaining of E16.5 control, CtcfNes-cre, and CtcfNes-cre;Puma-/- cortical 
cryosections. The inset demonstrates fewer BrdU+ cells in the CtcfNes-cre and CtcfNes-
cre;Puma-/- IZ compared with control. Scale bar, 50 µm. Original magnification, x100. (B) 
The number of cells in S phase was quantified by counting BrdU+ cells in 200-µm-wide 
cortical images (n = 3). Error bars represent SEM. Original magnification, (A) x100. 
 
 
 
 
 
 
 
 
 
 
 
fected (Fig. 9A,B), suggesting that differentiation of apical pro-
genitors into basal progenitors is increased. Next, we measured
the proportion of cells exiting the cell cycle by labeling embryos
with BrdU for 24 h and analyzing Ki67! and BrdU! cells in E14
control and CtcfNes-cre cortex. Cell cycle exit (BrdU!Ki67" cells/
total BrdU! cells) was significantly higher in CtcfNes-cre cortex
compared to controls (Fig. 9C,D).
The cortical plate is established by projection neurons that
organize themselves in an “inside-out” manner, such that early-
born neurons populate deeper cortical layers (layer VI, then layer
V), and late-born neuronsmigrate past the early-born neurons to
populate the more superficial layers of the cortex (layer IV, then
layer II/III; Greig et al., 2013). Increased cell cycle exit and differ-
entiation at E13–E14 is predicted to result in an increased num-
ber of layer VI corticothalamic projection neurons (TBR1!),
layer V subcerebral projection neurons (CTIP2!), and callosal
projection neurons (SATB2!). We found that the relative gener-
ation of these neuronal subtypes was increased in the CtcfNes-cre
cortex compared to control (Fig. 8E--G), confirming premature
differentiation of Ctcf-null apical progenitors, which is predicted
to result in a reduced number of this progenitor pool by late
neurogenesis.
Discussion
This study provides evidence that CTCF is required at very early
stages of telencephalon development for the maintenance and
survival of neuroprogenitor cells. We found that ablation of
CTCF leads to Puma-dependent apoptosis of NPCs using two
different conditional deletion strategies. Increased apoptosis cor-
related with p53-dependent Puma transcription, suggesting that
CTCF loss results in p53 stabilization and transcriptional activa-
tion of its downstream targets. CTCF loss might also result in a
more open chromatin environment at the Puma gene, facilitating
p53-dependent activation of transcription and elongation of
RNA polymerase II (Gomes and Espinosa, 2010a,b). Ctcf inacti-
vation in postmitotic cortical and hippocampal neurons does not
induce apoptosis (Hirayama et al., 2012), pointing to a specific
survival role for CTCF in proliferating cells. However, CTCF loss
of function may not induce apoptosis in all types of proliferating
cells in vivo, as Ctcf deletion in thymocytes was shown previously
to induce cell cycle arrest without induction of apoptosis (Heath
et al., 2008). It is possible that the outcome of CTCF deficiency
leads to either p53-dependent cell cycle arrest or apoptosis, de-
pending on varying cell-specific or temporal cues. This could be
similar to the outcomes described uponNbs1 (Nijmegen breakage
syndrome 1/Nibrin) deletion in the CNS, which leads to p53-
dependent apoptosis in the cerebellum, but causes p53-
dependent cell cycle arrest in the neocortex (Li et al., 2012).
In the present report, we demonstrate that deletion of Puma
effectively rescues apoptotic cell death observed at E16.5 in the
CtcfNes-cre brain (Fig. 4). Despite this apparent recovery at E16.5,
Figure6. Ctcf-deficient cells that are rescued fromapoptotic deathdisplay reducedproliferative capacity. Pregnant femaleswere subjected to a 1hBrdUpulse before being killed.A, BrdU (green)
immunostaining of E16.5 control, Ctcf Nes-cre, and Ctcf Nes-cre;Puma"/" cortical cryosections. The inset demonstrates fewer BrdU! cells in the Ctcf Nes-cre and Ctcf Nes-cre;Puma"/" IZ compared with
control. Scale bar, 50!m. Original magnification, 100#. B, The number of cells in S phase was quantified by counting BrdU! cells in 200-!m-wide cortical images (n$ 3). Error bars represent
SEM.
Figure 7. Ctcf-deficiency results in PUMA-dependent apoptosis of basal progenitor cells. Pregnant femaleswere subjected to a 1 h BrdU pulse before being killed.A, TBR2 (red) and BrdU (green)
coimmunostaining of E16.5 cortical cryosections. Arrowheads indicate TBR2!/BrdU! cells in the IZ and VZ/SVZ. Scale bar, 50!m. Original magnification, 100#. B, TBR2! cells were quantified
in 200-!m-wide cortical images (n$ 3). C, TBR2!/BrdU! cells were quantified in 200-!m-wide cortical images (n$ 3). Error bars represent SEM.
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Three NPC subtypes exist in the embryonic cortex: apical radial glia (apical progenitors), 
basal progenitors, and outer radial glia. Apical progenitors can be identified by their 
expression of SOX2 and PAX6 transcription factors (Bani-Yaghoub et al., 2006; Gotz et 
al., 1998; Shitamukai and Matsuzaki, 2012; Tarabykin et al., 2001). They undergo 
interkinetic nuclear migration and divide at the ventricular surface to either self-renew or 
differentiate into basal progenitors, outer radial glia, or cortical neurons (Shitamukai et 
al., 2011; Shitamukai and Matsuzaki, 2012). Basal progenitors reside in the 
subventricular zone and uniquely express the T-box transcription factor TBR2 (Englund 
et al., 2005). They are reported to have the potential to self-renew; however, the majority 
of their divisions are neurogenic (Haubensak et al., 2004; Miyata et al., 2004; Noctor et 
al., 2004). Outer radial glia are similar to radial glia in that they have a basal process and 
express SOX2 and PAX6; however, oRG cells are located outside of the VZ in the outer 
SVZ. They are able to divide asymmetrically, producing one oRG and one neuron-
committed cell with each division (Reillo et al., 2011; Shitamukai et al., 2011; 
Shitamukai and Matsuzaki, 2012; Wang et al., 2011a; Wang et al., 2011b). We performed 
acute BrdU-labeling for 1 h and coimmunostained E16.5 cortical sections with antibodies 
against BrdU and TBR2 or SOX2 to examine the behavior of different progenitor 
subtypes after loss of CTCF (Figure 3-7,8). 
The total number of TBR2+ basal progenitor cells was reduced in the CtcfNes-cre cortex 
compared to control (Figure 3-7a,b). The number of basal progenitors was restored to 
control levels in the CtcfNes-cre;Puma−/− cortex, and most rescued cells were still able to 
enter S phase (Figure 3-7a,c). Despite the correct overall number of TBR2+ cells in the 
CtcfNes-cre;Puma−/− cortex, the localization of basal progenitors appeared to be shifted 
apically compared to control (Figure 3-7a,b). This is perhaps due to an inability of the 
rescued basal progenitors to correctly delaminate from the ventricular surface. 
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Figure 3-7 Ctcf-deficiency results in PUMA-dependent apoptosis of basal progenitor 
cells 
Pregnant females were subjected to a 1 h BrdU pulse before being killed. (A) TBR2 (red) 
and BrdU (green) coimmunostaining of E16.5 cortical cryosections. Arrowheads indicate 
TBR2+/BrdU+ cells in the IZ and VZ/SVZ. Scale bar, 50 µm. Original magnification, 
x100. (B) TBR2+ cells were quantified in 200-µm-wide cortical images (n = 3). (C) 
TBR2+/BrdU+ cells were quantified in 200-µm-wide cortical images (n = 3). Error bars 
represent SEM.  
 
 
 
 
 
 
 
 
 
 
fected (Fig. 9A,B), suggesting that differentiation of apical pro-
genitors into basal progenitors is increased. Next, we measured
the proportion of cells exiting the cell cycle by labeling embryos
with BrdU for 24 h and analyzing Ki67! and BrdU! cells in E14
control and CtcfNes-cre cortex. Cell cycle exit (BrdU!Ki67" cells/
total BrdU! cells) was significantly higher in CtcfNes-cre cortex
compared to controls (Fig. 9C,D).
The cortical plate is established by projection neurons that
organize themselves in an “inside-out” manner, such that early-
born neurons populate deeper cortical layers (layer VI, then layer
V), and late-born neuronsmigrate past the early-born neurons to
populate the more superficial layers of the cortex (layer IV, then
layer II/III; Greig et al., 2013). Increased cell cycle exit and differ-
entiation at E13–E14 is predicted to result in an increased num-
ber of layer VI corticothalamic projection neurons (TBR1!),
layer V subcerebral projection neurons (CTIP2!), and callosal
projection neurons (SATB2!). We found that the relative gener-
ation of these neuronal subtypes was increased in the CtcfNes-cre
cortex compared to control (Fig. 8E--G), confirming premature
differentiation of Ctcf-null apical progenitors, which is predicted
to result in a reduced number of this progenitor pool by late
neurogenesis.
Discussion
This study provides evidence that CTCF is required at very early
stages of telencephalon development for the maintenance and
survival of neuroprogenitor cells. We found that ablation of
CTCF leads to Puma-dependent apoptosis of NPCs using two
different conditional deletion strategies. Increased apoptosis cor-
related with p53-dependent Puma transcription, suggesting that
CTCF loss results in p53 stabilization and transcriptional activa-
tion of its downstream targets. CTCF loss might also result in a
more open chromatin environment at the Puma gene, facilitating
p53-dependent activation of transcription and elong tion of
RNA polymerase II (Gomes and Espinosa, 2010a,b). Ctcf inacti-
vation in postmitotic c rtical nd hippocampal neurons does not
induce apoptosis (Hirayama et al., 2012), pointing to a specific
survival role f r CTCF in proliferating cells. However, CTCF loss
of function may not induce apoptosis in all types of proliferating
cells in vivo, as Ctcf deletion in thymocytes was shown previously
to induce cell cycle arrest without induction of apoptosis (Heath
et al., 2008). It is possible that the outcome of CTCF deficiency
leads to either p53-dependent cell cycle arrest or apoptosis, de-
pending on varying cell-specific or temporal cues. This could be
similar to the outcomes described uponNbs1 (Nijmegen breakage
syndrome 1/Nibrin) deletion in the CNS, which leads to p53-
dependent apoptosis in the cerebellum, but causes p53-
dependent cell cycle arrest in the neocortex (Li et al., 2012).
In the present report, we demonstrate that deletion of Puma
effectively rescues apoptotic cell death observed at E16.5 in the
CtcfNes-cre brain (Fig. 4). Despite this apparent recovery at E16.5,
Figure6. Ctcf-deficient cells that are rescued fromapoptotic deathdisplay reducedproliferative capacity. Pregnant femaleswere subjected to a 1hBrdUpulse before being killed.A, BrdU (green)
immunostaining of E16.5 control, Ctcf Nes-cre, and Ctcf Nes-cre;Puma"/" cortical cryosections. The inset demonstrates fewer BrdU! cells in the Ctcf Nes-cre and Ctcf Nes-cre;Puma"/" IZ compared with
control. Scale bar, 50!m. Original magnification, 100#. B, The number of cells in S phase was quantified by counting BrdU! cells in 200-!m-wide cortical images (n$ 3). Error bars represent
SEM.
Figure 7. Ctcf-deficiency results in PUMA-dependent apoptosis of basal progenitor cells. Pregnant femaleswere subjected to a 1 h BrdU pulse before being killed.A, TBR2 (red) and BrdU (green)
coimmunostaining of E16.5 cortical cryosections. Arrowheads indicate TBR2!/BrdU! cells in the IZ and VZ/SVZ. Scale bar, 50!m. Original magnification, 100#. B, TBR2! cells were quantified
in 200-!m-wide cortical images (n$ 3). C, TBR2!/BrdU! cells were quantified in 200-!m-wide cortical images (n$ 3). Error bars represent SEM.
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Quantification of SOX2+ cells indicated a dramatic reduction in the number of apical 
progenitors and oRGs in the CtcfNes-cre cortex (Figure 3-8a,b). The number of SOX2+ 
apical progenitors was only partially rescued in the CtcfNes-cre;Puma−/− cortex, indicating 
that CTCF may control the size of the apical progenitor pool independently of apoptosis 
(Figure 3-8a,b). Conversely, oRG (SOX2+ cells in the intermediate zone) numbers were 
restored to control levels in the CtcfNes-cre;Puma−/− cortex, indicating that these cells are 
lost via Puma-mediated apoptotic cell death upon deletion of Ctcf (Figure 3-8a,b). The 
proliferative capacity of apical progenitors (SOX2+/BrdU+ cells in the VZ/SVZ) was 
severely diminished in the CtcfNes-cre cortex compared to control, and was not restored in 
the CtcfNes-cre;Puma−/− cortex (Figure 3-8a,c). Similarly, BrdU incorporation in the 
rescued CtcfNes-cre;Puma−/− oRG cells was extremely low, indicating that they are likely 
arrested in the cell cycle and fail to correctly enter S phase (Figure 3-8a,c). To confirm 
that these cells are oRG progenitors, we performed SOX2 and PAX6 coimmunostaining 
and indeed observed a decreased number of SOX2+PAX6+ cells in the intermediate zone 
of CtcfNes-cre embryos compared to control and CtcfNes-cre;Puma−/− at E16.5 (Figure 3-8d). 
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Figure 3-8 Ctcf-deficiency results in PUMA-dependent apoptosis of apical and outer 
radial glia progenitors 
Apical and outer radial glia progenitors that are rescued from apoptotic death fail to 
proliferate. Pregnant females were subjected to a 1 h BrdU pulse before being killed. A, 
SOX2 (red) and BrdU (green) coimmunostaining of E16.5 cortical cryosections. The 
inset demonstrates fewer SOX2+ cells in the CtcfNes-cre IZ than control or CtcfNes-cre;Puma-
/-. Scale bar: 50 µm. (B) SOX2+ cells were quantified in 200-µm-wide cortical images (n 
= 3). (C) SOX2+/BrdU+ cells were quantified in 200-µm-wide cortical images (n = 3). (D) 
Immunodetection of SOX2 (green) and PAX6 (red) in the E16.5 cortical IZ demonstrates 
restoration of oRG progenitors in CtcfNes-cre;Puma-/- cortex compared to CtcfNes-cre. Scale 
bar: 10 µm. Arrowheads indicate SOX2+/PAX6+ oRG cells. Error bars represent SEM. 
Original magnification: (A, D) x100.  
 
 
 
 
 
 
the double mutant brain at birth appeared hypocellular and was
nearly undistinguishable histologically from the CtcfNes-cre brain
(Fig. 5). We showed that CtcfNes-cre;Puma!/! apical and oRG
progenitors that cannot activate the apoptotic pathway fail to
incorporate BrdU, which might be explained by a p53-mediated
cell cycle arrest. Further investigations into the mechanism un-
derlying increased p53 levels in the Ctcf-null brain will be impor-
tant to fully elucidate the role of CTCF in progenitor cell survival.
Given that oRG cells are implicated in neocortical expansion in
humans, their reduced ability to proliferate in the double mutant
cortex might partly explain the failure to recover cortical size at
birth, andmay be relevant to microcephaly caused by CTCFmu-
tations in humans (Hansen et al., 2010; Lui et al., 2011; Reillo et
al., 2011).
A key observation is that deletion of Puma did not completely
restore the number of apical cells in the CtcfNes-cre;Puma!/! cor-
igure 8. Ctcf-deficiency results in PUMA-dep ndent apoptosis of apical and outer radial glia progenitors. Apical and outer r dial glia progenitors that are rescued from apoptotic death fail to
proliferate. Pregnant females were subjected to a 1 h BrdU pulse before being killed. A, SOX2 (red) and BrdU (green) coimmunostaining of E16.5 cortical cryosections. The inset demonstrates fewer
SOX2" cells in the Ctcf Nes-cre IZ than control or Ctcf Nes-cre;Puma!/!. B, SOX2" cells were quantified in 200-!m-wide cortical images (n# 3). C, SOX2"/BrdU" cells were quantified in
200-!m-wide cortical images (n# 3). D, Immunodetection of SOX2 (green) and PAX6 (red) in the E16.5 cortical IZ demonstrates restoration of oRG progenitors in Ctcf Nes-cre;Puma!/! cortex
compared to Ctcf Nes-cre. Arrowheads indicate SOX2"/PAX6" oRG cells. Error bars represent SEM. Original magnification: A, D, 100$. Scale bars: A, 50!m; D, 10!m.
Figure 9. Ctcf-deficiency causes premature neurogenesis.A, Immunodetection of SOX2 (red) and TBR2 (green) in E14 control and Ctcf Nes-cre cortex.B, SOX2", TBR2", and SOX2"/TBR2" cells
were quantified in 150-!m-wide cortical images and expressed as a percentage of total DAPI" cells (n# 3). C, Pregnant femalemicewere subjected to a 24 h BrdU pulse before being killed. Ki67
(red) and BrdU (green) immunostaining was used to determine the percentage of cells exiting the cell cycle in control and Ctcf Nes-cre E14 cortex. Arrowheads indicate BrdU"Ki67! cells that have
exited the cell cycle. D, Cell cycle exit indices were calculated bymeasuring the ratio of BrdU"Ki67! cells to total BrdU" cells in control and Ctcf Nes-cre cortex at E14 (n# 3). E, Immunodetection
of TBR1 (red) and SATB2 (green) in E14 control and Ctcf Nes-cre cortex.F, Immunodetection of CTIP2 (green) in E14 control and Ctcf Nes-cre cortex.G, SATB2", TBR1", and CTIP2" cellswere quantified
and expressed as a percentage of DAPI" cells (n# 3). Error bars represent SEM. Original magnification: A, C, E, F, 100$. Scale bars: A, C, 50!m; E, F, 50!m.
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3.3.6 Ctcf loss causes premature differentiation of apical progenitors 
Incomplete restoration of the apical progenitor population in the CtcfNes-cre;Puma−/− 
cortex suggests that loss of CTCF leads to an apoptosis-independent reduction of these 
cells (Figure 3-8a,b). To identify the cause of reduced apical cell numbers, we analyzed 
the progenitor pool composition, cell cycle exit indices, and postmitotic projection 
neuron subtypes in control and CtcfNes-cre cortex at E14. 
Apical progenitors begin to produce projection neurons at approximately E11.5 (Figure 
1-5a). At the same time, they generate neuron-committed basal progenitors and oRG 
progenitors (Figure 1-5a). Since the majority of basal progenitor divisions are terminal 
and result in the production of two neurons, this would result in increased generation of 
neurons at the expense of the progenitor pool (Haubensak et al., 2004; Miyata et al., 
2004; Noctor et al., 2004; Watson et al., 2014). The relative abundance of TBR2+ basal 
progenitors was significantly increased in the E14 CtcfNes-cre cortex compared to control, 
whereas the number of SOX2+ apical progenitors was not affected (Figure 3-9a,b), 
suggesting that differentiation of apical progenitors into basal progenitors is increased. 
Next, we measured the proportion of cells exiting the cell cycle by labeling embryos with 
BrdU for 24 h and analyzing Ki67+ and BrdU+ cells in E14 control and CtcfNes-cre cortex. 
Cell cycle exit (BrdU+Ki67− cells/total BrdU+ cells) was significantly higher in CtcfNes-cre 
cortex compared to controls (Figure 3-9c,d). 
The cortical plate is established by projection neurons that organize themselves in an 
“inside-out” manner, such that early-born neurons populate deeper cortical layers (layer 
VI, then layer V), and late-born neurons migrate past the early-born neurons to populate 
the more superficial layers of the cortex (layer IV, then layer II/III; (Greig et al., 2013) 
(Figure 1-5a). Increased cell cycle exit and differentiation at E13–E14 is predicted to 
result in an increased number of layer VI corticothalamic projection neurons (TBR1+), 
layer V subcerebral projection neurons (CTIP2+), and callosal projection neurons 
(SATB2+) (Figure 1-5a). We found that the relative generation of these neuronal subtypes 
was increased in the CtcfNes-cre cortex compared to control (Figure 3-9e-g), confirming 
premature differentiation of Ctcf-null apical progenitors, which is predicted to result in a 
reduced number of this progenitor pool by late neurogenesis. 
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Figure 3-9 Ctcf-deficiency causes premature neurogenesis 
(A) Immunodetection of SOX2 (red) and TBR2 (green) in E14 control and CtcfNes-cre 
cortex. Scale bar: 50 µm. (B) SOX2+, TBR2+, and SOX2+/TBR2+ cells were quantified in 
150-µm-wide cortical images and expressed as a percentage of total DAPI+ cells (n = 3). 
(C) Pregnant female mice were subjected to a 24 h BrdU pulse before being killed. Ki67 
(red) and BrdU (green) immunostaining was used to determine the percentage of cells 
exiting the cell cycle in control and CtcfNes-cre E14 cortex. Arrowheads indicate 
BrdU+Ki67+ cells that have exited the cell cycle. Scale bar: 50 µm. (D) Cell cycle exit 
indices were calculated by measuring the ratio of BrdU+Ki67- cells to total BrdU+ cells in 
control and CtcfNes-cre cortex at E14 (n = 3). (E) Immunodetection of TBR1 (red) and 
SATB2 (green) in E14 control and CtcfNes-cre cortex. Scale bar: 50 µm. (F) 
Immunodetection of CTIP2 (green) in E14 control and CtcfNes-cre cortex. Scale bar: 50 
µm. (G) SATB2+, TBR1+, and CTIP2+
 
cells were quantified and expressed as a 
percentage of DAPI+ cells (n = 3). Error bars represent SEM. Original magnification: (A, 
C, E, F) x100. 
 
 
the double mutant brain at birth appeared hypocellular and was
nearly undistinguishable histologically from the CtcfNes-cre brain
(Fig. 5). We showed that CtcfNes-cre;Puma!/! apical and oRG
progenitors th t cannot ctivate the apoptotic pathway fail
incorporate BrdU, which might be explained by a p53-mediated
cell cycle arrest. Further investigations into the mechanism un-
derlying increased p53 levels in the Ctcf-null brain will be impor-
tant to fully elucidate the role of CTCF in progenitor cell survival.
Given that oRG cells are implicated in neocortical expansion in
humans, their reduced ability to proliferate in the double mutant
cortex might partly explain the failure to recover cortical size at
birth, andmay be relevant to mic ocephaly caused by CTCFmu-
tations in humans (Hansen et al., 2010; Lui et al., 2011; Reillo et
al., 2011).
A key observation is that deletion of Puma did not completely
restore the number of apical cells in the CtcfNes-cre;Puma!/! cor-
Figure 8. Ctcf-deficiency results in PUMA-dependent apoptosis of apical and outer radial glia progenitors. Apical and outer radial glia progenitors that are rescued from apoptotic death fail to
proliferate. Pregnant females were subjected to a 1 h BrdU pulse before being killed. A, SOX2 (red) and BrdU (green) coimmunostaining of E16.5 cortical cryosections. The inset demonstrates fewer
SOX2" cells in the Ctcf Nes-cre IZ than control or Ctcf Nes-cre;Puma!/!. B, SOX2" cells were quantified in 200-!m-wide cortical images (n# 3). C, SOX2"/BrdU" cells were quantified in
200-!m-wide cortical images (n# 3). D, Immunodetection of SOX2 (green) and PAX6 (red) in the E16.5 cortical IZ demonstrates restoration of oRG progenitors in Ctcf Nes-cre;Puma!/! cortex
compared to Ctcf Nes-cre. Arrowheads indicate SOX2"/PAX6" oRG cells. Error bars represent SEM. Original magnification: A, D, 100$. Scale bars: A, 50!m; D, 10!m.
Figure 9. Ctcf-deficiency causes premature neurogenesis.A, Immunodetection of SOX2 (red) and TBR2 (green) in E14 control and Ctcf Nes-cre cortex.B, SOX2", TBR2", and SOX2"/TBR2" cells
were quantified in 150-!m-wide cortical images and expressed as a percentage of total DAPI" cells (n# 3). C, Pregnant femalemicewere subjected to a 24 h BrdU pulse before being killed. Ki67
(red) and BrdU (green) immunostaining was used to determine the percentage of cells exiting the cell cycle in control and Ctcf Nes-cre E14 cortex. Arrowheads indicate BrdU"Ki67! cells that have
exited the cell cycle. D, Cell cycle exit indices were calculated bymeasuring the ratio of BrdU"Ki67! cells to total BrdU" cells in control and Ctcf Nes-cre cortex at E14 (n# 3). E, Immunodetection
of TBR1 (red) and SATB2 (green) in E14 control and Ctcf Nes-cre cortex.F, Immunodetection of CTIP2 (green) in E14 control and Ctcf Nes-cre cortex.G, SATB2", TBR1", and CTIP2" cellswere quantified
and expressed as a percentage of DAPI" cells (n# 3). Error bars represent SEM. Original magnification: A, C, E, F, 100$. Scale bars: A, C, 50!m; E, F, 50!m.
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3.4 Discussion 
This study provides evidence that CTCF is required at very early stages of telencephalon 
development for the maintenance and survival of neuroprogenitor cells. We found that 
ablation of CTCF leads to Puma-dependent apoptosis of NPCs using two different 
conditional deletion strategies. Increased apoptosis correlated with p53-dependent Puma 
transcription, suggesting that CTCF loss results in p53 stabilization and transcriptional 
activation of its downstream targets. CTCF loss might also result in a more open 
chromatin environment at the Puma gene, facilitating p53-dependent activation of 
transcription and elongation of RNA polymerase II (Gomes and Espinosa, 2010a, b). Ctcf 
inactivation in postmitotic cortical and hippocampal neurons does not induce apoptosis 
(Hirayama et al., 2012), pointing to a specific survival role for CTCF in proliferating 
cells. However, CTCF loss of function may not induce apoptosis in all types of 
proliferating cells in vivo, as Ctcf deletion in thymocytes was shown previously to induce 
cell cycle arrest without induction of apoptosis (Heath et al., 2008). It is possible that the 
outcome of CTCF deficiency leads to either p53-dependent cell cycle arrest or apoptosis, 
depending on varying cell-specific or temporal cues. This could be similar to the 
outcomes described upon Nbs1 (Nijmegen breakage syndrome 1/Nibrin) deletion in the 
CNS, which leads to p53-dependent apoptosis in the cerebellum, but causes p53-
dependent cell cycle arrest in the neocortex (Li et al., 2012). 
In the present report, we demonstrate that deletion of Puma effectively rescues apoptotic 
cell death observed at E16.5 in the CtcfNes-cre brain (Figure 3-4). Despite this apparent 
recovery at E16.5, the double mutant brain at birth appeared hypocellular and was nearly 
undistinguishable histologically from the CtcfNes-cre brain (Figure 3-5). We showed that 
CtcfNes-cre;Puma−/− apical and oRG progenitors that cannot activate the apoptotic pathway 
fail to incorporate BrdU, which might be explained by a p53-mediated cell cycle arrest. 
Further investigations into the mechanism underlying increased p53 levels in the Ctcf-
null brain will be important to fully elucidate the role of CTCF in progenitor cell survival. 
Given that oRG cells are implicated in neocortical expansion in humans, their reduced 
ability to proliferate in the double mutant cortex might partly explain the failure to 
recover cortical size at birth, and may be relevant to microcephaly caused by CTCF 
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mutations in humans (Hansen et al., 2011; Lui et al., 2011; Reillo et al., 2011). 
A key observation is that deletion of Puma did not completely restore the number of 
apical cells in the CtcfNes-cre;Puma−/− cortex, suggesting that while a proportion of this 
progenitor population undergoes Puma-dependent death in the absence of CTCF, apical 
cells exhibit an independent defect. We found that Ctcf-null apical progenitors 
differentiate prematurely, causing an initial increase in the production of basal 
progenitors and early-born postmitotic neurons (Figure 3-9). However, the increased 
number of basal progenitors is later counteracted by a reduction of the progenitor pool 
from which they are derived, and exacerbated by increased levels of apoptosis. Given that 
CTCF colocalizes with the cohesin complex and is required for cohesin localization to 
specific genomic sites to influence gene expression (Parelho et al., 2008; Wendt and 
Peters, 2009), it is conceivable that premature neurogenesis in the CtcfNes-cre cortex results 
from dysregulation of CTCF target genes. 
The number of basal progenitor cells marked by TBR2 expression was completely 
restored in the double mutant brain, indicating that PUMA activation causes basal 
progenitor cell death in the absence of CTCF. Simultaneous labeling of brain sections 
with TBR2 and BrdU showed that rescued basal progenitors are still able to proliferate, 
unlike rescued apical and oRG cells. Despite the overall equivalent number of TBR2+ 
cells in the control and double mutant cortex, several rescued basal progenitors did not 
move basally out of the ventricular zone, perhaps due to a defect in apical radial glia or 
an inability to correctly delaminate from the apical surface of the Ctcf-deficient cortex. 
In summary, we demonstrated that CTCF is required in the early developing mouse brain 
for neuroprogenitor cell survival and that its deletion induces p53- and PUMA-dependent 
apoptosis. Independent from its role in promoting cell survival, CTCF is required for the 
correct balance of proliferative versus differentiative divisions and maintenance of the 
apical progenitor pool. Together, these functions of CTCF contribute to the normal 
development of the mammalian neocortex. 
169 
 
3.5 References 
Bani-Yaghoub, M., Tremblay, R.G., Lei, J.X., Zhang, D., Zurakowski, B., Sandhu, J.K., 
Smith, B., Ribecco-Lutkiewicz, M., Kennedy, J., Walker, P.R., et al. (2006). Role of 
Sox2 in the development of the mouse neocortex. Developmental biology 295, 52-66. 
Berube, N.G., Mangelsdorf, M., Jagla, M., Vanderluit, J., Garrick, D., Gibbons, R.J., 
Higgs, D.R., Slack, R.S., and Picketts, D.J. (2005). The chromatin-remodeling protein 
ATRX is critical for neuronal survival during corticogenesis. The Journal of clinical 
investigation 115, 258-267. 
Dou, C.L., Li, S., and Lai, E. (1999). Dual role of brain factor-1 in regulating growth and 
patterning of the cerebral hemispheres. Cerebral cortex 9, 543-550. 
Englund, C., Fink, A., Lau, C., Pham, D., Daza, R.A., Bulfone, A., Kowalczyk, T., and 
Hevner, R.F. (2005). Pax6, Tbr2, and Tbr1 are expressed sequentially by radial glia, 
intermediate progenitor cells, and postmitotic neurons in developing neocortex. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 25, 247-251. 
Fedoriw, A.M., Stein, P., Svoboda, P., Schultz, R.M., and Bartolomei, M.S. (2004). 
Transgenic RNAi reveals essential function for CTCF in H19 gene imprinting. Science 
303, 238-240. 
Gloster, A., El-Bizri, H., Bamji, S.X., Rogers, D., and Miller, F.D. (1999). Early 
induction of Talpha1 alpha-tubulin transcription in neurons of the developing nervous 
system. The Journal of comparative neurology 405, 45-60. 
Gomes, N.P., and Espinosa, J.M. (2010a). Disparate chromatin landscapes and kinetics of 
inactivation impact differential regulation of p53 target genes. Cell cycle 9, 3428-3437. 
Gomes, N.P., and Espinosa, J.M. (2010b). Gene-specific repression of the p53 target gene 
PUMA via intragenic CTCF-Cohesin binding. Genes & development 24, 1022-1034. 
Gotz, M., Stoykova, A., and Gruss, P. (1998). Pax6 controls radial glia differentiation in 
the cerebral cortex. Neuron 21, 1031-1044. 
Gregor, A., Oti, M., Kouwenhoven, E.N., Hoyer, J., Sticht, H., Ekici, A.B., Kjaergaard, 
S., Rauch, A., Stunnenberg, H.G., Uebe, S., et al. (2013). De novo mutations in the 
genome organizer CTCF cause intellectual disability. American journal of human 
genetics 93, 124-131. 
Greig, L.C., Woodworth, M.B., Galazo, M.J., Padmanabhan, H., and Macklis, J.D. 
(2013). Molecular logic of neocortical projection neuron specification, development and 
diversity. Nature reviews Neuroscience 14, 755-769. 
Handoko, L., Xu, H., Li, G., Ngan, C.Y., Chew, E., Schnapp, M., Lee, C.W., Ye, C., 
Ping, J.L., Mulawadi, F., et al. (2011). CTCF-mediated functional chromatin interactome 
in pluripotent cells. Nature genetics 43, 630-638. 
170 
 
Hansen, D.V., Rubenstein, J.L., and Kriegstein, A.R. (2011). Deriving excitatory neurons 
of the neocortex from pluripotent stem cells. Neuron 70, 645-660. 
Haubensak, W., Attardo, A., Denk, W., and Huttner, W.B. (2004). Neurons arise in the 
basal neuroepithelium of the early mammalian telencephalon: a major site of 
neurogenesis. Proceedings of the National Academy of Sciences of the United States of 
America 101, 3196-3201. 
Heath, H., Ribeiro de Almeida, C., Sleutels, F., Dingjan, G., van de Nobelen, S., Jonkers, 
I., Ling, K.W., Gribnau, J., Renkawitz, R., Grosveld, F., et al. (2008). CTCF regulates 
cell cycle progression of alphabeta T cells in the thymus. The EMBO journal 27, 2839-
2850. 
Hebert, J.M., and McConnell, S.K. (2000). Targeting of cre to the Foxg1 (BF-1) locus 
mediates loxP recombination in the telencephalon and other developing head structures. 
Developmental biology 222, 296-306. 
Hirayama, T., Tarusawa, E., Yoshimura, Y., Galjart, N., and Yagi, T. (2012). CTCF is 
required for neural development and stochastic expression of clustered Pcdh genes in 
neurons. Cell reports 2, 345-357. 
Holwerda, S.J., and de Laat, W. (2013). CTCF: the protein, the binding partners, the 
binding sites and their chromatin loops. Philosophical transactions of the Royal Society 
of London Series B, Biological sciences 368, 20120369. 
Jeffers, J.R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J., MacLean, K.H., Han, 
J., Chittenden, T., Ihle, J.N., et al. (2003). Puma is an essential mediator of p53-
dependent and -independent apoptotic pathways. Cancer cell 4, 321-328. 
Kernohan, K.D., Jiang, Y., Tremblay, D.C., Bonvissuto, A.C., Eubanks, J.H., Mann, 
M.R., and Berube, N.G. (2010). ATRX partners with cohesin and MeCP2 and contributes 
to developmental silencing of imprinted genes in the brain. Developmental cell 18, 191-
202. 
Li, R., Yang, Y.G., Gao, Y., Wang, Z.Q., and Tong, W.M. (2012). A distinct response to 
endogenous DNA damage in the development of Nbs1-deficient cortical neurons. Cell 
research 22, 859-872. 
Lui, J.H., Hansen, D.V., and Kriegstein, A.R. (2011). Development and evolution of the 
human neocortex. Cell 146, 18-36. 
Miyata, T., Kawaguchi, A., Saito, K., Kawano, M., Muto, T., and Ogawa, M. (2004). 
Asymmetric production of surface-dividing and non-surface-dividing cortical progenitor 
cells. Development 131, 3133-3145. 
Moore, J.M., Rabaia, N.A., Smith, L.E., Fagerlie, S., Gurley, K., Loukinov, D., Disteche, 
C.M., Collins, S.J., Kemp, C.J., Lobanenkov, V.V., et al. (2012). Loss of maternal CTCF 
is associated with peri-implantation lethality of Ctcf null embryos. PloS one 7, e34915. 
171 
 
Mukhopadhyay, R., Yu, W., Whitehead, J., Xu, J., Lezcano, M., Pack, S., Kanduri, C., 
Kanduri, M., Ginjala, V., Vostrov, A., et al. (2004). The binding sites for the chromatin 
insulator protein CTCF map to DNA methylation-free domains genome-wide. Genome 
research 14, 1594-1602. 
Nakahashi, H., Kwon, K.R., Resch, W., Vian, L., Dose, M., Stavreva, D., Hakim, O., 
Pruett, N., Nelson, S., Yamane, A., et al. (2013). A genome-wide map of CTCF 
multivalency redefines the CTCF code. Cell reports 3, 1678-1689. 
Nakano, K., and Vousden, K.H. (2001). PUMA, a novel proapoptotic gene, is induced by 
p53. Molecular cell 7, 683-694. 
Noctor, S.C., Martinez-Cerdeno, V., Ivic, L., and Kriegstein, A.R. (2004). Cortical 
neurons arise in symmetric and asymmetric division zones and migrate through specific 
phases. Nature neuroscience 7, 136-144. 
Ohlsson, R., Bartkuhn, M., and Renkawitz, R. (2010). CTCF shapes chromatin by 
multiple mechanisms: the impact of 20 years of CTCF research on understanding the 
workings of chromatin. Chromosoma 119, 351-360. 
Parelho, V., Hadjur, S., Spivakov, M., Leleu, M., Sauer, S., Gregson, H.C., Jarmuz, A., 
Canzonetta, C., Webster, Z., Nesterova, T., et al. (2008). Cohesins functionally associate 
with CTCF on mammalian chromosome arms. Cell 132, 422-433. 
Reillo, I., de Juan Romero, C., Garcia-Cabezas, M.A., and Borrell, V. (2011). A role for 
intermediate radial glia in the tangential expansion of the mammalian cerebral cortex. 
Cerebral cortex 21, 1674-1694. 
Shitamukai, A., Konno, D., and Matsuzaki, F. (2011). Oblique radial glial divisions in the 
developing mouse neocortex induce self-renewing progenitors outside the germinal zone 
that resemble primate outer subventricular zone progenitors. The Journal of neuroscience 
: the official journal of the Society for Neuroscience 31, 3683-3695. 
Shitamukai, A., and Matsuzaki, F. (2012). Control of asymmetric cell division of 
mammalian neural progenitors. Development, growth & differentiation 54, 277-286. 
Slack, R.S., El-Bizri, H., Wong, J., Belliveau, D.J., and Miller, F.D. (1998). A critical 
temporal requirement for the retinoblastoma protein family during neuronal 
determination. The Journal of cell biology 140, 1497-1509. 
Soshnikova, N., Montavon, T., Leleu, M., Galjart, N., and Duboule, D. (2010). 
Functional analysis of CTCF during mammalian limb development. Developmental cell 
19, 819-830. 
Tarabykin, V., Stoykova, A., Usman, N., and Gruss, P. (2001). Cortical upper layer 
neurons derive from the subventricular zone as indicated by Svet1 gene expression. 
Development 128, 1983-1993. 
172 
 
Villunger, A., Michalak, E.M., Coultas, L., Mullauer, F., Bock, G., Ausserlechner, M.J., 
Adams, J.M., and Strasser, A. (2003). p53- and drug-induced apoptotic responses 
mediated by BH3-only proteins puma and noxa. Science 302, 1036-1038. 
Wan, L.B., Pan, H., Hannenhalli, S., Cheng, Y., Ma, J., Fedoriw, A., Lobanenkov, V., 
Latham, K.E., Schultz, R.M., and Bartolomei, M.S. (2008). Maternal depletion of CTCF 
reveals multiple functions during oocyte and preimplantation embryo development. 
Development 135, 2729-2738. 
Wang, X., Lui, J.H., and Kriegstein, A.R. (2011a). Orienting fate: spatial regulation of 
neurogenic divisions. Neuron 72, 191-193. 
Wang, X., Tsai, J.W., LaMonica, B., and Kriegstein, A.R. (2011b). A new subtype of 
progenitor cell in the mouse embryonic neocortex. Nature neuroscience 14, 555-561. 
Watson, L.A., Solomon, L.A., Li, J.R., Jiang, Y., Edwards, M., Shin-ya, K., Beier, F., and 
Berube, N.G. (2013). Atrx deficiency induces telomere dysfunction, endocrine defects, 
and reduced life span. The Journal of clinical investigation 123, 2049-2063. 
Watson, L.A., Wang, X., Elbert, A., Kernohan, K.D., Galjart, N., and Berube, N.G. 
(2014). Dual effect of CTCF loss on neuroprogenitor differentiation and survival. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 34, 2860-
2870. 
Wendt, K.S., and Peters, J.M. (2009). How cohesin and CTCF cooperate in regulating 
gene expression. Chromosome research : an international journal on the molecular, 
supramolecular and evolutionary aspects of chromosome biology 17, 201-214. 
Yu, J., Zhang, L., Hwang, P.M., Kinzler, K.W., and Vogelstein, B. (2001). PUMA 
induces the rapid apoptosis of colorectal cancer cells. Molecular cell 7, 673-682. 
Yusufzai, T.M., and Felsenfeld, G. (2004). The 5'-HS4 chicken beta-globin insulator is a 
CTCF-dependent nuclear matrix-associated element. Proceedings of the National 
Academy of Sciences of the United States of America 101, 8620-8624. 
Yusufzai, T.M., Tagami, H., Nakatani, Y., and Felsenfeld, G. (2004). CTCF tethers an 
insulator to subnuclear sites, suggesting shared insulator mechanisms across species. 
Molecular cell 13, 291-298. 
 
173 
 
Chapter 4 
4 CTCF is required to prevent replication-associated DNA 
damage in neuroprogenitor cells 
This chapter aims to address the molecular mechanism underlying p53/PUMA-dependent 
apoptosis downstream of CTCF loss by investigating a role for CTCF in genomic 
stability. Several reports have identified that CTCF is and important regulator of 
replication (Bergstrom et al., 2007; Cleary et al., 2010), and one study reported telomere 
dysfunction as a consequence of CTCF depletion (Deng et al., 2012a), however the exact 
roles for CTCF in replication are not well understood. This is the first study to identify 
that CTCF loss causes replication-associated damage. 
4.1 Introduction 
The CCCTC-binding factor (CTCF) is implicated in higher-order genome organization 
through its ability to mediate intra- and inter-chromosomal contacts, bringing disparate 
regions of the genome into close proximity (Kurukuti et al., 2006; Ling et al., 2006; 
Splinter et al., 2006). This function of CTCF has been primarily studied in the context of 
transcriptional regulation, whereby CTCF controls enhancer-promoter interactions. 
Additionally, transcription-independent roles for CTCF have been described in the 
literature: CTCF regulates stability of trinucleotide repeats implicated in expansion 
disorders such as spinocerebellar ataxia type 7 (SCA7) and myotonic dystrophy type I 
(DM1) (Filippova et al., 2001; Libby et al., 2008; Sopher et al., 2011). At the DM1 locus, 
CTCF binding upstream of the repeat is required to slow DNA polymerase before 
replication of the repetitive tract, and mutations in the CTCF binding site results in repeat 
expansion likely due to strand slippage (Cleary et al., 2010). Intriguingly, DM1 is 
asymmetrically replicated (Rajcan-Separovic 1998) and CTCF regulates asymmetric 
replication of the H19/Igf2 imprinted domain (Bergstrom et al., 2007). CTCF is thus an 
important factor for DNA replication, although its actions may be limited to certain loci 
as direct roles for the protein have only been described at asymmetrically replicated 
regions. CTCF has also been implicated in replication origin firing. Overexpression of the 
oncogenic replication licensing factor Cdc6 causes CTCF dissociation from the 
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promoters of the tumour-suppressor genes CDH1 and INK4/ARF, resulting in reduced 
expression and activation of adjacent replication origins (Sideridou et al., 2011). It was 
suggested that because replication origins are defined by structural chromatin context 
rather than DNA sequence CTCF might facilitate higher-order organization of replication 
origins (Antequera, 2004; Cvetic and Walter, 2005).  
Whereas the CTCF partner cohesin is implicated in organizing replication factories and 
controlling S phase progression, CTCF depletion had little effect on cell cycle dynamics 
or the overall size of replicon units identified by the DNA halo assay (Guillou et al., 
2010). A more global role for CTCF in DNA replication have not yet been thoroughly 
investigated, but is of interest given the importance of CTCF for replication timing, 
progression, and origin firing at individual loci. Furthermore, the finding that TADs 
regulate replication timing suggests that CTCF may participate in this process if indeed 
CTCF is involved in orchestrating TAD organization (Dixon et al., 2012; Pope et al., 
2014). 
Human mutations in CTCF cause intellectual disability associated with microcephaly and 
autistic features (Gregor et al., 2013) and single nucleotide polymorphisms (SNPs) at the 
CTCF locus are associated with schizophrenia (Juraeva et al., 2014). Deletion at 16q22.1, 
the genomic locus of CTCF, is one of the most frequent genetic events in breast cancer 
and is well documented in several other cancers (Filippova et al., 1998; Rakha et al., 
2006). Together, this suggests that CTCF is important for correct brain development and 
to suppress tumourigenesis, however the molecular underpinnings of these associations 
are unknown. 
CTCF is an essential factor for cellular survival (Fedoriw et al., 2004; Heath et al., 2008; 
Moore et al., 2012; Soshnikova et al., 2010; Wan et al., 2008; Watson et al., 2014). 
However, the mechanisms responsible have not been characterized. We previously 
reported that CTCF loss in neuroprogenitor cells (NPCs) causes p53 stabilization, Puma 
upregulation, and PUMA-dependent apoptosis (Watson et al., 2014). Here, we provide 
novel evidence that CTCF is required to safeguard the genome through S phase during 
early stages of fate restriction in NPCs. CTCF localizes to damage sites under conditions 
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of replicative stress but it does not appear to be required for repair of exogenous 
replication-associated damage, perhaps reflecting a more general role for CTCF in 
organizing chromatin domains during replication to facilitate replication and prevent 
genetic instability.  
4.2 Materials and Methods 
4.2.1 Mouse husbandry and genotyping 
Mice were exposed to 12 h light/dark cycles and fed tap water and regular chow ad 
libitum. The CtcfloxP mice, in which loxP sites flank exons 3–12, have been described 
previously (Heath et al., 2008). Mice conditionally deficient in CTCF were generated by 
crossing CtcfloxP/+ females (C57BL/6 background) with heterozygous Foxg1Cre knock-in 
male mice (129/sv background) or with NestinCre heterozygous male mice (C57BL/6 
background; (Berube et al., 2005; Hebert and McConnell, 2000). To account for 
decreased Foxg1 expression due to knock-in of the Cre recombinase gene, Cre+ males 
were used as controls (Ctcf+/+Foxg1-cre+/−) unless stated otherwise. Using the NestinCre 
driver line, CtcfloxP/loxP mice were crossed with CtcfloxP/+;Nestin+ mice to generate 
Ctcflox/P/loxP or CtcfloxP/+ (controls) and CtcfloxP/loxP;Nestin+ (CtcfNes-cre). DNA from tail 
biopsies of newborn pups or yolk sac from embryos was genotyped by PCR, as 
previously described (Watson et al., 2014).  
4.2.2 Immunostaining, histology, and antibodies 
For immunofluorescence staining, cryosections and cells were incubated with the primary 
antibody overnight at 4°C, washed in PBS/0.3% Triton-X 100, and incubated with the 
secondary antibody for 1 h at room temperature. Sections and cells were counterstained 
with DAPI (Sigma-Aldrich) and mounted in SlowFade Gold (Invitrogen). Primary 
antibodies used were as follows: rabbit anti-CTCF (1:400; Cell Signaling Technology), 
rabbit anti-γH2AX (S139; 1:100; Cell Signaling Technology), mouse anti-PCNA (1:400; 
Santa Cruz Biotechnology), mouse anti-BrdU (1:50; BD Biosciences), rabbit anti-
phosphorylated H3 (S10; 1:500; Millipore). Secondary antibodies used were as follows: 
goat-anti-rabbit Alexa 594 (1:800; Invitrogen), goat-anti-mouse Alexa 488 (1:800; 
Invitrogen), donkey-anti-sheep Alexa 594 (1:800; Invitrogen), and donkey-anti-mouse 
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Alexa 488 (1:800; Invitrogen). Sections were subjected to antigen retrieval (incubated in 
0.1 mM sodium citrate, pH 6.0, heated to ∼95°C and microwaved on low for 10 min) 
before overnight incubation. For histological studies, slides were stained with 
hematoxylin and eosin (H&E). 
4.2.3 BrdU labeling  
Pregnant mice were injected intraperitoneally with cell proliferation labeling reagent [10 
mM bromodeoxyuridine (BrdU) and 1 mM fluorodeoxyuridine (FdU) in H2O] at 1 
ml/100 g body weight, or 0.3 mg/g body weight (GE Healthcare Life Sciences). Animals 
were killed after 1 h by CO2 asphyxiation, and the embryos were recovered in ice-cold 
PBS, pH 7.4, and were fixed in 4% paraformaldehyde. Tissue was equilibrated in 30% 
sucrose/PBS and frozen in OCT (Tissue Tek). Before immunofluorescence analysis, 
cryosections (8 µm) were treated with 2N HCl to denature the DNA, and neutralized with 
0.1 M Na2B4O7, pH 8.5. 
4.2.4 Primary NPC cultures and manipulation 
Cortical progenitor cultures were prepared as described previously (Gloster et al., 1999; 
Slack et al., 1998; Watson et al., 2013) using cortices dissected from E12.5 embryos. 
Cells were seeded on polyornithine-coated (Sigma-Aldrich) plastic plates or glass 
coverslips. Cells were fixed in 4% paraformaldehyde for 10 min, washed in PBS, and 
processed for immunofluorescence. Cell viability was measured using the trypan blue dye 
exclusion method. Cell counts were determined with a hemacytometer. 
4.2.5 Western blot analysis 
Total protein was extracted using RIPA buffer and quantified using the Bradford assay. 
Protein (20 µg) was resolved on a 6% SDS-polyacrylamide gel and transferred onto a 
nitrocellulose membrane (Bio-Rad). The membrane was probed with primary antibodies 
followed by the appropriate horseradish peroxidase-conjugated secondary antibodies 
(1:4000; GE Healthcare Life Sciences). The membrane was incubated in ECL before 
exposure to x-ray film or on a ChemiDoc™ MP (BioRad). Densitometry analysis was 
performed using ImageJ software (version 1.47). 
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4.2.6 Cell cycle profiling 
Primary NPCs were cultured for two days and pulse-labeled with cell proliferation 
labeling reagent [10 mM bromodeoxyuridine (BrdU) and 1 mM fluorodeoxyuridine 
(FdU) in H2O] at 5 µl/ml media (GE Healthcare Life Sciences), fixed, and stained with 
propidium iodide (PI). The proportion of cells in each phase of the cell cycle was 
determined by flow cytometry on a Beckman-Coulter Epics XL-MCL instrument, as 
described (Isaac et al., 2006). 
4.2.7 Immunoprecipitation 
Total cell lysates were obtained from primary NPC cultures using RIPA buffer for 30 
minutes on ice. 500 µg of protein was treated with 100U/ml DNase I (Sigma) for 10 
minutes at 37oC, followed by incubation with 1 µg mouse anti-PCNA antibody (Santa 
Cruz Biotechnologies) while rotating overnight at 4oC. Normal mouse IgG (Santa Cruz 
Biotechnologies) was used as a negative control. Samples were then incubated with 
Dynabeads protein G (Invitrogen) for 2 h at 4oC. Immunoprecipitates were washed three 
times with 1XPBS/0.2% Tween-20, eluted at 70oC for 10 minutes, and resolved on 8-
12% SDS-PAGE. Western blot analysis was carried out with a rabbit anti-CTCF 
(1:1,000; Cell Signaling) and mouse anti-PCNA (1:500; Santa Cruz Biotechnology). 
4.2.8 Molecular Combing 
Primary NPCs were cultured for two days and pulse-labeled with CldU (25µM) for 30 
minutes, followed by washing with 1XPBS, and IdU (125µM) labeling for 30 minutes. 
Cells were trypsinized and embedded into 1% low melt-grade agarose plugs (Bioshop) to 
a final concentration of 1x106 cells/ml. The plugs were incubated in 1% N-lauryl sarcosyl 
plus 1mg/ml proteinase K until processing. Plugs were washed, immunostained, and 
analyzed as previously described (Yang et al., 2012). 
4.2.9 Microscopy 
Experiments demonstrating co-localization of γH2AX/PCNA and repair capacity 
(resolution of γH2AX foci) were captured using a laser scanning confocal microscope 
(FV1000, Olympus). Stacks were obtained at 0.25-µm z intervals generally spanning 10–
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20 µm. Overlapping signal was scored as a co-localization event. All other images were 
captured with a digital camera (ORCA-ER; Hamamatsu) using an inverted microscope 
(DMI 6000b; Leica). Openlab imaging software (PerkinElmer) was used for manual 
image capture, and processing was performed using Volocity software (PerkinElmer). 
For quantification of γH2AX foci, nuclei were counted in a defined area in at least three 
serial cortical cryosections, and the ratio of γH2AX foci to area (mm2) was calculated. 
For BrdU and phosphorylated histone H3 (S10) quantification, at least three serial 
cortical cryosections were quantified in 150µm-wide sections per embryo.  
4.2.10 Statistical analyses 
Statistical analysis was performed using GraphPad Prism software (GraphPad Software; 
version 4.02), and all results are expressed as the mean ± SEM. Unless indicated 
otherwise, p values were generated using Student's t test (unpaired, two-tailed) to 
compare between two independent data sets. For replication fork rates, P values were 
determined using the Mann-Whitney U-test for non-parametric data. 
 
4.3 Results 
4.3.1 CTCF loss causes an accumulation of endogenous DNA 
damage in the embryonic brain 
CTCF loss in NPCs causes p53 stabilization, Puma upregulation, and PUMA-dependent 
apoptosis (Watson et al., 2014). Given the essential nature of CTCF for cellular survival 
(Fedoriw et al., 2004; Heath et al., 2008; Moore et al., 2012; Soshnikova et al., 2010; 
Watson et al., 2014) and aspects of chromatin organization (Zuin et al., 2014) we 
hypothesized that CTCF may be required to prevent genomic instability, an upstream 
activator of p53/PUMA signaling in NPCs (Jeffers et al., 2003).  
To test this hypothesis we evaluated the nuclear pattern and levels of γH2AX, a marker of 
DNA double-strand breaks (DSBs) in two models of embryonic brain-specific Ctcf 
deficiency (CtcfFoxg1-cre and CtcfNes-cre). We observed that in both models of Ctcf 
deficiency, the number of γH2AX foci were elevated, indicating that endogenous DNA 
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damage accumulation is likely responsible for activation of p53/PUMA-dependent 
apoptosis in the two systems (Figure 4-1a-c). We observed that γH2AX-positive cells 
were primarily localized to the ventricular/subventricular zone (VZ/SVZ) of the 
embryonic CtcfNes-cre neocortex. Moreover, γH2AX foci were rarely present in post-
mitotic cells of the cortical plate (CP) (Figure 4-1b). These observations indicate that 
damage accumulation in Ctcf-deficient embryonic brain might be linked to proliferative 
state.  
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Figure 4-1 CTCF loss in the developing mouse brain is associated with increased 
endogenous DNA damage 
(A) γH2AX (green) immunostaining in E11.5 control and Foxg1-cKO cortical 
neuroepithelium. Scale bar: 50µm. Nuclei were counterstained with DAPI (blue). (B) 
γH2AX (green) immunostaining in E14 control and Nestin-cKO neocortex. Scale bar: 
100µm. Nuclei were counterstained with DAPI (blue). (C) Quantification of γH2AX foci 
per area (mm2) in E14 control and Nestin-cKO neocortex, n = 3; *P <0.0001. Data is 
represented as mean ± standard error of the mean. (D) Western blot analysis of E16.5 
control and Nestin-cKO forebrain extracts probed for CTCF and γH2AX. Histone H3 was 
used as a loading control.  
 
E11.5
Figure 1. CTCF loss is associated with increased endogenous DNA damage. (A) γH2AX 
(green) immunostaining in E11.5 control and CtcfFoxg1-cre cortical neuroepithelium. Scale bar: 
50µm. Nuclei were counterstained with DAPI (blue). (B) γH2AX (green) immunostaining in E14 
control and CtcfNes-cre neocortex. Scale bar: 100µm. Nuclei were counterstained with DAPI (blue). 
(C) Quantification of γH2AX foci per area (mm2) in E14 control and CtcfNes-cre neocortex, n = 3; 
*P <0.0001. Data is represented as mean ± standard error of the mean. (D) Western blot analysis 
of E16.5 control and Nestin-cKO forebrain extracts probed for CTCF and γH2AX. H3 was used 
as a loading control.  
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Figure 3. Ctcf-deficient NPCs exhibit excessive DNA damage, sensitivity to replicative 
stress, and p53-dependent PUMA activation. (A) Immunodetection of γH2AX in control 
and Nes-cKO E14 cortex demonstrates increased DNA double-strand breaks in Ctcf-null 
cortical cells. Scale bar: 200μm. (B) Control and Nes-cKO NPCs were treated with 
hydroxyurea (HU) for 6 hours and cell viability was measured at 24 hours after treatment (n 
= 3 for HU). *P<0.05. (C) Control and Nes-cKO NPCs were γ-irradiated at the indicated 
doses and cell viability was measured 6 hours after treatment (n = 2). (D) Immunoblotting for 
p53 and INCENP using nuclear lysates (20μg) from control and Nes-cKO E16.5 forebrain. 
Intensity of signal was measured using ImageJ, corrected to the loading control (INCENP) 
and expressed relative to control. (E) Quantitative real-time PCR (qRT-PCR) analysis of Ctcf 
and Puma-! expression in control and cKO E16.5 forebrain using primers spanning Puma 
exons 3-4 (n = 3). Expression was normalized to β-actin. (F-H) Immunodetection of PUMA 
in E11.5 control and Foxg1-cKO cortical neuroepithelium (F), E15.5 control and Nes-cKO 
forebrain (G), and control and Nes-cKO NPCs at 4 D.I.V.(H). Scale bars: 50μm (F,G) and 25 
μm (H).!
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4.3.2 CTCF protects against endogenous replicative stress 
To investigate the relationship between damage accumulation and proliferative state, we 
assessed PCNA and γH2AX immunoreactivity in control and CtcfNes-cre neocortex (Figure 
4-2). PCNA is a cell cycle marker present at high levels during late-G1, appears in a 
punctate pattern during mid/late-S phase, and is downregulated in G2 before the onset of 
mitosis (Arai et al., 2011; Bravo and Macdonald-Bravo, 1987). PCNA-positive Ctcf-
deficient NPCs exhibited an elevated number of γH2AX foci per cell than PCNA-
negative cells, and both populations had a significant increase in the number of γH2AX 
foci over control cells (Figure 4-2b). Additionally, the percentage of γH2AX foci that co-
localize with punctate PCNA foci was increased in CtcfNes-cre cells (Figure 4-2c), despite 
the finding that CTCF loss was associated with a reduced number of PCNA foci (Figure 
4-2b,d). Since punctate PCNA staining is typically observed in mid/late-S phase, when 
heterochromatin is replicated, Ctcf-null cells may have difficulties in replicating 
heterochromatin. Together, these data point to a link between damage accumulation and 
DNA replication sites during S phase in Ctcf-deficient NPCs. 
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Figure 4-2 CTCF loss induces replication-associated damage in NPCs 
(A) PCNA and γH2AX immunostaining in E14 control and CtcfNes-cre neocortex. Scale 
bar: 20µm. (B) Quantification of γH2AX foci per cell in PCNA-positive and PCNA-
negative populations, n = 3; 100 cells counted per genotype and population; *P < 0.05. 
(C) Percentage of γH2AX foci that co-localize with PCNA foci, n = 3; 100 cells counted 
per genotype and population; *P < 0.05. (D) Number of PCNA foci per cell, n = 3; 100 
cells counted per genotype and population; *P < 0.05. 
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Figure 3. CTCF loss induces replication-associated damage and a replicative stress response 
in NPCs. (A) PCNA and γH2AX immunostaining in E14 control and Nes-cKO neocortex. Scale 
bar: 20µm. (B) Quantification of γH2AX foci per cell in PCNA-positive and PCNA-negative 
populations, n = 3; 100 cells counted per genotype and population; *P < 0.05. (C) Percentage of 
γH2AX foci that co-localize with PCNA foci, n = 3; 100 cells counted per genotype and 
population; *P < 0.05. (D) Number of PCNA foci per cell, n = 3; 100 cells counted per genotype 
and population; *P < 0.05. (E-I) Cells were treated with a variety of DNA damaging agents for 
24h (except for acute γ-irradiation) and viability was measured 24h later, n = 4; *P < 0.05. 
(J)Control and Ctcf-null NPCs were cultured in the presence or absence of aphidicolin (10µM, 
6h) and lysates were probed for pRPAS33, total RPA, γH2AX, and pChk1S345. H3 was used as a 
loading control. Graphical data is represented as mean ± standard error of the mean.  
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To gain more insight into the type of DNA damage incurred in the absence of CTCF, 
NPCs were subjected to a variety of exogenous damaging agents. Ctcf-null NPCs were 
hypersensitive to the DNA polymerase inhibitor aphidicolin (Berger et al., 1979), the 
ribonucleotide reductase inhibitor hydroxyurea (Young and Hodas, 1964) and the 
interstrand crosslinking agent mitomycin C (Nakata et al., 1961), but not γ-irradiation or 
the topoisomerase II inhibitor etoposide (Minocha and Long, 1984) (Figure 4-3a-e). 
Collectively, these findings implicate CTCF in either the response to, or repair of, DNA 
replication-related damage. 
Replicative stress has been broadly defined as any event that alters fulfillment of the 
DNA replication program (Magdalou et al., 2014; Zeman and Cimprich, 2014). 
Replication fork stalling results in a build-up of single stranded DNA (ssDNA), 
accumulation and phosphorylation of replication associated protein A (pRPAS33), 
recruitment of the PI-3 kinase ataxia telangiectasia and Rad3 related (ATR), and 
activation of the checkpoint kinase Chk1 (pChk1S345) (Zeman and Cimprich, 2014). 
Replication stress can also occur if the replication fork encounters barriers to its 
progression i.e. transcriptional complexes, unresolved DNA secondary structures, or 
double-stranded breaks (DSBs) (Allen et al., 2011; Mirkin and Mirkin, 2007). 
Replication stress can itself result in DSB formation, as prolonged replication fork 
stalling can result in collapse of the fork (Zeman and Cimprich, 2014). Western blot 
analysis of control and CtcfNes-cre NPCs established from E12.5 telencephalon and 
cultured for two days in vitro demonstrated modest increases in pRPAS33, pChk1S345 
and γH2AX levels under basal conditions, suggesting that CTCF loss induces a 
replicative stress response (Figure 4-3f,g). Induction of exogenous replicative stress by 
the addition of aphidicolin resulted in a similar increases in pRPAS33, pChk1S345 and 
γH2AX levels in CtcfNes-cre compared to control NPCs (Figure 4-3f,g). These results 
indicate that CTCF is not required for signaling downstream of replicative stress through 
these molecules (Figure 4-3f,g). A more detailed analysis of replication fork dynamics by 
molecular combing revealed decreased replication fork speed in CtcfNes-cre NPCs relative 
to control, suggesting that CTCF is required for normal replication fork progression 
(Figure 4-3h). Together, these experiments demonstrate that CTCF is required to prevent 
replication-associated damage and a replicative stress response in NPCs. 
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Figure 4-3 Ctcf-null NPCs exhibit evidence of replicative stress 
(A-E) Cells were treated with a variety of DNA damaging agents for 24h (except for 
acute γ-irradiation) and viability was measured 24h later, n = 4; *P < 0.05. (F) Control 
and CtcfNes-cre NPCs were cultured in the presence or absence of aphidicolin (Aph; 10µM, 
6h) and lysates were probed for pRPAS33, total RPA, γH2AX, and pChk1S345. H3 was 
used as a loading control. Densitometry analysis of γH2AX, pRPAS33, and pChk1S345 
relative to H3 is depicted in (G), n = 2. Graphical data is represented as mean ± standard 
error of the mean. (H) The distribution of replication fork progression rates in control 
and CtcfNes-cre (KO) NPCs are represented in a box plot. Track lengths were converted 
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into kilobase pairs using a conversion factor for λ DNA and the median fork rate for each 
biological replicate is shown. P values were determined using the Mann-Whitney U-test 
for non-parametric data to compare the distributions of fork rates (kb/min) between two 
samples.  
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Activation of the replicative stress response can result in intra-S or G2/M arrest (Feijoo et 
al., 2001; Walworth et al., 1993). Flow cytometry was performed to determine the effect 
of CTCF loss on cell cycle progression of NPCs established from E12.5 telencephalon 
and cultured for two days in vitro (Figure 4-4a). Analysis of BrdU/propidium iodide 
incorporation indicated a modest increase in the proportion of Ctcf-null NPCs in S phase, 
with a concomitant decrease in G0/G1 cells (Figure 4-4a). This trend was not statistically 
significant, likely owing to variability between biological replicates. In vivo 
immunofluorescence analysis of E14 cryosections using a G2/M marker (pH3S10) in 
conjunction BrdU (1h injection of pregnant dam prior to sacrifice) indicated no 
significant differences between the proportion of cells in S phase (BrdU+/pH3-) or G2 
phase (BrdU+/pH3+) in control and CtcfNes-cre neocortex (Figure 4-4b-d). There was a 
slight increase in the number of mitoses (pH3+/BrdU-) in the basal SVZ, while there was 
no difference in the number of apical mitoses along the VZ (Figure 4-4e). This data fits 
with our previous results showing an increase in the population of TBR2+ basal 
progenitor cells, which undergo mitosis in the SVZ (Haubensak et al., 2004; Miyata et 
al., 2004; Noctor et al., 2004; Watson et al., 2014). In summary, despite evidence that 
supports activation of a replicative stress response as measured by phosphorylation of 
RPA (pRPAS33) and Chk1 (pChk1S345), cell cycle profiles are similar between control 
and Ctcf-null NPCs (Figure 4-4). 
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Figure 4-4 Cell cycle profiles of control and CtcfNes-cre NPCs are similar both in vitro 
and in vivo 
(A) Control and Ctcf-null NPCs were cultured for three days and labeled with BrdU for 
1.5h. Cell cycle profiles were generated by BrdU and propidium iodide labeling followed 
by flow cytometry, n = 4. (B) BrdU (1h; green) and phosphorylated histone H3S10 
(pH3S10; red) immunostaining in E14 control and CtcfNes-cre neocortex. White box 
indicates region of higher magnification; arrowheads point to BrdU+/pH3+ cells presumed 
to be in G2 phase. The percentage of cells in S (BrdU+/pH3-; C) and G2 (BrdU+/pH3+; D) 
phase were quantified in 150µm-wide sections, n = 4. (E) The number of solid-staining 
pH3+ cells were quantified in 600µm-wide sections of E14 control and CtcfNes-cre 
neocortex within 20µm of the ventricle (apical mitoses) and in the SVZ (basal mitoses), n 
= 2. Graphical data is represented as mean ± standard error of the mean. 
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4.3.3 An interaction between CTCF and PCNA is DNA-mediated 
An important role for CTCF in DNA replication has been supported by the finding that 
CTCF is important for asynchronous replication of the H19/Igf2 imprinted domain, and 
that CTCF binding upstream of the DM1 repetitive tract in the myotonic dystrophy gene 
is required to slow the replication fork before encountering repetitive DNA to ensure 
replicative fidelity (Bergstrom et al., 2007; Cleary et al., 2010; Libby et al., 2008). 
Additionally, mass spectrometry analysis of CTCF binding partners in embryonic stem 
cells revealed numerous binding partners that participate in DNA replication such as 
PCNA, RCF1, RCF2, RCF4, Orc1, and DNA polymerase delta (van de Nobelen, 2008). 
We validated the interaction between CTCF and PCNA by immunoprecipitation of 
PCNA in control NPCs, followed by immunoblotting for CTCF (Figure 4-5a). 
Pretreatment of the protein lysates with DNAse I prior to immunoprecipitation 
demonstrated a diminished interaction between CTCF and PCNA, indicating an indirect 
interaction mediated by DNA but supporting a close association between the two proteins 
(Figure 4-5a).  
4.3.4 CTCF is not required for timely repair of exogenous replication-
associated damage 
We next considered that the increased endogenous replication-associated damage 
observed in Ctcf-deficient cells might result from a requirement for CTCF in DNA repair. 
Indeed, NPCs encounter a high degree of replicative stress due to their high proliferative 
index (McKinnon, 2013), and CTCF localizes to replicative stress-induced damage foci 
in NPCs (Figure 4-5b). Given the close relationship between CTCF and the cohesin 
complex (Parelho et al., 2008; Rubio et al., 2008; Wendt et al., 2008), and the fact that 
cohesin is required for post-replicative repair by homologous recombination (Sjogren and 
Nasmyth, 2001), this became an intriguing hypothesis. To test this, we subjected control 
and Ctcf-null NPCs to aphidicolin treatment and measured repair kinetics by assessing 
γH2AX levels over time (Figure 4-5b,c). Control NPCs exhibited a 6-fold increase in 
γH2AX foci 6 h after aphidicolin treatment that was reduced by 24 h post treatment 
(Figure 4-5b,c). The number of γH2AX foci in Ctcf-null NPCs followed a similar trend, 
despite the basal level of γH2AX foci (Figure 4-5c,d). This experiment provides evidence 
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that CTCF is not required for resolution of γH2AX foci after the induction of exogenous 
replicative stress. Interestingly, the DNA-mediated interaction between CTCF and PCNA 
was enhanced under conditions of replicative stress (10µM aphidicolin, 6h; Figure 4-5a), 
however the functional significance of this relationship is not yet understood. 
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Figure 4-5 An indirect interaction between CTCF and PCNA is enhanced under 
conditions of replicative stress, however CTCF is not required for repair of 
replication-associated damage 
(A) Control NPCs were cultured in the presence or absence of 10µM aphidicolin for 6h 
and subjected to PCNA immunoprecipitation (IP) followed by immunoblotting for 
CTCF. Lysates were pretreated with Dnase I prior to IP where indicated. (B) Confocal 
images of γH2AX immunostaining in control and Ctcf-null NPCs post 10 µM aphidicolin 
for the length of time indicated. Scale bar: 5 µm. (C) The number of γH2AX foci per 
DAPI+ nucleus was quantified at 0, 6, and 24 hours post 10 µM aphidicolin treatment, n = 
4; 50-100 nuclei counted per treatment. Graphical data is represented as mean ± standard 
error of the mean. 
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4.4 Discussion 
We, and others, have previously demonstrated that CTCF is an essential factor for 
cellular survival (Fedoriw et al., 2004; Heath et al., 2008; Moore et al., 2012; Soshnikova 
et al., 2010; Wan et al., 2008; Watson et al., 2014). Despite this important role in the cell, 
the mechanism underlying apoptosis of Ctcf-deficient cells is largely unknown. Here, we 
provide evidence that CTCF is required to prevent replication-associated DNA damage in 
NPCs.  
Mice in which Ctcf was deleted from early forebrain progenitors using Foxg1-cre 
exhibited massive apoptosis resulting in near-complete ablation of telencephalic 
structures (Watson et al., 2014). Remarkably, when Ctcf was deleted a few days later 
using Nestin-cre, cortical progenitor loss was reduced (Watson et al., 2014). Both models 
of CTCF loss exhibited elevated DNA damage concurrent with apoptosis. This is 
reminiscent of models of Topbp1 deletion, where levels of apoptosis were higher upon 
deletion of Topbp1 in early progenitors (using Emx1-cre) compared to later progenitors 
(using Nestin-cre) despite similar levels of DNA strand breaks in the two models (Lee et 
al., 2012a). The results presented here support the idea that earlier NPCs have a lower 
threshold for DNA damage-induced apoptosis compared with progenitors generated at a 
later developmental stage. 
In response to DNA damage, p53 activates cell cycle arrest and/or apoptosis (Amundson 
et al., 1998). Ctcf-deficient NPCs have increased levels of γH2AX, exhibit replicative 
stress, and are sensitive to exogenous agents that perturb replication. However, the 
increased replication-associated DNA damage was not sufficient to dramatically alter cell 
cycle progression, perhaps indicating that DNA damage levels only exceeded a threshold 
sufficient to activate cell cycle arrest in a proportion of mutant cells. This idea is 
supported by the modest increases observed in activation of the effector proteins involved 
in replicative stress-associated cell cycle arrest, and a subtle trend towards increased Ctcf-
deficient S phase cells in vitro and in vivo (Figures 4-3f, 4-4a,c). Since neurogenic 
progenitors have a lengthened G1 phase, and postmitotic neurons behave like cells in G1 
in their DNA content and failure to incorporate BrdU, then the increased basal progenitor 
population and increased generation of postmitotic neurons observed in the Ctcf-null 
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neocortex would result in an artificially high G1 population by flow cytometry. Since 
flow cytometry is a population-based measure, the proportion of cells in other phases 
would be compromised. Analysis of strictly proliferative progenitors by analyzing Tis21-
negative cells (Calegari and Huttner, 2003) would more accurately identify S phase 
populations. 
Our experiments provide evidence that CTCF is not required for repair of exogenous 
replication-associated DNA damage since Ctcf-null NPCs exhibited similar capacity to 
resolve γH2AX foci relative to control cells after aphidicolin treatment (Figure 4-5a,b). 
This result must be interpreted with caution, however, since different types of stress elicit 
different cellular responses. More sensitive assays to measure repair kinetics such as the 
comet assay to directly measure single- and double-stranded breaks without relying on a 
cellular marker like γH2AX will provide more insight into the ability of Ctcf-null cells to 
repair DNA damage. The finding that CTCF is not required for repair of aphidicolin-
induced damage but that Ctcf-null cells are sensitive to the drug indicates that additional 
replicative stress in the absence of CTCF likely exceeds the threshold for apoptosis. 
Interestingly, CTCF is enriched at aphidicolin-induced damage foci and indirectly 
interacts with PCNA and γH2AX under conditions of replicative stress. While CTCF 
may not be required for repair of aphidicolin-induced damage per se, it may play a role in 
organizing higher-order chromatin structure surrounding DNA breaks to help facilitate 
timely repair.   
Genome-wide maps of chromatin interaction revealed that the genome is organized into 
specific domains within the nucleus, termed topologically associating domains (TADs), 
whose borders are enriched for CTCF binding sites, suggesting a role for CTCF in 
establishment of this type of genome organization (Dixon et al., 2012). Recently, it was 
demonstrated that chromatin loops bound by CTCF demarcate TAD borders (Rao et al., 
2014) and that TADs show a striking correlation with replication timing domains (Pope 
et al., 2014). Thus, if CTCF is important for TAD organization, it may also be important 
for the organization of replication timing. Indeed, RNAi-mediated CTCF knockdown 
results in the loss of some TAD boundary activity (Zuin et al., 2014). Furthermore, large 
changes to the replication-timing program can result in replicative stress, and thus CTCF 
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may function to organize TADs and by extension replication timing domains to suppress 
this type of damage (Buonomo et al., 2009; Cornacchia et al., 2012). In light of our 
findings, it will be important to test this hypothesis by assessing genome-wide replication 
timing profiles of control and Ctcf-null NPCs in the future.  
Collectively, our findings provide insight into the mechanism underlying CTCF function 
in cellular survival. CTCF is required to prevent replication-associated damage, p53 
activation, and apoptotic induction. It remains unclear whether CTCF is required directly 
for repair of endogenously occurring replicative stress, or rather if increased DNA 
damage resulting from CTCF loss are a secondary consequence of its functions in 
chromatin organization. Future studies addressing the contributions of CTCF function to 
DNA replication and repair will be critical to further our understanding of the 
requirements for CTCF in cellular survival.  
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Chapter 5 
5 Discussion and Future Directions 
The body of work presented in this thesis provides molecular evidence that epigenetic 
regulators, such as those involved in organizing higher-order chromatin structure, are 
necessary for NPC survival and growth by promoting genomic stability to support correct 
brain development. This data aligns with the finding that intellectual disability, 
microcephaly, and/or neuropsychiatric disorders are enriched for mutations in epigenetic 
regulators (De Rubeis et al., 2014; Gibbons et al., 1995a; Gregor et al., 2013; Iossifov et 
al., 2014; Pinto et al., 2014; Ronemus et al., 2014), and that human cancers are enriched 
for alterations in epigenetic pathways (Elsasser et al., 2011; Filippova et al., 1996; 
Huether et al., 2014; Jiao et al., 2011; Schwartzentruber et al., 2012).  
In chapter two, I demonstrate that ATRX is required for stability of repetitive elements, 
such as telomeres and pericentromeric heterochromatin, particularly during DNA 
replication. I began exploring a mechanism underlying genomic instability in the absence 
of ATRX and found that Atrx-null NPCs are sensitive to G4-DNA stabilization, 
suggesting that ATRX may resolve G4-DNA structures that have the propensity to form 
at telomeric sequences. More globally, ATRX may aid in the replication of repetitive 
sequences through incorporation of H3.3, explaining the instability observed at 
pericentromeric heterochromatin, which is AT- rather than GC-rich. Systemically, loss of 
ATRX in the forebrain and anterior pituitary resulted in aging-associated phenotypes, 
endocrine dysregulation, and reduced lifespan. Together, these findings implicate ATRX 
in suppressing genome instability, which when restricted to the forebrain and anterior 
pituitary can cause systemic defects that resemble accelerated aging. 
Chapter three and four focus on characterizing the role of CTCF in embryonic brain 
development. I found that CTCF is required for NPC survival by suppressing replication-
associated DNA damage and p53/PUMA-dependent apoptotic signaling. Additionally, 
CTCF controls the balance between NPC proliferation and differentiation to support 
correct brain growth and size. Taken together, these studies identify CTCF as an 
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important regulator of brain development through controlling cell cycle dynamics and 
cellular survival. 
Collectively, the work presented in this thesis highlights the dynamic interplay between 
chromatin structure, genomic stability, and brain development by revealing that ATRX 
and CTCF are essential genomic stability factors in NPCs. The findings also begin to 
dissect the mechanism underlying neurodevelopmental abnormalities stemming from loss 
of ATRX or CTCF by identifying that loss of either factor causes replication-associated 
DNA damage, highlighting the requirement of safeguarding the genome for correct 
development of the central nervous system.  
 
5.1 ATRX is a critical regulator of genomic stability 
At the outset of this study, ATRX had not been implicated in promoting genomic 
stability. In fact, it was believed that although ATRX is a homolog of the DNA repair 
protein Rad54, it was unlikely to play a role in maintaining stability of the genome since 
ATR-X patient cells do not display UV sensitivity (Gibbons et al., 1995b). My work 
clearly demonstrates a requirement for ATRX in promoting genomic stability, providing 
an explanation for p53-dependent apoptosis of Atrx-null NPCs (Seah et al., 2008). Other 
studies have since shown that ATRX is required to prevent DNA damage during DNA 
replication in myoblasts, HCT116 human colon cancer cells, limb bud cells, and ES cells 
(Clynes et al., 2014; Conte et al., 2012; Huh et al., 2012; Leung et al., 2013; Solomon et 
al., 2013).  
ATRX-mediated genomic stability is critical for cellular survival, however it is not yet 
known whether accumulation of DNA damage in Atrx-null cells is primary or secondary 
to defects in replication. This remains difficult to distinguish since replication defects can 
cause DNA damage and vice versa. For instance, DNA DSBs can impede the replication 
fork to cause replication stalling and S phase lengthening. At the same time it is equally 
possible that problems during replication, like fork slowing or failure to resolve complex 
secondary structures, could cause stalling and collapse of the replication fork into DSBs.  
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Several studies have demonstrated a role for ATRX in correct cell division (Baumann et 
al., 2010; De La Fuente et al., 2004; Ritchie et al., 2008; Ritchie et al., 2014). Given the 
close relationship between DNA replication, cell division, and cell cycle progression, it 
has been difficult to decipher whether meiotic/mitotic defects stemming from ATRX loss 
are primary or secondary to replicative stress. Issues during replication, such as under-
replication of DNA sequences, failure to repair DSBs, or telomere uncapping can 
manifest as anaphase bridges and/or micronuclei (Burrell et al., 2013; Gauthier et al., 
2012; Hampel et al., 2013; Incles et al., 2004; Kim et al., 2003; Sofueva et al., 2011; 
Tahara et al., 2006). At the same time it is possible to envision mitotic defects, such as 
congression and cohesion failure, to be capable of inducing DNA double-strand breaks 
and issues during replication. For instance, mutation- or drug-induced mitotic spindle 
disruption can induce DSBs that are found in centromere-containing micronuclei (Dalton 
et al., 2007; Guerrero et al., 2010; Quignon et al., 2007). Moreover, chromosomal 
instability can result from chromosome missegregation during mitosis (Dobles et al., 
2000).  
Current evidence in the literature supports a model wherein ATRX functions to promote 
replication fork processivity through notoriously difficult-to-replicate repetitive genomic 
regions, thereby preventing fork stalling and collapse into DSBs that can aberrantly affect 
cell division (Figure 5-1). This is substantiated by the findings that ATRX targets 
repetitive DNA (Law et al., 2010), that Atrx-null cells exhibit replication defects (Clynes 
et al., 2014; Leung et al., 2013), the particular sensitivity of Atrx-null cells to replicative 
stress-inducing drugs (Clynes et al., 2014; Conte et al., 2012; Leung et al., 2013; Watson 
et al., 2013), and that DNA damage foci in Atrx-null cells colocalize with late-replicating 
heterochromatin (Huh et al., 2012; Watson et al., 2013). Further evidence for this model 
of ATRX function is presented below. 
ATRX genomic binding sites are predicted to adopt non-B form secondary structures 
(Law et al., 2010), which have been shown to impede replication fork progression leading 
to fork stalling or collapse into DSBs (Paeschke et al., 2011; Sarkies et al., 2012; Sarkies 
et al., 2010). It is tempting to speculate that ATRX may facilitate replication by resolving 
G4-DNA structures, an idea supported by the particular sensitivity of Atrx-null cells to 
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replication stressors and the G4 ligand telomestatin (TMS) (Watson et al., 2013). 
However, although recombinant ATRX can interact with G4-DNA oligonucleotides in 
vitro (Law et al., 2010), it performed poorly in a G4-DNA unwinding assay compared to 
the Bloom Syndrome helicase protein BLM (Clynes et al., 2014), suggesting that ATRX 
does not directly unwind G4-DNA. ATRX may, however, indirectly overcome these 
secondary structures by incorporating H3.3 into chromatin to maintain B-form DNA, or 
alternatively through template switching. The ATPase domain of ATRX is similar to the 
homologous recombination (HR) protein Rad54 (Picketts et al., 1998), which stabilizes 
Rad51 onto presynaptic filaments to enable HR repair (Alexiadis and Kadonaga, 2002; 
Golub et al., 1997; Tan et al., 1999) and to resolve stalled replication forks (Maher et al., 
2011). Atrx-deficient cells have decreased Rad51 levels (Huh et al., 2012), suggesting 
ATRX may also function to stabilize Rad51 in some capacity.  
We now know that ATRX interacts with the MRN complex (Clynes et al., 2014; Leung 
et al., 2013), although the functional implications of this interaction are unclear. MRN is 
required for DNA damage detection, signaling, and repair (Dinkelmann et al., 2009; Rass 
et al., 2009; Taylor et al., 2010; Xie et al., 2009), as well as for promoting fork restart 
after replicative stress (Bryant et al., 2009; Falck et al., 2012). MRN localizes to 
telomeres in S and G2 phase, Mre11 can interact with G4-DNA in yeast (Ghosal and 
Muniyappa, 2005; Leung et al., 2013; Verdun and Karlseder, 2006; Zhu et al., 2000), and 
MRN is implicated in the alternative lengthening of telomeres (ALT) phenotype, 
providing additional parallels with ATRX functions (Jiang et al., 2005; Zhong et al., 
2007). Human mutations in MRN components cause a spectrum of disease. For instance, 
MRE11 mutations cause ataxia telangiectasia-like disorder (A-TLD) characterized by 
ataxia and neurodegeneration, which shares similarities to A-T resulting from mutations 
in ATM (Gatti et al., 1988; Stewart et al., 1999), and mutations in NBS1 cause Nijmegen 
breakage syndrome (NBS) characterized by microcephaly, immunodeficiency, and cancer 
predisposition (Carney et al., 1998; Rodrigues et al., 2013; Varon et al., 1998). The 
parallels between ATR-X and NBS, like microcephaly, are intriguing since ATRX 
interaction with MRN appears to be mediated by NBS1 (Leung et al., 2013), suggesting 
that the overlapping phenotype may result from cooperative functions of the proteins. 
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Chapter two of this thesis describes a requirement for ATRX in preventing accumulation 
of endogenous DNA damage in the embryonic brain. The first indication that genomic 
instability was linked to cellular proliferation came with the finding that the post-
replicative juvenile Atrx-null mouse brain does not exhibit elevated DNA damage (Figure 
2-9). However, Atrx-null cells do not display a typical response to replicative stress in 
that mutant cells exhibit increased activation of ATM (pATMS1981) rather than ATR 
(pATRS428) (Figure 2-1). A mouse model of Seckel syndrome carrying a hypomorphic 
Atr mutation demonstrated that replicative stress activates an ATM-dependent DNA 
damage response resulting in increased γH2AX levels (Murga et al., 2009). There is also 
extensive cross-talk among the ATM and ATR kinases in NPCs (McKinnon, 2013). In 
fact, telomere dysfunction in NPCs results in ATR-to-ATM-dependent signaling (Lee et 
al., 2014), evoking the possibility that ATM and ATR may both be activated in Atrx-null 
cells. Since ATR is phosphorylated on a number of different residues to mediate its 
activation, it will be worthwhile to assess activation status of downstream targets of 
ATR-dependent signaling like Chk1 and RPA in Atrx-deficient NPCs (Durocher and 
Jackson, 2001; Shiloh, 2001). In human HCT116 cells, deletion of ATRX resulted in 
reduced phosphorylation of Chk1 on serine 317 (Leung et al., 2013), suggesting ATRX is 
required for correct checkpoint signaling downstream of ATR. Therefore, our observation 
of increased ATM signaling in Atrx-null NPCs may result from defective ATR signaling 
in response to the replicative stress induced by ATRX loss. The exact molecular details 
of ATRX function in DNA damage signaling are clearly not completely understood and 
require further examination. 
The novel role for ATRX in genomic stability requires a thorough evaluation of the DNA 
damage response in patient cells. Indeed, ATR-X patient lymphocytes exhibited 
increased γH2AX and p53 phosphorylation suggestive of an increased DNA damage 
response (Huh et al., 2012). However, it remains unclear whether patient cells exhibit 
evidence of replicative stress or increased occurrence of unresolved secondary structures 
like G4-DNA. With the recent generation of a G4-DNA-specific antibody (Biffi et al., 
2013) it will be possible to test this hypothesis in cellular models of Atrx deficiency as 
well as in ATR-X patient cells. 
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Figure 5-1 Model of ATRX function in genomic stability 
ATRX is critical for stability of heterochromatin, presumably via incorporation of histone 
H3.3 to maintain heterochromatin function. H3.3 incorporation may also help resolve G4-
DNA structures, which have the propensity to form at telomeres and GC-rich ssDNA 
exposed during replication or transcription. The consequences of ATRX loss is (1) failure 
to incorporate H3.3 at heterochromatin, resulting in dysfunction, DNA damage, and 
mitotic defects and (2) failure to resolve G4-DNA structures, resulting in their over-
abundance that could cause replication stress and transcriptional dysregulation. The 
relationship between H3.3 incorporation and G4-DNA resolution is not well 
characterized.  
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5.2 ATRX is a novel telomere-binding protein 
This study is one of many to identify ATRX as an important component of telomeres 
(Goldberg et al., 2010; Huh et al., 2012; Watson et al., 2013; Wong et al., 2010). In 2010, 
two groups demonstrated that ATRX is required for H3.3 deposition at telomeric 
sequences (Goldberg et al., 2010; Wong et al., 2010). The functional significance of H3.3 
incorporation at telomeres remains unclear, especially in light of conflicting findings 
regarding the effect of ATRX loss on transcription of the non-coding telomeric transcript 
TERRA (Goldberg et al., 2010; Levy et al., 2014) and given that H3.3 enrichment was 
generally observed in regions of active transcription (Hake et al., 2006). ATRX is also 
involved in restricting the repressive variant macroH2A incorporation at telomeres 
(Ratnakumar et al., 2012). Therefore, ATRX may be required to balance active and 
repressive modifications at chromosome ends to promote their stability, a phenomenon 
that has been observed at centromeres wherein a dual open and closed chromatin state is 
necessary for stability (Chueh et al., 2009; Nakano et al., 2008; Wong et al., 2007). Loss 
of this balancing act may render telomeres hypercondensed, leading to defects in TERRA 
transcription or DNA replication. Furthermore features intrinsic to repetitive elements, 
such as DNA bending and the propensity to form of G4 structures, can adversely affect 
nucleosome occupancy and telomeres have decreased tendency to form nucleosomes in 
vitro (Cacchione et al., 1997). The ATRX-DAXX complex may function to re-establish 
H3.3 containing nucleosomes at these elements to help maintain proper nucleosome 
density for heterochromatin formation, serving as a specialized chromatin assembly 
pathway for repetitive regions such as telomeres, centromeres, and other regions of 
constitutive heterochromatin. Defects in nucleosome assembly pathways, like the ATRX-
DAXX pathway, may therefore lead to increased DNA damage and genomic instability. 
Telomere damage and mitotic fusions imply disintegration of the shelterin complex that 
protects telomere ends from being recognized as DSBs (de Lange, 2005), therefore it 
would be interesting to assess telomeres in Atrx-deficient cells for the presence of the 
protective components.  
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This thesis also describes a role for ATRX in PCH stability. PCH is AT-rich and 
therefore not enriched for G4-forming sequence, suggesting that the mechanism 
underlying destabilization of the major satellite repeats in an ATRX-deficient context 
differs from that of telomeric repeats. The common link between telomeric and 
pericentromeric heterochromatin is enrichment of H3K4me0-K9me3 and the requirement 
for ATRX in H3.3 deposition (Drane et al., 2010; Goldberg et al., 2010; Lewis et al., 
2010). Therefore the mechanism underlying ATRX-dependent stability of repetitive 
elements may more broadly involve H3.3 deposition rather than specific resolution of 
G4-DNA structures. The recent discovery that ATRX can tolerate the histone H3K9me3-
S10ph modification is intriguing since other H3K9me3 readers, such as HP1, are unable 
to bind this signature and become displaced (Kunowska et al., 2015). H3S10ph is induced 
during late G2 and remains associated with chromatin during mitosis (Jeong et al., 2010; 
Nigg, 2001). It is possible that ATRX functions at heterochromatin are particularly 
relevant in actively cycling cells due to its ability to remain bound to H3K9me3-S10ph 
residues, when other proteins required for heterochromatin stability are displaced. 
Telomeres and PCH also express non-coding RNA transcripts that act as structural 
components implicated in heterochromatin formation and maintenance (Azzalin et al., 
2007; Bulut-Karslioglu et al., 2012; Nergadze et al., 2009; Schoeftner and Blasco, 2008). 
Given that ATRX can interact with RNA (Sarma et al., 2014), the non-coding transcripts 
originating from telomeres and PCH may play a role in ATRX targeting and/or 
suppression of the DDR at these structures in the absence of ATRX. Indeed, 
dysregulation of PCH transcripts results in mitotic dysfunction (Bulut-Karslioglu et al., 
2012) and alterations in TERRA levels causes activation of the DDR at telomeres (Deng 
et al., 2009; Deng et al., 2012b).  
The mechanism of ATRX recruitment to telomeres is unknown. Telomeric chromatin is 
enriched for inactive histone post-translational modifications recognized by the ATRX 
ADD domain, such as H3K9me3 (Dhayalan et al., 2011; Eustermann et al., 2011; Iwase 
et al., 2011; Mitson et al., 2011), providing one explanation for ATRX recruitment to the 
genomic structures. ATRX interaction with G4-DNA, at least in vitro (Law et al., 2010), 
provides another explanation. Moreover, ATRX recruitment may also be mediated or 
stabilized by protein-protein or protein-RNA interactions, as ATRX was recently 
208 
 
identified as an RNA-binding protein (Sarma et al., 2014), and interacts with telomere-
enriched proteins such as the MRN complex (Verdun et al., 2005), HP1 (Fanti et al., 
1998; Fanti and Pimpinelli, 2008), the cohesin complex (Remeseiro et al., 2012). 
Moreover, the ATRX partner MeCP2 interacts with TERRA RNA (Deng et al., 2009), 
indicating the possibility that ATRX recruitment may occur via MeCP2. Future studies 
aimed at identifying the ATRX protein domains required for targeting to telomeres will 
be pivotal in furthering our understanding of ATRX contributions to telomere biology 
and genomic stability. 
 
5.3 ATRX functions as a tumour-suppressor protein 
Somatic loss-of-function mutations in ATRX were first described in pancreatic 
neuroendocrine tumours (PanNETs) and later in CNS tumours such as glioma and 
astrocytoma (Chen et al., 2014; Jiao et al., 2012; Jiao et al., 2011; Kannan et al., 2012; 
Liu et al., 2012; Molenaar et al., 2012; Schwartzentruber et al., 2012). Genomic 
instability is a hallmark of the early stages of tumourigenesis (Negrini et al., 2010). 
Exacerbation of the DNA damage phenotype in cells lacking ATRX and p53 highlights 
the tumour suppressive functions of p53 in mediating cell death to protect against 
acquisition of genomic instability (Seah et al., 2008; Watson et al., 2013). Moreover, the 
data fit well with the finding that ATRX/DAXX mutations commonly occur in conjunction 
with mutations in the tumour suppressors p53 or IDH1 (Liu et al., 2012; 
Schwartzentruber et al., 2012) and support a model wherein epigenetic factors like ATRX 
may act as “backseat drivers” in a tissue-specific manner to suppress oncogenic pathways 
upstream of master regulators common to a broad range to tumours, like p53 (Elsasser et 
al., 2011). Studying mice and human cells lacking ATRX and p53 will improve our 
understanding of the mechanisms underlying ATRX mutations promote tumourigenesis.  
ATR-X syndrome patients do not display increased cancer susceptibility (Gibbons, 
2005). This is likely due to the differential mutational landscape observed in ATR-X 
syndrome versus ATRX-null tumours: ATR-X syndrome mutations are hypomorphic and 
result in reduced activity or levels of the protein (Argentaro et al., 2007; Higgs et al., 
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2005), while mutations identified in cancers render the protein non-functional. Perhaps 
decreased quantity or activity of ATRX protein renders specific cell types, like NPCs and 
myoblasts (Huh et al., 2012; Watson et al., 2013), susceptible to DNA damage-induced 
apoptosis during development, while cancer progression requires additional mutations in 
tumour suppressors like p53 to prevent apoptosis and/or drive tumourigenesis. 
Tumours harboring ATRX/DAXX mutations often utilize the alternative lengthening of 
telomeres (ALT) pathway to confer immortality (Bower et al., 2012; Heaphy et al., 
2011a; Lovejoy et al., 2012; Schwartzentruber et al., 2012). The mechanism by which 
ATRX mutations result in the ALT phenotype and drive cancer progression is largely 
unknown. While my data demonstrates that ATRX loss causes telomere dysfunction, 
deletion of ATRX alone is not sufficient to drive ALT (Clynes et al., 2014; Flynn et al., 
2015; Lovejoy et al., 2012), suggesting that additional genetic or epigenetic changes are 
necessary to establish the phenotype. Accordingly, ATRX loss in NPCs did not 
dramatically affect telomere FISH signal intensity (a surrogate for telomere length), 
although this was not assessed in ATRX/p53 mutant cells. 
Interestingly, ALT is associated with the appearance of large PML-NBs (referred to as 
ALT-associated PML-NBs, or APBs) that contain telomeric DNA, the DNA repair MRN 
complex, replication factor A (RPA), and telomeric-repeat binding proteins TRF1 and 
TRF2 (Luciani et al., 2006; Wu et al., 2003; Wu et al., 2000; Yeager et al., 1999). The 
appearance of APBs is a robust marker for tumours that utilize ALT, and APBs rapidly 
assemble upon ALT induction (Costa et al., 2006; Henson et al., 2005; Perrem et al., 
2001), suggesting that APBs may be involved in the mechanism underlying ALT. PML 
or MRN knockdown results in disassembly of ALT-associated PML-NBs, leading to 
inhibition of telomere elongation in ALT cells (Jiang et al., 2005; Jiang et al., 2007; Wu 
et al., 2000; Yu et al., 2010a). This is intriguing since ATRX/DAXX/H3.3 are PML-
associated factors (Chang et al., 2013; Ishov et al., 2004; Luciani et al., 2006), ATRX 
interacts with the MRN complex (Clynes et al., 2014; Leung et al., 2013), and mutations 
in this pathway drive cancers with a high frequency of ALT. It is possible that defects in 
the ATRX/DAXX pathway results in a loss of heterochromatic features at telomeres, 
such as H3.3 enrichment, increased TERRA transcription, and persistent RPA-ssDNA, 
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leading to increased homologous recombination rates that are associated with ALT 
activity. However it remains unclear as to how PML-NBs fit into this picture exactly.  
5.4 Future Directions: ATRX Functions in Genomic Stability 
Several questions remain unanswered with regards to ATRX function in promoting 
cellular survival through genomic stability. These questions along with strategies to 
address them are discussed below. 
First, where exactly does DNA damage localize in Atrx-null cells? Is it concentrated at 
telomeres and PCH, or does it also occur genome-wide? While my data provides 
evidence that damage occurs at repetitive elements like telomeres and PCH, it is unclear 
if these are the only regions susceptible to DNA damage in the absence of ATRX. 
Evaluation of γH2AX occupancy genome-wide by ChIP-sequencing would identify the 
landscape of DNA damage accumulation in Atrx-null cells. Given that ATRX targets 
repetitive DNA (Law et al., 2010), the prediction would be that damage is enriched at 
these sites if indeed ATRX plays a direct role in preventing γH2AX accumulation.  
Next, what role, if any, does H3.3 incorporation play in the DNA damage phenotype 
stemming from ATRX loss? While heavily speculated upon, the role for H3.3 
incorporation in ATRX-dependent genomic stability is largely unknown. HIRA-
dependent H3.3 deposition is required for replication fork restart after UV damage 
(Adam et al., 2013). It is possible that other pathways of H3.3 deposition, like ATRX-
DAXX, are responsible for replication fork restart after endogenous replicative stress. 
Although H3.3 is only unique in five amino acids relative to H3.1 (Maze et al., 2014), the 
recent generation of H3.3-specific antibodies allows for analysis of H3.3 enrichment 
genome-wide. Our group recently demonstrated a requirement for ATRX in H3.3 
deposition within gene bodies to promote transcriptional elongation (Levy et al., 2014). 
Therefore it would be worthwhile to test whether ATRX is required for H3.3 
incorporation at specific sites of damage, which can be induced using lasers or rare-
cutting endonucleases (Jasin, 1996; Kim et al., 2007a). An additional hypothesis that has 
gained much attention is that ATRX resolves G4-DNA structures to facilitate 
transcription and replication (Clynes and Gibbons, 2013; Clynes et al., 2013). The recent 
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generation of a G4-DNA antibody demonstrated the in vivo occurrence of these structures 
(Biffi et al., 2013), and provides a useful tool in testing the aforementioned hypothesis.  
5.5 Hormone signaling from the CNS: Implications for understanding 
aging? 
A surprising finding from chapter two was that Foxg1Cre-mediated deletion of ATRX 
from the forebrain and anterior pituitary causes systemic defects manifested by decreased 
body weight and length, kyphosis, degeneration of subcutaneous fat, cloudy lenses that 
resemble cataracts, altered relative organ sizes, and decreased bone mineral density. We 
determined that the systemic defects correlated with altered endocrine signaling, as the 
mutant mice displayed decreased thyroxine (T4) and insulin-like growth factor 1 (IGF-1) 
levels compared to age- and littermate-matched controls (Figure 2-6). Moreover, the 
mutant mice exhibited reduced lifespan even when controlling for competition amongst 
littermates (Figure 2-4). Overall, the systemic phenotypes we described for the 
conditional knockout (cKO) animals were characteristic of aged mice and resembled 
mouse models of accelerated aging. 
Numerous accelerated aging syndromes are caused by defects in the cellular response to 
DNA damage, including Cockayne syndrome, Werner syndrome, and ataxia 
telangiectasia (Hasty et al., 2003). Most of these syndromes are segmental, in that they do 
not fully recapitulate all aspects of normal human aging, making the relevancy of these 
disorders to human aging controversial (Kipling et al., 2004). However, the segmental 
nature of the syndromes is congruent with the DNA damage theory of aging that posits 
that aging results from DNA damage accumulation (Gensler and Bernstein, 1981; 
Kirkwood and Holliday, 1979; Szilard, 1959), since damage is stochastic and each tissue 
has different requirement for repair mechanisms and damage thresholds (Kirkwood, 
2005).  
The most consistent determinant of lifespan is the IGF-1 pathway (Bartke, 2005; Kenyon, 
2005). IGF-1 is typically regulated by the action of growth hormone (GH), however T4 
has been demonstrated to regulate IGF-1 during prepubescent development, particularly 
in the context of bone development (Xing et al., 2012). The regulation of IGF-1 by T4 
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was especially relevant in our study, since we did not observe changes in GH that could 
explain the dramatic reduction in IGF-1 levels. This study was one of the first to 
acknowledge a potential link between T4 and aging-like phenotypes. Moreover, 
thyroxine is critical for development and maturation of the CNS, particularly neuronal 
differentiation, migration, and myelination (de Escobar et al., 2004; Oppenheimer and 
Schwartz, 1997; Porterfield and Hendrich, 1993). It is therefore possible that many of the 
congenital neurological defects resulting from ATRX mutation or deletion in humans and 
mice could be caused by thyroxine deficiency. This intriguing concept could be tested by 
administering thyroxine to mouse models of Atrx-deficiency, as well as by measuring 
thyroxine levels in ATR-X patients. Intriguingly, ATR-X patients display kyphosis, 
muscle hypotonia, and delayed ambulation (Gibbons, 2006), however it is currently 
unknown whether this is relevant to the endocrine defects observed in the cKO mice 
described herein.  
A key observation is that the somatotroph axis is suppressed in the ATRX cKO mice, 
which correlates with increased DNA damage. This is consistent with genetic deletion of 
the nucleotide excision repair factor ERCC1 (Niedernhofer et al., 2006), SIRT6 
(Mostoslavsky et al., 2006), and overexpression of the short isoform of p53 (Maier et al., 
2004). Furthermore, chronic exposure of wild-type mice to genotoxic stress can also 
dampen the somatotroph axis (Niedernhofer et al., 2006). Collectively, these studies 
provide strong evidence of a link between genome maintenance and somatotroph axis 
signaling. Our findings are unique in that deletion of ATRX, resulting in DNA damage 
accumulation, occurred only in the forebrain and anterior pituitary. This suggests that 
damage restricted to these regions can result in defective endocrine signaling and 
promotion of systemic aging-like characteristics. Furthermore, telomeres are heavily 
implicated in aging and cellular attrition (Sousounis et al., 2014), and this study links 
telomeric dysfunction with specific features of aging. However, it remains unclear 
exactly how telomere dysfunction fits into the systemic defects observed in ATRX cKO 
mice. Short telomeres have been linked to premature aging-like phenotypes, which can be 
rescued by reintroduction of telomerase (Samper et al., 2001). If the systemic defects in 
the cKO mice are due to abnormal telomere shortening, then overexpression of 
telomerase may constitute a means to rescue those phenotypes.  
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5.6 CTCF regulates NPC proliferation, differentiation, and survival 
Prior to my studies, virtually nothing was known regarding CTCF functions in the 
context of brain development. In fact, CTCF activities had rarely been approached in an 
organismal context. Given the critical role for CTCF in development (Fedoriw et al., 
2004; Heath et al., 2008; Moore et al., 2012; Soshnikova et al., 2010; Splinter et al., 
2006; Wan et al., 2008; Watson et al., 2014) and the finding that human CTCF mutations 
cause autism and schizophrenia (Gregor et al., 2013; Iossifov et al., 2014; Juraeva et al., 
2014), CTCF has emerged as a critical regulator of brain development. In particular, my 
data indicates that CTCF regulates brain size by balancing NPC proliferation, 
differentiation, and survival.  
CTCF deletion in mouse NPCs results in microcephaly. I discovered that the 
microcephaly phenotype of mutant mice could not be fully explained by increased cell 
death in the absence of CTCF, since rescue of caspase-mediated apoptosis through Puma 
deletion failed to restore brain size at birth. A contributing factor to the microcephaly 
phenotype is the fact that CTCF influences timing of NPCs differentiation. Ctcf deletion 
causes precocious differentiation of NPCs into early-born deep layer cortical neurons, 
resulting in premature depletion of the progenitor pool and a failure to sustain the correct 
number of later-born superficial neurons. Together, aberrant differentiation timing and 
increased apoptosis of NPCs likely accounts for the neurodevelopmental abnormalities 
observed in NestinCre-mediated Ctcf deletion. The phenomenon of a premature switch 
form symmetric to asymmetric NPC divisions has been observed in many mouse models 
of microcephaly, and more recently induced pluripotent stem cell (iPSC)-based 3D 
neuronal culture models (Gilmore and Walsh, 2013; Lancaster et al., 2013), indicating 
that alterations in division mode can affect brain size.   
An important distinction from the work presented in this thesis is that mutations 
identified in intellectual disability/microcephaly patients are de novo and only affect one 
copy of the CTCF gene (Gregor et al., 2013), as opposed to complete loss of CTCF. 
Detailed analysis of the consequences of three patient mutations indicated that frameshift 
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mutations resulted in an approximately 50% reduction in CTCF levels, while a missense 
mutation in the ZF domain did not affect transcript or protein levels (Gregor et al., 2013). 
This suggests that both the reduction of CTCF levels and alterations in its targeting or 
functions can cause neurological abnormalities. Further investigations into the functional 
consequences of human CTCF mutations will be necessary to fully resolve CTCF 
contributions to brain development and function. 
Fate determination of NPCs is orchestrated by intrinsic and extrinsic mechanisms. Many 
studies indicate an essential role for centrosomes in neurogenesis (Doxsey et al., 2005; 
Higginbotham and Gleeson, 2007; Knoblich, 2008; Wang et al., 2009), functioning to 
maintain the neuroprogenitor pool while inducing the neuronal fate. CTCF has been 
positioned at the centrosome in HeLa cells (Rosa-Garrido et al., 2012; Zhang et al., 
2004), raising the intriguing possibility that centrosomal activities of CTCF may regulate 
neurogenesis. However my analysis of CTCF localization in NPCs indicated enrichment 
at the mitotic spindle rather than at centrosomes per se (data not shown). Future 
experiments aimed at uncovering CTCF activities at the mitotic spindle and/or 
centrosomes will likely provide important insights into fate determination of NPCs.   
Given that CTCF is a well-documented transcriptional regulator, it is also possible that 
altered NPC fate results from dysregulation of cell cycle regulators or other genes that 
play important roles in fate determination. Preliminary transcriptional profiling of the 
Ctcf-deficient embryonic brain has indicated altered expression of several cell cycle 
genes such as decreased expression of Cdkn2a and upregulation of cyclin D1 and Cdk6, 
which is predicted to promote the G1 to S phase transition and fits with the slight increase 
in the proportion of Ctcf-null S phase NPCs (Figure 4-4a). The Ctcf-null neocortex was 
characterized by an increase in the basal progenitor (BP) population, similar to what is 
observed after overexpression of cyclinD1 in neural stem cells (Lange et al., 2009). 
CDK6 mutations cause microcephaly in humans, and were shown to affect progenitor cell 
proliferation (Hussain et al., 2013). Furthermore, alterations in the retinoblastoma (Rb) 
and Cdkn1a (p21) cell cycle regulators cause neurological phenotypes that resemble 
CTCF loss (McClellan and Slack, 2006; Seoane, 2004; Slack et al., 1998). Global 
transcriptional analysis failed to detect differences in the mRNA levels of Rb or p21, 
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however these genes have been documented as direct CTCF targets in the literature (De 
La Rosa-Velazquez et al., 2007; Filippova, 2008; Qi et al., 2003). In vivo analysis of cell 
cycle progression failed to indicate any overt differences between control and Ctcf-null 
cells (Figure 4-4), but a more detailed investigation of cell cycle parameters including 
BrdU pulse-chase experiments and calculations of individual phase lengths may indicate 
subtle differences in Ctcf-null NPCs that could have dramatic consequences on brain 
development and growth. 
Microcephaly can also result from increased cell death during brain development. Indeed, 
CTCF deletion using two separate Cre driver lines caused increased NPC death. 
Investigation of the mechanism underlying cell death indicated an increase in Puma 
transcript and protein levels. PUMA is a potent activator of the mitochondrial cell death 
pathway (Nakano and Vousden, 2001). Ctcf deletion in the developing limb bud also 
caused increased Puma levels (Soshnikova et al., 2010), and analysis of Puma regulation 
in HCT116 colon carcinoma cells indicated a p53-independent role for CTCF in 
suppressing Puma transcription (Gomes and Espinosa, 2010a, b). This led to the 
hypothesis that loss of CTCF-specific Puma repression causes ectopic induction of 
apoptosis in a p53-independent manner. Analysis of p53 activation as well as generation 
of Ctcf/Puma double mutant mice demonstrated that this hypothesis does not accurately 
describe the complexity of apoptotic induction downstream of CTCF loss. Ctcf-
deficiency resulted in evidence of p53 activation such as increased total p53 protein 
levels and its translocation to the Puma promoter (Figure 3-3). Caspase-mediated 
apoptosis is PUMA-dependent in Ctcf-null NPCs, as caspase activation was inhibited in 
the Ctcf/Puma-deficient forebrain. However, the microcephaly phenotype at birth was not 
restored in the double mutant brain, presumably due to upstream activation of p53. 
Generation of Ctcf/p53 double mutant mice would be helpful in delineating apoptotic 
from cell cycle defects downstream of CTCF loss.   
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5.7 Towards understanding CTCF functions in cellular survival 
Genotoxic stress triggers activation of p53/PUMA-dependent signaling in NPCs (Jeffers 
et al., 2003). Since CTCF is regarded as an important organizer of global chromatin 
structure (Ong and Corces, 2014), and Ctcf-null NPCs activate the p53/PUMA-dependent 
signaling axis, I hypothesized that CTCF may regulate genomic stability to promote NPC 
survival. Indeed, Ctcf mutant cells display elevated endogenous DSB levels and 
sensitivity to exogenous stressors, particularly replicative stress-inducing agents. Further 
analysis indicated a correlation between endogenous damage and active proliferation, 
suggesting CTCF may protect cells from replicative stress. Despite this relationship, the 
exact mechanism of CTCF function in preventing damage accumulation remains 
enigmatic. My data suggests that CTCF is not involved in replicative stress signaling or 
repair, however more thorough analysis is required to substantiate this claim. Given the 
existing links between CTCF and replication (Cleary et al., 2002; Cleary et al., 2010; 
Libby et al., 2008), the protein may play a more indirect role in preventing genomic 
instability by facilitating DNA replication or the organization of replication timing 
domains. 
CTCF binding upstream of repetitive tracts is hypothesized to slow the replication fork 
before progressing through difficult-to-replicate regions (Cleary et al., 2010). This idea is 
similar to the proposed role for CTCF in alternative splicing regulation, wherein CTCF 
binding downstream of weak exons promotes RNAPII pausing and exon inclusion 
(Shukla et al., 2011). Therefore CTCF may be required globally to slow polymerase 
progression, which in the context of replication may have important consequences for 
repeat stability. In particular, CTCF depletion causes a telomere dysfunction phenotype 
in U2OS cells (Deng et al., 2012a), indicating that at the very least CTCF is required for 
telomeric stability. 
The downstream consequences of Ctcf deletion using two different Cre driver lines were 
remarkably distinct. In both instances, CTCF loss in NPCs resulted in elevated 
endogenous DNA damage levels, Puma upregulation, and apoptotic induction. However, 
deletion of CTCF from early progenitors at approximately E8.5 via Foxg1-cre was more 
severe than deletion at approximately E11 using Nestin-cre. This result is reminiscent of 
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inactivation of the replicative stress-signaling protein TopBP1. Deletion of TopBP1 in 
early progenitors using Emx1-cre results in profound loss of forebrain structure, while 
deletion in progenitors later in development using Nestin-cre causes a milder apoptotic 
phenotype (Lee et al., 2012a). Moreover, irradiation-induced DNA damage results in 
similar levels of DNA breaks in early and later progenitors, however apoptosis is elevated 
in response to radiation in early progenitors versus later-born progenitors (Lee et al., 
2012a).  Together, these data indicate that NPCs early in development trigger apoptosis 
to prevent the propagation of damaged genetic material to daughter cells. Furthermore, it 
provides a mechanism underlying the disparate phenotypes associated with CTCF loss 
using two different Cre driver lines. 
DNA lesions activate PARP1, triggering the synthesis of ADP-ribose and PARylation of 
DNA repair proteins (Davies et al., 1978; Durkacz et al., 1980). Furthermore, PARP1 
activity is required for efficient reversal of stalled replication forks (Ray Chaudhuri et al., 
2012). CTCF is poly(ADP-ribosyl)ated by PARP1 (Yu et al., 2004) and activates PARP1 
by acting as a link between DNA and poly(ADP-ribosyl)ation (Farrar et al., 2010). 
However, the CTCF and PARP1 interaction has primarily been studied in the context of 
chromatin insulation and transcriptional regulation. My findings suggest a reevaluation of 
the interaction between CTCF and PARP1 in the DDR and during replication fork restart. 
The CTCF gene is located on chromosome 16q22.1, a deletion region well documented 
in several human cancers (Filippova et al., 1998; Rakha et al., 2006). Ctcf functions as a 
haploinsufficient tumour suppressor protein in mice (Kemp et al., 2014), strengthening 
the link between CTCF loss and cancer progression. Ctcf+/- tumours exhibited widespread 
DNA methylation changes, however it was unclear whether this effect was a primary or 
secondary cause of CTCF loss, and if it is the direct upstream source of Ctcf+/- tumour 
formation. My findings provide an additional avenue by which CTCF loss may promote 
tumourigenesis. Indeed, genomic instability and replicative stress are potent mediators of 
cancer progression, suggesting that replication-associated DNA damage may drive 
tumour formation in the absence of CTCF. Furthermore, there are existing links between 
DNA methylation status and genomic instability (O'Hagan et al., 2008; Robertson and 
Jones, 1997), suggesting that altered methylation profiles could explain damage 
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accumulation in the absence of CTCF. It is possible to test this by profiling global DNA 
methylation in Ctcf-null NPCs by next-generation bisulfite mutagenesis sequencing. 
However, it will be important to assess genomic stability in cells heterozygous for Ctcf as 
well as in tumours harboring CTCF mutations. 
5.8 Future Directions: CTCF Functions in Genomic Stability 
The body of work described in chapters three and four of this thesis demonstrates that 
CTCF is required for NPC survival through suppression of genomic instability. CTCF 
impinges on the p53 signaling network to mediate survival and likely to control cellular 
proliferation (Figure 5-2a). Several questions remain unanswered regarding CTCF 
activities in preventing endogenous DNA damage accumulation, namely, is CTCF 
directly or indirectly involved in the DDR?  
Preliminary evidence suggests that CTCF is not required for timely repair of replication-
associated damage, as Ctcf-null NPCs were able to resolve aphidicolin-induced γH2AX 
foci to baseline levels 24 hours post treatment (Figure 4-5). A more detailed analysis of 
DNA repair capabilities in the absence of CTCF will be required to exclude a role for 
CTCF in repair, especially given its localization at damage foci. The DR-GFP HR assay 
would be an excellent method to assess whether Ctcf-null NPCs are repair-competent, 
especially since replication-associated damage is typically repaired via HR (Jasin, 1996; 
Pierce et al., 1999). DR-GFP consists of two expression plasmids: (1) containing two 
tandem GFP genes, the first is a full-length GFP gene mutated with the 18 bp SceI 
endonuclease recognition sequence and the second is a truncated GFP that can be utilized 
as a template for repair, and (2) an SceI expression plasmid. Expressing both of the 
plasmids in cells results in a SceI-mediated DSB in the full-length GFP gene. If cells are 
capable of HR repair, they will utilize the truncated GFP for repair and will express the 
GFP reporter (Pierce et al., 1999). It would also be worthwhile to induce damage with 
different types of stressors, such as γ-irradiation or mitomycin C, to test whether CTCF is 
required for the repair specific types of lesions.  
An equally plausible scenario is that CTCF loss causes global chromatin dysregulation, 
resulting in endogenous DNA damage. Global analysis of DNA damage sites via γH2AX 
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ChIP-sequencing in mutant cells will be informative in understanding the role of CTCF 
in suppressing endogenous damage accumulation. CTCF depletion causes global 
chromosome compaction (Tark-Dame et al., 2014). Intriguingly, chromatin condensation 
can lead to DDR signaling (Burgess et al., 2014), raising the distinct possibility that 
global changes in chromatin organization artificially signal activation of the DDR 
downstream of CTCF loss. Alternatively, changes to global chromosome architecture or 
subnuclear domain organization may cause changes to the replication timing program 
that can induce replicative stress (Cornacchia et al., 2012; Pope et al., 2014) (Figure 1-3), 
a possibility that can be tested by profiling replication timing in Ctcf-deficient cells.  
CTCF may instead function more directly during DNA replication, which is supported by 
the finding that CTCF binding upstream of the repetitive DM1 locus is required for its 
efficient and correct replication (Cleary et al., 2010) (Figure 5-2b) and my findings of 
altered replication dynamics in NPCs (Figure 4-3h). Moreover, the work herein 
demonstrates an interaction between CTCF and PCNA, albeit indirect, which would 
support the model that CTCF binding upstream of repetitive elements is required for 
polymerase fidelity (Figure 5-2b). Alternatively, CTCF may be involved in organizing 
replication factories with cohesin (Figure 5-2c), which is supported by the interaction 
between CTCF and the cohesin complex, namely the SA1 subunit that has been 
implicated in telomere replication and stability (Remeseiro et al., 2012). Evidence also 
points to a role for CTCF in organizing TAD boundaries (Dixon et al., 2012; Narendra et 
al., 2015; Nora et al., 2012), which have recently been shown to regulate replication 
timing (Pope et al., 2014). Profiling the timing (early and late-replicating) of control and 
Ctcf-null cell DNA replication is the most direct method to test whether CTCF is required 
for replication timing (Ryba et al., 2011) (Figure 5-2d). Together, my data suggests that 
CTCF is required to prevent replication-associated damage in NPCs, however the 
upstream molecular mechanism is currently unknown. The interaction between CTCF 
and PCNA requires further examination, especially since the interaction appeared to be 
enhanced under conditions of replicative stress. This finding may indicate a requirement 
for the partnership between CTCF and cohesin in postreplicative repair (Figure 5-3e), as 
cohesin is a well-established postreplicative repair factor (Sjogren and Nasmyth, 2001). 
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Figure 5-2 Possible mechanisms underlying CTCF-dependent suppression of DNA 
damage and p53-dependent signaling 
(A) In NPCs, CTCF is required to suppress DNA damage and p53-dependent signaling. 
Potential mechanisms of CTCF-dependent DNA damage suppression supported by the 
literature and this work are presented in panels B-E. (B) CTCF binding upstream of 
repetitive elements such as the DM1 locus (Cleary et al., 2010) and telomeres (Deng et 
al., 2012a) is required for fork/polymerase slowing, as represented by green arrows, prior 
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to progression through the elements to prevent fork slippage and collapse. (C) CTCF may 
help organize replication factories through its ability to mediate higher-order chromatin 
organization and interact with the cohesin complex and PCNA. (D) CTCF may be 
required for the establishment of TADs, which play important roles in regulating 
genome-wide replication timing domains (Pope et al., 2014). The diagram highlights 
CTCF binding at TAD borders, which demarcate the boundaries between early-
replicating active euchromatin (green) within the nuclear interior and passive replicating 
regions (red arrows) that represent the transition regions between early- and late-
replicating (heterochromatin found at the nuclear exterior; red) domains. (E) CTCF may 
interact with cohesin and assist with postreplicative repair of DNA damage acquired 
during S phase. 
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5.9 Implications of Aberrant Chromatin Structure to Brain 
Development 
A key finding of this work is that proteins that regulate higher-order chromatin structure 
are essential for correct brain development through the balance of NPC proliferation, 
differentiation, and survival. Deficiency of either Atrx or Ctcf in the embryonic brain 
causes profound neurodevelopmental abnormalities, providing some insights into the 
pathologies stemming from human ATRX and CTCF mutations.  
The physiological ramifications of aberrant chromatin structure are still widely unknown, 
however alterations in epigenetic regulators appear to particularly affect brain 
development and cognition (Kleefstra et al., 2014). A high proportion of ID disorders are 
caused by heterozygous de novo mutations in epigenetic regulators, suggesting that gene 
dosage is critically important for correct brain development and functioning. Mutations in 
ATRX and CTCF both cause intellectual disability disorders characterized by 
microcephaly and autistic features (Gibbons et al., 1995b; Gregor et al., 2013; Iossifov et 
al., 2014). Phenotypic similarities observed in these disorders may reflect common 
molecular pathways affected by mutations in different genes. 
The overlapping phenotype associated with Atrx- and Ctcf-deficiency, namely 
accumulation of endogenous replication-associated DNA damage, indicates that the 
proteins may function together to regulate NPC survival. Given that ATRX is required 
for nucleosome remodeling and CTCF recruitment to imprinting control regions (ICRs) 
(Kernohan et al., 2014), it may be worthwhile to assess whether ATRX is required for 
CTCF localization in NPCs. Interestingly, CTCF sites are enriched for H3.3 (Jin et al., 
2009) and H3.3 deposition at CTCF sites facilitates H3K27me3 removal in HeLa cells 
(Weth et al., 2014). Moreover, CTCF binds to human and mouse subtelomeric sequences, 
and its depletion results in decreased TERRA transcription and telomere dysfunction in 
U2OS cells (Deng et al., 2012a). ATRX may therefore facilitate CTCF recruitment to 
subtelomeric regions to promote telomere stability. ATRX loss is correlated with 
increased TERRA levels, however, suggesting that the relationship between ATRX, 
CTCF, and telomere stability is not straightforward. It is also important to interpret 
telomeric data derived from U2OS studies with caution since the cells do not express 
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ATRX and exhibit ALT (Lovejoy et al., 2012). Nevertheless, investigations of telomeric 
stability in Ctcf-null NPCs will provide insight into the genomic regions that acquire 
damage in the absence of CTCF and may point to the underlying molecular mechanism 
responsible for endogenous DNA damage downstream of CTCF loss. Unlike ATRX, 
however, CTCF binds to numerous genomic locations (Kim et al., 2007b), suggesting 
that CTCF function in preventing endogenous DNA damage is likely not telomere-
specific. More global approaches, such as γH2AX ChIP-sequencing, will be required to 
determine if specific DNA sequences are more susceptible to damage acquisition in the 
absence of CTCF. 
The finding that both Atrx and Ctcf deficient cells exhibit replication-associated damage 
may simply be a consequence of the loss of genomic stability factors in rapidly 
proliferating cortical NPCs. In other words, the genomic instability observed in Atrx- and 
Ctcf-null cells may be enhanced by the highly proliferative nature of NPCs. This idea is 
supported by the differences in cell viability after deletion of the genes using a Foxg1-cre 
or Nestin-cre driver line (Berube et al., 2005; Watson et al., 2014), which likely reflects 
the differential susceptibility of early and late NPCs to DNA damage (Lee et al., 2012a). 
However, it is not supported by the selective sensitivity of Atrx- and Ctcf-null NPCs to 
replicative stress-inducing agents. Furthermore, it is not supported by the finding that 
ATRX localizes to late-replicating heterochromatin foci, the majority of DNA foci in 
Atrx-null NPCs localizes to late-replicating foci, and the proposed model of ATRX 
functions in remodeling heterochromatin in G2.  It is also not supported by the finding 
that Ctcf-null NPCs in the same regions of the embryonic cortex exhibit cell cycle-
dependent DNA damage that correlates with PCNA staining. In conclusion, ATRX and 
CTCF may not be involved in preventing replicative stress per se but rather are critical to 
suppress DNA damage; the consequence of loss of these proteins being p53-dependent 
apoptosis in the quickly dividing NPC population. Alternatively, the phenotypes observed 
downstream of ATRX and CTCF loss may indicate critical cell cycle-dependent roles for 
these proteins. Future experiments aimed at uncovering the exact biochemical 
mechanisms of function for these proteins in different phases of the cell cycle will be 
instrumental in dissecting their true actions in protecting the genome from DNA damage. 
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Moreover, deficiency of either Atrx or Ctcf in NPCs causes precocious differentiation 
early in corticogenesis, resulting in depletion of the progenitor pool and a failure to 
sustain generation of late-born neurons (Ritchie et al., 2014; Watson et al., 2014). 
Selective lengthening of the cell cycle, particularly the G1 phase, is hypothesized to 
causally contribute to progenitor switching from proliferative to neuron-generating 
divisions (Calegari et al., 2005; Calegari and Huttner, 2003). Replication errors or 
unresolved replication intermediates generated during S/G2 phase can be converted into 
DSBs during mitosis and are repaired in the subsequent G1 (Lukas et al., 2011), which 
can induce G1 lengthening. If G1 lengthening is causal in promoting neurogenic divisions 
of progenitors, then G1 lengthening may be responsible for the precocious differentiation 
observed in the Atrx- and Ctcf-null neocortex (Figure 5-3). 
The most common disease linked to replication stress is cancer (Bartek et al., 2012). This 
fact is currently being exploited to induce synthetic lethality in tumour cells. For 
example, PARP inhibitors have been used to block repair of ssDNA breaks that are 
processed into DSBs during S phase, and results in apoptotic induction of HR-deficient 
tumour cells (Jackson and Bartek, 2009). Along the same lines, ALT-positive tumour 
cells, such as those with inactivating ATRX mutations, are sensitive to ATR inhibition 
(Flynn et al., 2015). Further investigation of the exact mechanism underlying 
tumourigenesis downstream of CTCF mutation will be necessary to advance cancer 
therapeutics, especially given the high occurrence of 16q22.1 deletions in various human 
cancers (Filippova et al., 1998; Rakha et al., 2004). 
Replicative stress has also been associated with human neurological diseases such as 
Seckel (OMIM# 210600), Aicardi-Goutieres (OMIM# 610333), Meier-Gorlin (OMIM# 
224690), Nijmegen breakage (OMIM# 613078), and Wold-Hirschhorn (OMIM# 194190) 
syndromes (Zeman and Cimprich, 2014). These syndromes feature overlapping 
characteristics with ATR-X syndrome and patients with mutations in CTCF such as 
intellectual disability and microcephaly, suggesting similar molecular mechanisms 
underlying disease pathogenesis. However, analysis of patient cells and/or generation of 
effective animal models of the disorders will be necessary to confirm or refute this claim. 
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The findings documented in this thesis broadly illustrate the importance of higher-order 
chromatin regulation for correct brain development. They also support the genome-wide 
association studies indicating that epigenetic pathway alterations play a major role in the 
pathogenesis of neurodevelopmental and neuropsychiatric disease (De Rubeis et al., 
2014; Pinto et al., 2014). Collectively, the data positions two important epigenetic 
regulators, ATRX and CTCF, at the intersection between chromatin structure and 
genomic stability, and demonstrates the importance of higher-order chromatin 
organization in safeguarding the genome to support correct brain development. 
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